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Introduction and outline 
INTRODUCTION  
Due to the increasing prostate cancer (Pca) awareness and screening on serum 
prostate-specific antigen (PSA), more than 80 percent of patients with prostate cancer (Pca) 
present now with clinically localized disease (1). Data, derived from the 2005 Dutch Cancer 
registration, show 7500 new diagnosed cases of Pca, comprising 20 % of all new male cancer 
cases. In the Netherlands, one out of 10 men will be confronted with this type of cancer. 
Patients with localized Pca can choose from a wide range of treatment options; surgery, 
irradiation (external beam or brachytherapy), hormones or watchful waiting. An excellent 
review on diagnosis and treatment options for Pca has been published by Peschel et al. (2), as 
part of the “Series on prostate cancer” published in the Lancet. Also a full issue of the Journal 
of Clinical Oncology (2005, volume 23, number 23) was dedicated to the management of Pca. 
Generally spoken, higher dose radiotherapy for intermediate and high risk Pca leads to a 
longer period of tumor control (3). This is recently confirmed by a large Dutch randomized trail 
in 664 patients, treated with 68 Gy or 78 Gy (4). But a higher dose also leads to higher late 
toxicity, mainly rectal bleeding and fecal incontinence, as shown in the same Dutch trial (5). 
The toxicity rate in radiotherapy is closely related to the irradiated volume of an organ at risk, 
e.g. the rectal wall, leading to late rectal bleeding (6). So reduction of the irradiated volume, 
may lead to decreased late toxicity and improved quality of life.   
 
Focusing on external beam radiotherapy for localized Pca, as being the topic of this 
thesis, technical improvements in radiotherapy treatment preparation and delivery, such as the 
use of a CT scan in treatment preparation and shielding of normal tissues during treatment (7, 
8), patient position verification and correction during daily treatment (9-11), intensity-
modulated radiotherapy (IMRT) (12) and incorporation of advanced radiological imaging 
techniques into the radiotherapy treatment (13, 14) has lead to a more targeted irradiation. In 
this context, targeted treatment stands for high precision radiotherapy leading to the highest 
possible tumor control, with lowest as possible radiation-induced toxicity.  
 
In this thesis, the steps are described we took in the past years to improve the 
Nijmegen radiation treatment for localized Pca. Our first goal was to reduce the irradiated 
volume of the surrounding normal tissues (e.g. rectum and bladder) by implementing tools for 
high-precision treatment and to analyze the possible benefits of these additional tools. Next 
goal was to explore the possibilities of defining a radiotherapy target within the prostatic gland, 
based on advanced magnetic resonance (MR) techniques, for extra high-dose application 
locally on tumor-bearing regions. Implementation of IMRT, in which intensity-modulated dose 
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profiles are applied, rather than flat dose profiles, is opening the possibility of dose painting on 
a biological target volume, as proposed by Ling et al. (15).  
 
OUTLINE 
 In chapter 2, a new method of Pca patient positioning (set-up), at the radiotherapy 
treatment table, and a patient position verification and correction protocol is described. By 
reducing the daily position variation during the course of treatment (i.e. 28 - 32 daily 
treatments on the lineair accelerator), the margin around the prostate, accounting for these 
variations, could be reduced. As a consequence, the amount of surrounding irradiated tissue 
could thereby be reduced.  
Since 2001, the urologist implants four small gold markers (1 x 7 mm) into the prostate 
in patients, referred for radiotherapy with curative intent. These markers are well visible on the 
megavolt images (so-called portal images) that are taken of the pelvic region during the actual 
radiation treatment. These implanted markers can be used for prostate localization and 
position verification. In chapter 3, the complications and risk factors for toxicity, due to the 
transrectal gold marker implantation, in 209 consecutive men are presented. 
In 2002, we introduced the endorectal balloon (ERB) in clinical practice after promising 
data, showing benefits in terms of improved prostate immobilization and extra sparing of the 
rectal wall (Rwall) during radiotherapy (16-18). In chapter 4, our first clinical experiences with 
the ERB are described; patients’ tolerance, staff acceptance and workload. The daily prostate 
position variations, measured on implanted gold markers, were compared in patients treated 
with and without an ERB, to test its prostate immobilizing capacities. 
A full bladder during treatment is recommended, because then a part of the bladder 
wall will be out of the high dose region and the probability of urinary toxicity will be reduced. A 
full bladder before daily treatment is also advised, because large variation in bladder filling can 
cause additional unwanted day-to-day shifts of the prostate, requiring an extra safety margin to 
be irradiated to account for (19). In chapter 5, this issue, using a bladder ultrasound scanner 
for daily bladder filling checks, is discussed. A biofeedback protocol, aiming at a more constant 
bladder volume, was developed and tested clinically. Additionally, bladder filling and prostate 
motion were correlated, using gold marker based portal imaging data. 
Gradually, the ERB was introduced into daily practice at our department. So far in 
literature, three types of ERB were described, having different shapes, volumes and manual 
handling. In chapter 6, a planning study is described, investigating the spatial dose distribution 
and Rwall sparing effect of these three ERBs for high-dose conformal radiotherapy and IMRT. 
We have applied more sophisticated graphical displays (20, 21) of the absorbed radiation dose 
onto the Rwall mucosa, as being one of the most important critical structures in the 
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development of late rectal toxicity (22). The therapists, being the ones to apply the ERB on a 
daily basis, evaluated the three ERBs on practical issues. In collaboration with the department 
of Radiology, a gold-marker based tool was developed to integrate advanced MR imaging 
techniques (for precise delineation of the prostatic gland and pre-radiotherapy tumor 
assessment) into our treatment planning procedures (23). Simultaneously, inverse IMRT 
treatment planning became available for pre-clinical use. In Chapter 7, a feasibility planning 
study is described to incorporate two functional Pca MR imaging techniques into IMRT 
treatment planning for definition and potential irradiation of a dominant intra-prostatic lesion 
(DIL). Research work from the Radiology department has shown that is possible to detect this 
DIL (i.e. the tumor-bearing regions) within the prostatic gland (24, 25). In this planning study, 
an extra high-dose (a boost) of 90 Gy was applied to the DIL, while the other part of the 
prostate was planned to receive a moderate dose of 70 Gy. Estimations of the tumor control 
probability (TCP) and Rwall normal tissue complication probability (NTCP) were calculated to 
determine the possible gains of this form of targeted biological dose-painting, compared to a 
more traditional whole prostate irradiation. 
 
One of the a-fore mentioned ERBs has been clinically applied in a cohort of patients 
and they have been closely followed during and after radiotherapy. Over a period of 3,5 years, 
146 rectosigmoidoscopies were performed at the department of Gastroenterology and 
Hepatology in patients irradiated with and without an ERB. For each patient, the spatial dose 
distribution over the inner Rwall was calculated and displayed as Rwall surface dose maps. 
Per patient, multiple endoscopic assessments of the radiation-induced mucosal changes were 
performed. Acute and late toxicity for both patients groups were scored and compared. The 
results are described in chapter 8 
 
In chapter 9, the results and conclusions are summarized. Recommendations and future 
perspectives on the separate issues, investigated and discussed in this thesis, are given.
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ABSTRACT 
Purpose: To investigate set-up improvement caused by applying a couch height-based 
patient set-up method in combination with a technologist-driven off-line correction protocol in 
non-immobilized radiotherapy of prostate patients. 
Methods and Materials: A three-dimensional shrinking action level correction protocol is 
applied in two consecutive patient cohorts with different set-up methods: the traditional "laser 
set-up" group (n = 43) and the "couch height set-up" group (n = 112). For all directions, left-
right, ventro-dorsal and cranio-caudal, random and systematic set-up deviations were 
measured. 
Results: The couch height set-up method improves the patient positioning compared to the 
laser set-up method. Without application of the correction protocol, both systematic and 
random errors reduced to 2.2 - 2.4 mm (1 SD) and 1.7 - 2.2 mm (1 SD), respectively. By using 
the correction protocol, systematic errors reduced further to 1.3 - 1.6 mm (1 SD). One-
dimensional deviations were within 5 mm for  > 90 % of the measured fractions. The required 
number of corrections per patient in the off-line correction protocol was reduced significantly 
during the course of treatment from 1.1 to 0.6 by the couch height set-up method. The 
treatment time was not prolonged by application of the correction protocol. 
Conclusions: The couch height set-up method improves the set-up significantly, especially in 
the ventro-dorsal direction. Combination of this set-up method with an off-line correction 
strategy, executed by technologists, reduces the number of set-up corrections required. 
Effectiveness of couch height based patient set-up 
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INTRODUCTION  
Daily accurate patient positioning is one of the prerequisites of radiation oncology. 
According to ICRU-50/62, the planning target volume (PTV) has to account for internal organ 
motion and treatment set-up uncertainties in order to ensure adequate coverage of the clinical 
target volume (CTV). It appeared that patient set-up variations are of the same order (2 - 4 mm 
(1 SD)) as variations due to internal organ motion (1-3). So, improvement of set-up in prostate 
radiotherapy could result in reduction of the CTV-PTV margin. Margin reduction is especially 
important in the ventro-dorsal (VD) direction, where a reduction of the possible overlap of PTV 
and rectum will result in reduction of the irradiated rectum volume and decreased toxicity. 
 
Set-up errors consist of a systematic component, i.e., the same deviation in the same 
direction for each fraction throughout the whole treatment course, as well as a random 
component, i.e., varying from day to day (4). Earlier studies on the set-up accuracy in pelvic 
irradiation have shown substantial systematic and random deviations (5, 6). Several methods 
to improve patient set-up have been investigated. Studies using different types of patient 
immobilization showed controversial results (7-16). With different correction protocols using 
digital portal images it is possible to reduce set-up errors (17-22). It is well known but hardly 
reported in literature that standardized patient set-up methods improve patient set-up, for 
example using the treatment couch height independent from the lateral laser skin mark 
alignment (23, 24). Patient set-up deviations are dependent on set-up and immobilization 
procedures specific for each radiation department. Therefore, set-up errors reported by other 
institutes are an indication but cannot be easily translated into daily practice for one’s own 
patients. It is, therefore, advisable to obtain set-up deviations by repeated portal imaging in 
each institute (4, 25, 26). The actual accuracy can be compared with the literature and one 
can decide whether or not to try to improve patient positioning and how. In our institute, after 
installation of an electronic portal imaging device (EPID), an off-line set-up correction protocol 
was implemented for prostate irradiation. After installation of carbon-fibre inserts in the 
treatment couch top, it became possible to standardize our patient set-up by using a "couch 
height set-up" method for the ventro-dorsal direction. In this method, the (digital) couch height 
during simulation is applied during the actual treatment (see below). 
In the present study, first the extent of the set-up improvement, obtained from applying an off-
line correction protocol, has been investigated in a first cohort of prostate patients. In a second 
cohort, the set-up improvement has been investigated for the "couch height set-up" method in 
combination with the correction protocol. The magnitude of set-up improvements due to both 
the off-line correction protocol and the "couch height set-up" method has been investigated. 
This will enable us to calculate the size of set-up improvement by using the "couch height set-
up" method only, e.g. for use at accelerators not yet equipped with an EPID. In this study the 
additional workload of the used methods is documented as well. 
Effectiveness of couch height based patient set-up 
METHODS AND MATERIALS 
Patient group and treatment technique  
From 1997 to June 2000 155 patients were irradiated for localized prostate cancer and included 
in this study. After simulation and CT-scanning in treatment position, a beam's-eye-view based 
conformal treatment plan was performed with individual shielding of normal tissues (Cadplan treatment 
planning system, Varian). CTV included prostate only or prostate and seminal vesicles. PTV was defined by 
automatic 10-12 mm 3D expansion of the CTV at the physician's preference (27). An orthogonal four-field 
isocentric technique was used. If necessary, asymmetric fields were used around the isocenter, marked on 
the skin during simulation. Doses varied from 63 to 67.5 Gray in 7 to 7.5 weeks, depending on tumor-stage 
(fractionation four times a week using 2.25 Gray fractions). The investigated patient group was divided in 
two consecutive cohorts: in cohort 1 patient set-up was performed by laser alignment and controlled 
with an off-line correction protocol (n = 43, “laser set-up" group), in cohort 2 patient set-up was 
performed with the "couch height set-up" method described below and also controlled with an off-line 
correction protocol. (n = 112, “couch height set-up" group).  
 
Patient immobilization and set-up 
During simulation, CT-scanning and the actual treatment, all patients (cohort 1 and 2) were 
positioned supine on a flat couch that was solely covered with a thin disposable paper sheet. Only a pillow 
and a foam knee support (Kneefix TM cushion, Sinmed) were used for relaxed positioning of the head and 
legs (15). No formal patient immobilization such as a cast or a 
positioning device was applied (Fig. 1). The patient's skin was 
marked at the simulator with reference lines, using wall 
mounted lasers to indicate a tentative center: lateral vertical 
laser lines to prevent torsion of the patient and rotation of the 
pelvis, a sagital midline laser line to prevent torsion and to 
ensure a correct midline position of the patient, and lateral 
horizontal lines.  
 Fig. 1: Photo showing the applied patient set-up 
At the CT, following simulation, and in the treatment room, the same system of wall mounted alignment 
lasers was used to match the lines on the patient. No new isocenter was marked on the skin after 
planning: if necessary, slightly asymmetric fields were used. The patient's skin was marked at the 
simulator with reference lines, using wall mounted lasers to indicate a tentative center: lateral vertical 
laser lines to prevent torsion of the patient and rotation of the pelvis, a sagital midline laser line to 
prevent torsion and to ensure a correct midline position of the patient, and lateral horizontal lines. At the 
CT, following simulation, and in the treatment room, the same system of wall mounted alignment lasers 
was used to match the lines on the patient. No new isocenter was marked on the skin after planning: if 
necessary, slightly asymmetric fields were used. 
 
"Couch height set-up" method 
In our institute, before 1997, patients were treated on couch with flexible (mylar) membrane 
inserts. The sagging of this membrane was 5 – 7 mm in the center depending on patient's weight, 
leading to a systematic set-up error in the ventro-dorsal direction compared to the simulator couch with 
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a solid wooden top. Since 1997, our accelerator couches (ABB, GE) and CT couch are equipped with 
carbon-fibre inserts. Measurements showed equal sagging of simulator, treatment and CT couch under 
a patient's weight ( < 2 mm). The accuracy of the (digital) couch-height read-out for all couches was 
within ± 1 mm. It was, therefore, possible to use the (digital read-out of the) couch height obtained 
during simulation for more accurate set-up in the ventro-dorsal direction during the actual treatment. In 
cohort 2, the patients were set up during treatment by alignment of ink skin marks and lasers in the 
three main directions. In contrast to the laser set-up method (cohort 1), the lateral marks are only used 
to prevent rotation around the longitudinal axis. When this alignment is done, the digital couch-height is 
noted (for study reasons). Next, the couch is set at the height defined during simulation. The feasibility 
of this method was tested earlier in a pilot study with 18 patients for whom the set-up was checked by 
frequent portal imaging (three times a week during the whole treatment). In this pilot study no large set-
up errors in the ventro-dorsal direction were seen (data not shown), which led to the set-up of the 
patients of cohort 2 as described above, referred to as "couch height set-up" method. 
 
Portal image acquisition  
 Since 1996, a camera-based EPID (Theraview version 1.08) was used at our GE Saturne 42 
accelerator. Specific software was developed in-house to draw anatomy templates. Additional software to 
perform the registration of treatment and reference images was obtained from the B. Verbeeten Institute in 
Tilburg, The Netherlands (P.H. Vos). A working group, consisting of a radiation technologist, a radiation 
oncologist and a physicist has been responsible for the introduction of electronic portal imaging. From the 
beginning, the whole procedure of preparation, image acquisition, analysis and set-up correction was 
considered as the task of eight radiation technologists (25 % of total technologist group), participating in this 
study and especially trained for this task. The physicist and/or radiation oncologist were consulted if special 
problems arose. The simulator film was used as the reference image. After digitizing the reference 
simulator film, the field shape and an anatomy template consisting of contours of relevant bony structures 
were drawn. During the actual treatment, portal images were automatically acquired using 2 - 5 monitor 
units. For analysis the anterior - posterior (AP) and left-lateral (LL) fields were used.  
 
Registration procedure 
Measurement of set-up deviations was performed in two steps. First, the imaging system checks 
automatically the field shape i.e. the position of the field edges, and gives the message 'field shape correct' 
if reference and portal image completely match. Secondly, the anatomy template is displayed on the screen 
overlaying the portal image. This template is then manually aligned to the anatomic structures on the portal 
image using a mouse to obtain the best fit. Image quality of the portal images could be improved by the 
imaging system. In the registration of the images only translations were considered. Once adequately 
aligned, the vector coordinates  (X, Y and Z) of the measured deviations are displayed on the screen and 
entered into a spreadsheet. In this study, the X-axis corresponds to the left-right direction, Y-axis to the 
cranio-caudal direction and Z-axis to the ventro-dorsal direction. All set-up measurements were performed 
by two trained radiation technologists independently. The results were compared and the average of the 
two separate deviations was noted. If an inter-observer difference occurred larger than 3 mm for the left-
right and cranio-caudal deviation in the AP field, or in the ventro-dorsal deviation in the lateral field or if an 
inter-observer difference occurred larger than 5 mm for cranio-caudal direction in the lateral field, the 
Effectiveness of couch height based patient set-up 
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measurements were repeated. Due to overlying bony structures, the matching was more difficult for the 
lateral images. If the inter-observer differences exceeded these levels in the second round, the two 
technologists tried to reach consensus by checking each others matching procedures. If no consensus 
could be achieved, the first two measurements were averaged. Eight percent of all the measurements was 
repeated by the two observers. The accuracy of this procedure was tested earlier in a pilot study with 100 
AP and lateral prostate images of 10 patients. The inter-observer variability for the AP field was slightly 
smaller than for the lateral field. The registration of the left-lateral field is more difficult than for the AP field 
due to overlying bony structures (hips, pelvic bones). However, it turned out that all the portal images could 
be registered and that, due to the procedure followed, the registration procedure (after consensus) was 
adequate within ≈1 mm. The deviation in the X was inferred from the AP field and in the Z from the left 
lateral field. The set-up deviation in the Y direction was calculated from portal images of the AP and left 
lateral field, applying a higher weight to the measurement from the AP image, i.e.: <Y> =  [(2*Y ap + Y left-
lat. )/3]. 
 
Off-line correction protocol 
 For all patients an off-line verification and correction protocol was used, as described by Bel et al 
(28), i.e. image analysis and measurement of set-up deviations were performed later on the same day as 
the treatment to have the results ready prior to the next treatment fraction. The 3D verification procedure 
uses a shrinking action level protocol [(α/√N, with α the initial action level (9 mm) and N the number of 
measurements] and a fixed number of initial measurements (Nmax  = 3). Patient set-up correction is 
applied only when the vector length of the 3D set-up deviation, averaged over previous fractions, 
exceeds an action level. 
 
 The protocol consists of two stages.  
 In the first stage, action levels of size α/√N, approximated as 9, 7 and 5 mm, were chosen for 
the first three initial measurements. Values of  α and Nmax followed from an optimization, using a Monte-
Carlo simulation program, aiming to reduce the mean 3D-set-up deviation of each individual patient to 
within 5 mm at an acceptable workload, i.e. an acceptable number of measurements and set-up 
corrections (28). If the 3D vector length, averaged over previous measurements, was larger than the action 
level for that day, a set-up correction was performed, i.e. the patient was repositioned by moving the 
isocenter over the deviations found in the three directions. If set-up correction was carried out no new lines 
were drawn on the patient’s skin. Correction data were entered in the record and verify system of the 
accelerator to set a new isocenter. The patient was set-up according to the original lines drawn during 
simulation and subsequently the couch was shifted according to the magnitude of the correction required. 
When a component of the required correction was smaller than 2 millimeters, the correction was not applied 
in that direction. Should set-up correction be mandatory after the first measured fraction (N=1), the applied 
correction was 2/3 of the 3D vector length to prevent a possible overshoot in the first stage of the 
verification procedure. After each correction, the calculation of the average 3D-vector was restarted and 
three measurements, with the corresponding actions levels of 9, 7 and 5 mm (3D-vector), had to be 
performed again to complete the first stage. The first stage of this protocol was complete when at least 3 
(=Nmax) measurements were done and when the average 3D set-up deviation was below the lowest 
action level (5 mm). 
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 In the next stage, patient positioning was checked by weekly taken digital portal images to deal with 
set-up deviations that may arise during the course of the treatment, due to possible time-trends (28). The 
average 3D displacement over the last three measurements was compared with the lowest action level, 5 
mm. If the 3D-vector length exceeded this level, the set-up was corrected and the first stage of the 
verification procedure was restarted, with three set-up measurements and the initial action levels of 9, 7 and 
5 mm. 
 
Patient set-up analysis 
 For all patients, both systematic and random deviations have been studied for the three directions 
separately. The random variation (denoted as σ) characterizing a patient group is then defined as the SD of 
the day-to-day set-up positions, averaged over all patients in the group. The systematic variation (denoted 
as Σ) is defined as the standard deviation of the distribution of average set-up deviations per patient in the 
group of patients. The overall mean deviation M is the average value over all fractions and all patients. A 
non-zero M indicates an overall systematic deviation, e.g. a difference in sag or read-out of the couch (4, 
17, 29). The overall set-up variation σt represents the combination of systematic and random variations for 
the whole group of patients, given by σt = √ ( σ2 + Σ2 ). The deviations in the three directions for a specific 
fraction are quadratically combined in one 3D-vector, indicating the 3D set-up deviation. This 3D-vector 
is used in the off-line correction protocol described above. 
 
In the analysis afterwards, for each individual patient and for the whole group of patients, the random, 
systematic and overall set-up deviations were calculated. Retrospectively, it was possible to calculate the 
deviations also as if patients had been irradiated without application of the correction procedure. 
Furthermore, both the group of mean 3D set-up deviations (all patients, one value per patient) has been 
analyzed as well as the group of all 3D set-up deviations (all patients, all measured fractions). It is clear that 
the first group is more relevant as representing the average displacement during the course of the 
treatment, and is generally analyzed in literature (17, 18). The latter group represents also the day-to-day 
variations. In both groups, the fraction of treatments with 3D set-up deviations larger than 5 and 10 mm has 
been determined. 
 
Workload registration 
 The workload is obviously very much dependent on organization. The multi-disciplinary approach in 
our institute facilitated smooth introduction of the involved procedures. Special attention was given to teach 
the technologists the principles of portal imaging, the definition of set-up deviations, methods of correction 
and achieved set-up improvements. Before actually performing imaging or image analysis, a technologist 
was trained by a more experienced colleague. Sets of previously analyzed images were used as training 
and for two weeks all new measurements done by the trainee were supervised and checked. For all 
patients, an estimation of additional workload for the radiation technologists was made. Per patient, the 
extra needed time (for image acquisition and for correction) on the accelerator and time for analysis and 
administration was noted. For both cohorts of patients, the set-up improvement and the number of 
corrections needed were registered separately and compared. 
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RESULTS  
In 155 patients, a total of 1562 fractions were analyzed with 6248 measurements in 
3124 portal images. An overview of the data obtained is given in table I. The first and third 
columns show the data related to the "laser set-up" group and "couch height set-up" group 
respectively, corrected as if no off-line correction protocol was applied. The second and fourth 
columns show the actual data of those groups.  
 
Systematic variations 
In the "laser set-up" group, the off-line correction protocol gave a marked reduction of 
the systematic set-up variation (Σ) from 2.8 - 4.1 mm down to 1.3 - 1.7 mm (1 SD). The largest 
improvement is in the ventro-dorsal direction: a reduction of the systematic variation from 4.1 
to 1.6 mm. The systematic variations in the "couch height" set-up group (calculated as if no 
correction protocol was applied) were 2.2 - 2.4 mm (1 SD) compared to 2.8 - 4.1 mm in the 
"laser set-up" group. Application of the correction protocol in the "couch set-up" group, the 
actual situation, resulted in further reduction of the systematic variation (table I) down to 1.3 - 
1.6 mm (1 SD). The results for the systematic deviations with the correction protocol applied 
are, thus, similar for both cohorts. 
 
Random variations 
Obviously, random set-up variation does not change by application of the off line 
correction protocol. In the "laser set-up" group, a random variation (σ) of 2 - 2.6 mm (1 SD) 
was found. In the "couch height set-up" group, the random variations were smaller, i.e. 1.9 - 
2.2 mm (1 SD). This indicates that having the couch height closer to the required position 
during patient set-up, also slightly reduces random set-up deviations.  
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 Patient cohort 1 
"Laser set-up" 
Patient cohort 2 
"Digital couch height set-up" 
 Without 
correction 
Actual, with 
correction 
Without 
correction 
Actual, with correction
Number of patients 43 43 112 112 
Number of measured fractions 439 439 1123 1123 
Systematic and random variations     
Σ − systematic variation     
Left-right (mm) 3.3 1.7 2.4 1.6 
Cranio-caud (mm) 2.8 1.3 2.3 1.3 
Ventro-dors (mm) 4.1 1.6 2.2 1.4 
σ − random variation     
Left-right (mm) 2.5 2.5 2.2 2.2 
Cranio-caudal (mm) 2.0 2.0 1.7 1.7 
Ventro-dorsal (mm) 2.6 2.6 1.9 1.9 
σt - overall set-up variation     
Left-right (mm) 4.0 3.1 3.4 2.9 
Cranio-caudal (mm) 3.4 2.5 3.0 2.2 
Ventro-dorsal (mm) 5.0 3.6 3.0 2.5 
Mean     
Left-right [mm] -0.5 -0.4 0.1 0.1 
Cranio-caudal [mm] 0.5 0.6 1.3 0.9 
Ventro-dorsal [mm] -1.0 -0.2 0.4 0.2 
Off-line correction protocol     
Number of corrections per patient     
Total number (all 3 directions)  1.1  0.6 
in left-right direction   0.7  0.4 
in cranio-caudal direction  0.6  0.4 
in ventro-dorsal direction  0.8  0.4 
3D set-up deviations in the group of 
all fractions. all patients 
    
  ≥ 5 mm [%] 42 23 28 12 
 ≥ 10 mm [%] 4 1 0.4 0.1 
     
Mean 3D set-up deviations in the 
group of all patients 
    
 ≥ 5 mm [%] 51 0.0 21 
Table 1: for legends, see next page 
0.0 
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Table 1: 
Data of both patient cohorts with patient set-up traditionally with the "laser set-up" method and  the 
"couch height set-up" method respectively (see text). In both patient cohorts the set-up variations are 
given both for the actual treatment and calculated as if no off-line correction protocol has been applied. 
For the presented quantities see text. 
 
 
Mean systematic deviation 
According to statistics, the mean systematic deviation M averaged over all patients 
should be of the order of Σ/√Np, with Np the number of patients considered, i.e. of the order of 
0.3 - 0.5 mm for all groups considered. This turned out to be true, except for the cranial-caudal 
direction in the "couch height" set-up group where an unexplained overall systematic deviation 
of ≈ 1 mm was found. 
 
3D set-up deviations 
In figure 2, the mean 3D set-up deviations are shown in a cumulative frequency 
distribution for both cohorts, actual and calculated as if no correction protocol was applied.  
0%
20%
40%
60%
80%
100%
0 1 2 3 4 5 6 7 8 9 10 11
3D set-up deviations [mm]
Fr
eq
ue
nc
y
 
Figure 2: Cumulative frequency distributions of mean 3D set-up deviations for the "laser set-up" group 
without correction protocol (thin dashed line) and with correction protocol (thick dashed line). and for the 
"couch height set-up" group without (thin solid line) and with correction protocol (thick solid line) . 
Vertical axis: percentage of 3D set-up deviations≥ a specific value. Horizontal axis: mean deviations in 
mm 
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Note that figure 2 applies to the group of mean 3D set-up deviations of each patient. In figure 2 
is shown that in the "laser set-up" group, without application of the correction protocol, 51% of 
the patients had a mean 3D set-up deviation of 5 mm or more and 12% even more than 9 mm. 
In the "laser set-up" group, the percentage of the mean 3D set-up deviation ≥ 5 mm was 
reduced from 51% to zero by using the off-line correction protocol. The use of the "couch 
height set-up" method alone, without off-line correction protocol, showed remarkably good 
results: only 21% of the patients has a mean 3D set-up deviation ≥ 5 mm, compared to 50% 
with the "laser set-up" method. Use of the "couch height set-up" method with correction 
protocol yields slightly better results as use of the "laser set-up" method with the off-line 
correction protocol: no patients featured a mean 3D set-up deviation larger than or equal to 4 
mm. 
Instead of the mean 3D set-up deviation per patient, one might consider the group of all 
3D set-up deviations (all patients, all fractions), in order to know how often in daily practice 
deviations occur. As shown in table I, the frequency of the 3D set-up deviations ≥ 5 mm and  
≥10 mm in the "laser set-up" group was reduced from 42% to 23% and from 4% to 1% 
respectively. In the "couch height set-up" group, the frequency of the 3D set-up deviations  ≥5 
mm is 28 % and is even reduced to 12% with the correction protocol. 
 
Off-line correction protocol characteristics 
As shown in Table I, the number of measured fractions in both cohorts was on average 
10 per patient, a direct consequence of the chosen values for the parameters in the off-line 
correction protocol. The number of corrections is significantly lower in the "couch height set-
up" group than in the "laser set-up" group: the number of corrections per patient was (on 
average) 1.1 and 0.6 respectively. The improvement is, as expected, most significant in the 
ventro-dorsal direction: from 0.8 in the first cohort down to 0.4 corrections per patient in the 
second cohort.  
 
Ventro-dorsal set-up deviation 
It is expected that the "couch height set-up" method gives especially a large 
improvement in the ventro-dorsal direction. In figure 3, the mean set-up deviations per patient 
in the ventral-dorsal direction  
are shown in a cumulative frequency distribution. In the "laser set-up" group, without 
application of a correction protocol, 33 % of the measured fractions has a ventro-dorsal 
deviation of ≥ 5 mm. With the "couch height set-up" method, this percentage is decreased to 
11 %. With application of the correction protocol, this decreases further to 5 %. It's remarkable 
that the accuracy of set-up in the ventral-dorsal direction is even better in the "couch height 
set-up" group without correction protocol than in the "laser set-up" group with correction 
protocol. For the left-right and cranio-caudal direction, the effect of the "couch height set-up 
Effectiveness of couch height based patient set-up 
method" was less pronounced. Combining the "couch height set-up" method with correction 
protocol resulted in deviations ≥ 5 mm in 7 % and 4 % of the measured fractions respectively 
(data not shown). 
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Figure 3: Cumulative frequency distribution of the ventral-dorsal set-up deviations for the "laser set-up" 
group without correction protocol (thin dashed line) and with correction protocol (thick dashed line). and 
for the "couch height set-up" group without (thin solid line) and with correction protocol (thick solid line) . 
Vertical axis: percentage of set-up deviations ≥ a specific value. Horizontal axis: ventro-dorsal 
deviations in mm 
 
Workload  
 It turned out that during treatment the time of a treatment session (standard time slot 10 
minutes for pelvic irradiation) was not prolonged due to image acquisition. This is in a situation 
where, generally, 2 or 3 technologists are executing the patient treatments at one accelerator. 
Image acquisition, i.e. entering patient data and starting the actual acquisition, is performed by 
one technologist while the others set up the patient. For each patient, in total about 40 minutes is 
needed for administrative preparation, verification, and data registration of the whole procedure, 
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partly the day before the first treatment and partly after each treatment during the day to have 
corrections ready for the next fraction. 
 
DISCUSSION AND CONCLUSION 
This study first confirms again that an off-line correction protocol combined with a "laser 
set-up" method can reduce the systematic set-up errors significantly without excessive extra 
workload (17, 18, 20, 21). The results are close to the results of Bel et al. and Lebesque et al. 
obtained in a multi-center study in The Netherlands (17, 18). They found that with an average 
of 0.7 set-up corrections per patients in a shrinking action level protocol, it was possible to 
reduce the 3D mean set-up deviation > 5 mm from 30 % to less than 2 percent. Our results 
are similar in terms of improvement of set-up and workload: the mean 3D-set-up deviation ≥ 5 
mm in the "laser set-up" group was reduced from 51 % to 0 %. Results are for instance also 
close to Hanley et al. (20), who reported systematic set-up variations of 1.3 – 1.9 mm (1 SD) 
and random set-up variations of 1.7 – 2.0 mm (1 SD); compared to table I. 
 
Secondly, this study clearly shows that use of a "couch height set-up" method improves the 
set-up in ventro-dorsal significantly. Obviously, a pre-requisite for this result is a similar low 
sag and accurate read-out of the couches at CT, simulator and accelerator. This large 
improvement, compared to the "laser set-up" method, can be explained by daily varying 
motion of the skin during patient set-up in the latter method. It is a significant result that the 
set-up variation in ventral-dorsal direction is even better for the "couch height set-up" method 
without correction protocol than for the "laser set-up" method with correction protocol. It's 
remarkable that also the set-up deviations in the cranial-caudal and left-right direction are 
reduced when applying the "couch height set-up" method. This might be a side effect of the 
reduced efforts of the technologists to align the laser lines to the skin lines and, thus, reduces 
motion of the skin. As a conclusion, this "couch height set-up" method can also be beneficially 
applied for accelerators without imaging and without correction protocol. 
 
The "couch height set-up" method is not new. We know that some colleagues use this 
method since carbon-fibre couch inserts and tops became available and "tennis rackets" and 
mylar couch top inserts were abandoned. In some literature this method is sideways 
mentioned (5, 14, 24). A similar method as ours was published, however, applied without 
correction protocol and evaluated only in the ventral-dorsal direction (23). In that study, the 
height of the isocenter above the couch top was used. In the present study, we use the digital 
couch height read-out from the simulator, thus including the differences in sag between the 
couches and the digital read-out inaccuracies. This might be the cause of the slightly lower 
systematic and random set-up variation in the ventro-dorsal direction found by Greet et al., i.e. 
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1.3 mm respectively 1.2 mm (1SD) compared to 2.2 mm respectively 1.9 mm (1SD) in our 
study (see table I - "couch height set-up" method without correction protocol). 
 
Immobilization 
 In this study, no immobilization was used. In literature, the discussion on immobilization 
in pelvic irradiation is ongoing. Several groups have investigated this issue with different ways 
of interpretation, presentation and different conclusions (7-15). We attribute our relatively small 
random set-up variations, e.g., compared to the results of Mitine et al. (7) for their non-
immobilized patient group to the stable patient position due to the use of a knee support (see 
fig.1). Our random set-up variations are also small compared to studies with immobilized 
patients (7,9). One might imagine that by fitting patients into immobilization devices the skin 
can move, which introduces additional random variations. So far, immobilization does not 
seem to yield lower random and systematic variations than the "couch height set-up" method 
discussed in this paper. This non-immobilized method might even be improved by using a 
support for the lower legs and ankles (1, 9,10) instead of the universal knee support applied in 
this study (fig. 1),(16). 
 
CTV - PTV margin 
 As a result of set-up improvement, the CTV-PTV margin can be reduced. In prostate 
irradiation, organ motion is an important factor. Prostate position variability has been shown to 
be larger in the ventro-dorsal direction (2 - 3 mm, 1 SD) and cranial-caudal (2.5 - 4 mm), both 
due to differences in rectal filling, and less in left-right direction (1 - 2 mm, 1 SD). The seminal 
vesicles have larger variability in the ventro-dorsal direction (3 - 5 mm, 1 SD) (1-3). Stroom et 
al. and Van Herk et al. developed a method for calculation of CTV – PTV margins including 
organ motion and set-up errors (29, 30). 
Their margin rules for CTV - PTV were 2Σ + 0.7σ and 2.5Σ + 0.7σ respectively. Reduction of 
the systematic set-up error has a major influence on the margin needed. Importing our set-up 
results into the margin calculations results in a reduction of CTV – PTV margin in the ventral 
dorsal direction of 3 – 4 mm and for the other directions of 1 – 2 mm. As a result, we have 
reduced our margins for prostate irradiated patients. Presently, we use a uniform 3D CTV-PTV 
margin of 8 mm around the prostate and 9 mm around the seminal vesicles in line with Fiorino 
et al. who have also reduced the ventro-dorsal margin from 10 mm to 8 mm as a result of 
improved set-up by using lower leg immobilization (9). 
 
Implementation of the "couch height set-up" method 
Implementation of the "couch-height set-up" method caused changes in the patient 
positioning methods. Previously, skin marks were used for all three directions. A visual check 
was performed whether the patient was set-up correctly. With the new method, the lateral 
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marks are only used to prevent torsion and rotation and the table is set at the prescribed 
couch height. Initially, this set-up method was rather confusing because a difference between 
laser lines on the skin and the drawn lateral marks could be present. Acceptance was gained 
by good communication between the involved disciplines regarding the improvement of set-up 
accuracy gained during this study. 
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ABSTRACT 
Purpose: To report the complication rates and risk factors of transrectally implanted gold 
markers, used for prostate position verification and correction procedures. 
Materials and Methods: In 209 consecutive men with localized prostate cancer four gold 
markers (1 x 7 mm) were inserted under ultrasound guidance in an outpatient setting and the 
toxicity was analyzed. All patients received a questionnaire, regarding complications after 
marker implantation. Complications and risk factors were further evaluated by reviewing the 
medical charts. 
Results: Thirteen patients (6.2 %) had a moderate complication, consisting of pain and fever 
that resolved after treatment with oral medication. In 1.9 % of the men, minor voiding 
complaints were observed. Other minor transient complications, defined as hematuria lasting 
more than 3 days, hematospermia and rectal bleeding occurred in 3.8%, 18.5% and 9.1% of 
the patients, respectively. These complications were seen more often in patients with higher 
tumor stage, younger age and shorter duration of hormonal therapy. 
Conclusions:  Transrectal gold marker implantation as part of the prostate radiotherapy 
treatment preparation is a safe and well-tolerated procedure. The complications are 
comparable to or even less than the complications observed in diagnostic prostate biopsies. 
The proven advantages of marker implantation for high-precision prostate radiotherapy 
outweigh the minor risks. 
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INTRODUCTION 
Dose escalation in external radiotherapy, for localized prostate cancer improves 
outcome with a lower PSA-recurrence rate (1, 2). Rectal toxicity is one of the limiting factors 
and is directly related to the total radiation dose prescribed and the volume of the rectal wall 
receiving a high dose (3). Prostate motion is considered a source of treatment error, with day-
to-day gland displacements between 3-5 mm (4). To account for these prostate movements, 
treatment margins up to 10-15 mm have to be defined around the gland and result in 
additional irradiation of the surrounding tissues. To enable margin reduction, radiopaque 
markers implanted in the prostate are being used as an aid for exact localization of the 
prostate during the radiotherapy (5-8). Electronic portal imaging systems are widely used for 
daily prostate position verification and correction procedures (9 - 12). The markers are 
implanted prior to the acquisition of the planning 
computer tomography (CT)-scan. Gold markers are 
well-visible fiducials both in pre-treatment imaging 
(CT, MR) and in megavolt portal imaging during 
radiotherapy treatment. Marker migration within the 
prostate, during the course of radiotherapy is 
negligible (13). Therefore, implanted gold marker 
detection is a reliable method for repetitive position 
verification. 
 
Fig 1 Portal image of anterior-posterior radiotherapy 
treatment beam, with four implanted gold markers in 
situ. 
Although the use of gold markers is 
increasingly common, complication rates 
have not been reported in a large patient 
population. It might be hypothesized, that the complication rates due to marker implantation 
may be comparable to the complications in patients undergoing diagnostic prostate biopsies. 
In prostate biopsies few moderate, but frequent minor complications are seen. Analysis was 
performed by several authors to identify risk factors for complications of prostate biopsies (7, 
14-16). The goals of this study are to report on the complication rate in patients with localized 
prostate cancer in whom gold markers were implanted transrectally and to identify risk factors 
for complications. 
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MATERIALS AND METHODS 
Patients and gold marker implantation 
In all patients referred for radiotherapy on localized prostate cancer (T1-3 N0 M0), the 
gold marker implantation was performed in the urology outpatient clinic. No preceding enema 
or anesthesia was used. A prophylactic antibiotic, ciprofloxacin 500 mg. b.i.d. for three days, 
was given. Anticoagulant medication was stopped 3 to 7 days before marker implantation.  
Patients were placed in a lateral decubitus position. 
First, the urologist measured the prostate volume with 
an ultrasound Kretz Voluson 530D device (GE Kretz, 
Zipf, Austria) with endorectal transducer. Next, the 
gold markers were placed, under ultrasound guidance, 
with a standard 18-gauge prostate biopsy tool (Micro-
vasive Topnotch, Boston Scientific, Natick, MA), 
mounted onto the endorectal ultrasound transducer 
(Fig 1a). Fine gold markers of 1 mm diameter  Fig. 2 Fine gold markers 
and 7 mm length were used (Hospimed International 
B.V., Dalfsen, The Netherlands) (Fig. 1b).  The length was chosen for reasons of visibility on 
the portal images and CT imaging. Two markers were placed left and right at the base, one in 
the central part next to the urethra and one at the apex of the prostate. After at least one week, 
to resolve swelling of the gland after implantation, the planning CT-scan (3 mm slice thickness) 
was obtained. In Fig 1c, an example of a portal image, showing the implanted markers, is 
displayed. 
 
Complications and risk factors 
All patients received a questionnaire, regarding complications after marker 
implantation. The questionnaire specifically asked for the presence and duration of hematuria, 
hematospermia, rectal bleeding, fever, and pain. Patients were also asked to report other 
complaints, symptoms and additional medication taken after the implantation. Pain was scored 
on a 0 to 10 scale (0=no pain, 10=worst pain imaginable). It was requested to compare the 
pain, experienced during marker implantation, to the pain at the diagnostic prostate biopsy 
procedure.  
Minor complications, were defined as side effects with transient minimal discomfort, 
requiring no additional medical intervention. The complications that resulted in moderate 
discomfort and required additional treatment were considered as moderate complications.  
In most cases (184/209) the questionnaires were sent to the patients by mail, after the 
marker implantation. For this particular retrospective analysis, inconsistencies were verified 
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with the patient. The notes, made by the urologist or radiation oncologist in the period of 
marker implantation, were checked retrospectively and all other occurring complications were 
noted.  
 
Possible risk factors for developing any moderate or any bleeding complications 
(hematuria, hematospermia or rectal blood loss) were evaluated by reviewing the medical 
charts: tumor stage, the urologist performing the marker implantation, the use of anticoagulant 
therapy, previous transurethral resection of prostate (TURP) or prostatitis, the prevalence of 
diabetes, prednisone use, age, duration of hormonal therapy, and the volume of the prostate. 
Statistical analysis was performed by T-tests for the comparison of continuous variables and 
Fisher exact tests (2 × 2 tables) or Chi-square tests (3 × 3 tables) for the comparison of 
categorical variables. To analyze the impact of retrospective analysis, the patients who 
received the questionnaire directly after the procedure, were evaluated separately and the 
outcomes were compared with the data obtained retrospectively.  
 
 
RESULTS 
Patients and gold marker implantation 
Between January 2001 and September 2005, gold markers were implanted in 236 
patients. The mean age was 70 years (range 40-84 years). Twenty-seven patients were lost to 
follow-up because of death (n=9) or other factors (n=18). In 209 patients the toxicity outcome 
could be analyzed and results reported concern this group of 209 patients. Of these patients, 
the tumor was staged as a T1 in 18 cases, T2 in 64 cases and a T3 tumor in 127 cases. 
In 8 patients, marker misplacement outside the gland boundaries was observed during 
the treatment planning CT-scan: 7 times into the bladder, 1 time to the rectum. On average, 
the whole implantation procedure took 10 minutes. Seventy-nine patients were on 
anticoagulant therapy: acetylsalicylic acid (n=64), acenocoumarol (n=12) or other (n= 3). 
Hormonal treatment (HT) was started in 202 patients, mainly before marker implantation, with 
a mean interval of 7 weeks until the procedure (range 0-40). Prostate volumes ranged from 5 
to 136 ml (mean 40 ml). For the retrospective complications analysis, the questionnaire was 
filled out at a mean time of 90 weeks after marker implantation. 
 
Complications and risk factors 
In Table 1 the observed complication rates are shown. No statistically significant 
differences in any of the complications were found between the patients who filled out the 
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questionnaire directly after the procedure and the patients who performed this later (data not 
shown). 
 
 
Patients N % 
Minor complications    
Hematuria > 3 days 8 3.8 
Hematospermia 15 7.2 
Rectal bleeding 19 9.1 
Voiding complaints 4 1.9 
Moderate complications   
Pain requiring analgesics  6 2.9 
Fever 4 1.9 
Nausea/vomiting 2 1.0 
Allergic reaction antibiotic 1 0.5 
 
Table 1. Complication rates 
 
 
Minor complications 
In all cases hematuria was self-limiting within 7 days. Hematospermia, noted by 15 
men, was counted only in the 81 patients who reported to have had ejaculations. The average 
duration of rectal bleeding was 2.5 days. In 13 out of 19 patients, the rectal bleeding lasted for 
1 day. One patient reported repeated minor blood loss during 21 days. The voiding complaints 
consisted of either an increase of previous complaints, or dysuria. 
 
Moderate complications 
For the patients with a moderate complication, no admission to the hospital was 
necessary. Patients with fever got additional antibiotics and the temperature normalized within 
a few days. The patient with the allergic reaction to ciprofloxacine recovered after termination 
of this antibiotic. 
 
Pain  
The mean pain score was 3.2 (range 0-9). Forty-eight percent of the patients scored 0-
2, 37% had a pain score of 3-5 and 15% of the patients scored 6-9. Fifty percent of the 
patients reported that the marker implantation was less painful than prostate biopsies, while 
40% of the patients recorded comparable pain and 10% noted more pain.  
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Risk factors 
Significantly increased bleeding complications were seen in patients with advanced 
tumor stage, younger age and shorter duration of hormonal treatment (Table 2 and 3). The 
use of anticoagulants yielded no increased rectal bleeding or other complications rates. None 
of the investigated risk factors were significantly correlated to any moderate complication. 
 
Risk factor  Bleeding complication % (n) p Moderate complication % 
(n) 
p 
Tumor stage T1 5.6    (1/18) 0.026* 0    (0/18) 0.57* 
 T2 9.4    (6/64)  6.3 (4/64)  
 T3 22.8  (29/127)  5.5 (7/127)  
Anticoagulant Yes 20.3  (16/79) 0.45 5.1 (4/79) 1.00 
 No 15.4  (20/130)  5.4 (7/130)  
TURP Yes 3.7    (1/27) 0.054 0    (0/27) 0.37 
 No 19.2  (35/182)  6    (11/182)  
Prostatitis Yes 16.7  (2/12) 1.00 8.3 (1/12) 0.49 
 No 17.3  (34/197)  5.1 (10/197)  
Diabetes Yes 22.2  (4/18) 0.52 0    (0/18) 0.60 
 No 16.8  (32/191)  5.8 (11/191)  
Prednisone Yes 0       (0/1) 1.00 0    (0/1) 1.00 
 No 17.3  (36/208)  5.3 (11/208)  
 
Key: TURP = transurethral resection of prostate; * = Chi-square test 
 
Table 2. Risk factors and complication rates (Fisher exact test) 
 
Risk factor Bleeding Major 
complication 
Mean p 
 
complication 
Mean p 
Age  Yes 68.1 years 0.022 Yes 70.6 years 0.85 
 No 70.8 years  No 70.3 years  
HT  Yes 4.4 weeks 0.028 Yes 5.1 weeks 0.51 
 No 7.2 weeks  No 6.8 weeks  
Prostate volume  Yes 42.8 ml 0.38 Yes 46.2 ml 0.11 
 No 39 ml  No 39.2 ml  
 
Key: HT=hormonal therapy 
Table 3. Risk factors and complication rates (T-test) 
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DISCUSSION 
In this study, the complications and risk factors were studied after transrectal 
implantation, under ultrasound guidance, of gold markers for position verification in prostate 
cancer radiotherapy. This is the first paper reporting the marker-induced toxicity of a large 
patient group. Minor complications such as hematuria and hematospermia were observed in 
3.8% and 18.5% of the patients, respectively. Rectal bleeding was seen in 9.1% of the 
patients, lasting for an average of 2.5 days. Henry et al. reported on twelve patients in whom 
gold markers were implanted transperineally (17). Three patients noted hematuria, one patient 
hematospermia and one patient rectal bleeding, which occurred after the marker was most 
likely implanted through the rectal wall. No infections were seen. The transperineal route is 
thought to give less rectal bleeding than the transrectal implantation. In this study, the duration 
of hematuria was not mentioned. Maximally three markers were implanted, which could be a 
factor in causing less rectal bleeding or hematospermia. The authors reported severe pain 
during the implantation in three patients and one patient needed analgesics. Comparison with 
our results is difficult because of the difference in patient numbers. The second study, 
reporting on implanted marker toxicity, comprises 10 patients and a maximum of three fiducial 
markers were implanted under ultrasound guidance (7). Three patients reported a transient 
hematuria the first 24 hours after implantation and seven patients reported an episode of rectal 
bleeding. Again, comparison to our results is difficult as we reported hematuria longer than 3 
days only. Occurrence of hematospermia was not mentioned and no moderate or major 
complications were observed. 
 
After prostate biopsies 64% - 78% minor complications (i.e. hematuria and 
hematospermia) are noted (15, 18-20). Moderate complications, mostly infections, are seen 
infrequently with a maximum of 4% (15, 21). Two studies noted a rate of 23% of hematuria 
lasting longer than 3 days, 45% hematospermia and 1,7% rectal bleeding (14, 16). We 
reported less hematuria and hematospermia after marker implantation but more rectal 
bleeding, although the duration was short. In literature, the percentage of voiding complaints 
after prostate biopsies varies between 1-12% (16, 20, 22, 23). In our group, only 1.9% of the 
patients had voiding complaints after the marker implantation. Table 4 shows, for comparison, 
complication rates after prostate biopsies, as reported in literature and our observed 
complication rates after marker implantation (depicted in the last line). In some studies, dealing 
with TRUS and transrectal prostate biopsies, minor or no discomfort is reported in up to 92% 
of patients and patients’ acceptance is high (20, 21).  
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Authors Year Patients   
 
(n) 
HU >3 days 
 
(%) 
HS  
 
(%) 
RB 
 
(%)
Voiding  
 
(%) 
Fever  
 
(%) 
Adm  
 
(%) 
Pain/ 
Analgesics 
(%) 
Patients’ 
acceptance 
(%) 
Clements 1993 80 20* 11.3 7.5 7.5 2.5 1.3 7.5 >70 
Rodriguez 1998 127 47 10 10 11.8 1.7 0.8 13 70 
Djavan 2001 1051 16.6 10.2 2.4 7.2 2.9 NA 11 89 
Collins 1993 89 18 29 37 7 4 NA 22 78 
Aus 1993 391 13 9 2.8 NA 2.5 1.8 8 92 
Raaijmakers 2002 5802 22.6 50.4 1.3 0.8 3.5 0.5 7.5 NA 
Rietbergen 1997 1687 23.6 45.3 1.7 NA 4.2 0.4 7.5 NA 
Langenhuijsen 2006 209 3.8 7.2 9.1 1.9 1.9 0 2.9 85 
 
Key: HU = hematuria; HS = hematospermia; RB = rectal bleeding; Adm = admission to hospital; NA = not 
available; *duration not defined 
 
Table 4. Reported complications in prostate biopsies & gold marker implantation  
 
However, there are also reports in which severe discomfort is mentioned in up to 30% 
of patients (18). Irani et al. evaluated 81 patients undergoing prostate biopsies (24). They 
found a mean painscore of 3, but 16% had significant discomfort (score>5). We found similar 
results with a mean painscore of 3.2 and 15% of patients having severe pain during the 
implantation. Only six patients, reporting pain, needed analgesics. Half of the patients reported 
that the marker implantation procedure was less painful than the diagnostic biopsies. This 
might be explained by the fact that only 4 markers are implanted, in contrast to the multiple (6 
– 8) biopsies. Furthermore, the uncertainty of the diagnosis during biopsies might play a role in 
experiencing more pain.  
 
Only 1.9 % of our patients got fever after marker implantation, less than most others 
reported after prostate biopsies (14, 15, 16, 18, 20-23). It was shown that an antibiotic 
prescribed for 3 days and started 1 day before the prostate biopsies reduced the number of 
infectious complications (15). We also started ciprofloxacin one day before marker 
implantation and continued it for 3 days. Two patients got nausea and vomiting after the 
implantation. This could be a consequence of the procedure and be a manifestation of 
bacterimea (23). These patients however did not get fever and the complaints resolved 
spontaneously. 
 
Anticoagulant medication was stopped 3-7 days before implantation. As a result no 
extra or longer bleeding complications occurred in this group. We have shown that patients 
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with higher tumor stage, younger age and with shorter duration of hormonal treatment had 
significantly more bleeding complications. In these patients, an increased prostatic 
vascularisation could be an explanation, although this is speculative. It might be advisable to 
wait with implantation until shortly before radiotherapy, so the hormonal therapy has caused 
maximal reduction of tumor volume. As we have experienced, a disadvantage of a smaller 
prostate can be the technical difficulty of the marker implantation. Studies have shown that 
younger patients experience more pain in prostate biopsies (18, 20). This could not be 
confirmed for in our study. Raaijmakers et al. (16) have identified risk factors for complications 
after prostate biopsies. An earlier episode of prostatitis was associated with more pain and 
hospital admission. Prostate volume was as a predictor for urinary retention. In our study, no 
specific risk factors for complications could be identified and urinary retention did not occur in 
any of the 209 studied patients. 
In each prostate radiotherapy patient referred to our department, gold markers are 
implanted transrectally. The role of the markers in accurate position verification and correction 
has been well established (10-12, 25). Recently, the first clinical data have been published of a 
new type of implantable radiofrequency emitting device, measuring continuously the position 
of the prostate during treatment (26). Implantation under ultrasound guidance of these 
markers, in size comparable to the gold markers, yielded also no severe complications. Apart 
from verification purposes, we have been using the gold markers for high precision magnetic 
resonance imaging (MRI) – CT fusion and prostate delineation during the treatment planning 
process (27). 
 
CONCLUSIONS 
Transrectal gold marker implantation for prostate position verification is safe and 
appears to be a well-tolerated procedure. In only 1.9 % of the studied patients, minor voiding 
complaints were observed. Other minor transient complications, defined as hematuria lasting 
more than 3 days, hematospermia and rectal bleeding occurred in 3.8%, 18.5% and 9.1% of 
the implanted patients. These minor bleeding complications were more frequently seen in 
patients with higher tumor stage, younger age and shorter duration of hormonal therapy. 
Moderate complications were rare (6.2%) and consisted mainly of pain and fever. These were 
treated with oral medication, which resolved the complaints quickly. The complications after 
gold marker implantation were comparable to or even less than in diagnostic prostate biopsies. 
The proven advantages of marker implantation for high-precision prostate radiotherapy 
outweigh the minor risks. 
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ABSTRACT 
Purpose: To investigate the effect of an endorectal balloon (ERB) and an off-line correction 
protocol on the day-to-day, interfraction prostate gland motion, in patients receiving external 
beam radiotherapy for prostate cancer. 
Methods and materials: In 22 patients, irradiated with an ERB in situ (“ERB group”) and in 30 
patients without an ERB (“No-ERB group”), prostate displacements were measured daily in 
three orthogonal directions with portal images. Implanted gold markers and an off-line 
electronic portal imaging correction protocol were used for prostate position verification and 
correction. Movie loops were analyzed to evaluate prostate motion and rectal filling variations. 
Results: The off–line correction protocol reduced the systematic prostate displacements, 
equally for the ERB and No-ERB group, to 1.3 – 1.8 mm (1 SD). The mean 3D displacement 
was reduced to 2.8 mm and 2.4 mm for the ERB and No-ERB group, respectively. The 
random interfraction displacements, relative to the treatment isocenter, were not reduced by 
the ERB and remained nearly unchanged in all three directions: 3.1 mm (1SD) left-right, 2.6 
mm (1SD) superior-inferior and 4.7 mm (1SD) for the anterior-posterior direction, respectively. 
These day-to-day prostate position variations can be explained by the presence of gas and 
stool besides the ERB.  
Conclusions:  The off-line corrections on the fiducial markers are effective in reducing the 
systematic prostate displacements. The investigated ERB does not reduce the interfraction 
prostate motion. Although the overall mean displacement is low, the day-to-day interfraction 
motion, especially in anterior-posterior direction, remains high compared to the systematic 
displacements.
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INTRODUCTION 
The prostate moves over the course of a radiation treatment. The interfraction motion 
in anterior-posterior (AP) direction, ranging from 1.5 – 4.5 mm, 1 Standard Deviation (1 SD), 
appears to be larger than in superior-inferior (SI), (ranging from 0.9 – 3.9 mm (1 SD)), and in 
left-right (LR) directions (ranging from 0.7 – 1.9 mm (1 SD)). (See overview by Langen et al. 
(1). According to the ICRU definitions, the CTV (clinical target volume) – PTV (planning 
treatment volume) margin accounts for organ motion. For prostate treatment, the largest CTV - 
PTV margin should be towards the rectum, usually 8 – 15 mm. The AP motion is mainly 
correlated with variations in rectal filling (2). Controlling the prostate motion may enable margin 
reduction, and consequently reduction of irradiated rectal wall volume. Rectal toxicity is one of 
the limiting factors in dose escalation and is directly related to the total radiation dose 
prescribed and the volume of the rectal wall receiving a high dose  (3). One of the challenges 
in prostate radiation therapy is elevating dose without increasing rectal toxicity. 
Two different methods have been investigated to control prostate motion: daily beam 
position adjustment and prostate gland immobilization. To localize and correct for the prostate 
displacement by adjustment of the beam positions, repetitive CT scanning (4), radiopaque 
markers, detectable on portal imaging systems (5-10), and ultra-sound systems have been 
used (11). Several investigators tested an endorectal balloon (ERB) for gland immobilization 
and rectal wall sparing (12-17). 
The advantages of the ERB may be threefold. First, the ERB is expected to immobilize 
the prostate gland by giving a constant rectal filling that pushes the prostate towards the pubic 
bone. Second, the ERB pushes the dorsal rectal wall away from the high dose region, 
resulting in rectal wall sparing and reduced rectal toxicity (15-17). Third, Teh et al. (15) showed 
that the air-filled ERB could give additional reduction of rectal wall dose at the air-tissue 
interface. 
To date, no comparative study has been conducted evaluating the systematic (i.e. 
same deviation present throughout the whole treatment) and random (i.e. deviation varying 
from day to day) variation in prostate position in patients irradiated with and without an ERB 
during the whole course of the treatment. The first goal of this study was to evaluate the 
interfraction prostate gland motion in patients treated with and without an ERB. The second 
goal was to distinguish between systematic and random prostate position variations, because 
they have a different impact on the magnitude of the CTV-PTV margins (18,19).
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MATERIALS AND METHODS 
Patient preparation and treatment 
Fifty-two patients were irradiated for localized prostate cancer (T1-3N0M0) and, after 
informed consent was given, included in this study. No exclusion criteria were applied, and 
patients were assigned to either patient group: treatment with or without ERB, over a period of 
twelve months, i.c. the year 2002. All patients received three to six months neo-adjuvant 
hormonal therapy. Four fine gold markers (1mm diameter, 7 mm length) were inserted under 
trans-rectal ultrasound guidance by a urologist. Two gold markers were inserted in the base, 
one at the apex and one in the central part (next to urethra) of the prostate gland. A standard 
18-gauge prostate biopsy tool was used (Micro-vasive topnotch, Boston Scientific, USA.) and 
prophylactic antibiotics were given (ciprofloxacin 500 mg, BID, for 3 days). To ensure proper 
localization of the gold markers, orthogonal pelvic X-rays were made, one hour after the 
marker placement. 
After at least one week, to resolve swelling of the gland after marker implantation, a 
planning CT-scan was obtained at 3mm slice thickness (AcQsim spiral CT, Philips Medical 
Systems). Prior to CT scanning and daily treatments patients were advised to use a laxative 
diet and, if necessary a laxans, and have a full bladder by drinking 500 ml of water. A beams-
eye-view based 3D-conformal treatment plan was designed, with individual shielding of normal 
tissues (Cadplan treatment planning system, Varian). The CTV included prostate only or prostate 
and seminal vesicles. The PTV was defined by automatic 10 mm 3D expansion of the CTV. An 
orthogonal four-field isocentric technique was used. Doses varied from 63 to 67.5 Gy, in 7 to 7.5 
weeks, depending on tumor-stage (fractionation four times a week using 2.25 Gy fractions). The 
investigated patient group was divided in two cohorts: patients treated without an ERB (n = 30, 
“No-ERB" group), and patients treated with a daily ERB in situ (n = 22, “ERB" group).  
The investigated ERB, originally designed as an endorectal coil for magnetic 
resonance (MR) imaging, was supplied by Medrad (Medrad, Pittsburgh, PA). This ERB has a 
specific anatomical concave shape to conform to the prostate gland-rectal interface (13). 
Deflated, the ERB has a diameter of 15 mm. The ERB was inflated with 80 cc of air (standard 
amount of air used for MR imaging) and had a length of 90 mm and a diameter of 45 mm (Fig. 
1a). For every treatment fraction, the radiation therapist placed a new ERB. Special attention 
was given to correct placement of the ERB, i.e. concavity of the balloon directed towards the 
prostate, and the ERB was gently pulled towards the anal sphincter, to ensure a proper 
position in relation to the prostate (Fig. 1b).  
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(a) (b) 
Fig. 1. 
Lateral view of ERB, inflated with 80 cc of air (a) and a saggital planning CT scan reconstruction, with 
endorectal balloon (ERB) inserted and prostate and seminal vesicles highlighted, surrounded by the 
PTV (b)  
 
During CT-scanning and all treatment fractions, patients were positioned supine on a flat couch 
that was covered with a thin disposable paper sheet. Only a pillow and a foam knee support 
(Kneefix TM cushion, Sinmed, Reeuwijk, The Netherlands) were used for relaxed positioning of the 
head and legs, respectively. For patient positioning, a system of wall-mounted alignment lasers 
was used. The digital read-out of the treatment couch height, obtained during CT-scanning, 
was used for more accurate set-up during the actual treatment, as described earlier (20).  
 
Portal Imaging and registration procedures 
 Daily portal images were acquired using a commercial camera-based electronic portal 
imaging device (EPID), equipped with a CCD camera (Theraview NT, Cablon Medical B.V., 
Leusden, The Netherlands) mounted at our GE Saturne 42 accelerator. The digitally 
reconstructed radiograph (DRR) derived from the planning CT-scan was used as the reference 
image. The field shape, an anatomy template consisting of contours of relevant bony structures 
and the contours of the four gold markers were delineated on the DRR. During the actual 
treatment, daily portal images were acquired using the first 30 monitor units of the orthogonal 
(anterior - posterior (AP) and left-lateral (LL)) treatment beams (Fig. 2).  
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 (a) 
 
(b) 
Fig. 2. 
EPID computer screen and reference images (right side) of anterior (a) and left lateral (b) portal images 
(left side). The four implanted gold markers and the contours of the endorectal balloon are indicated.  
 
 
The prostate position is measured both relative to the treatment isocenter (denoted as pr-iso) and 
relative to the bony structures (denoted as pr-bo) to evaluate the internal motion of the prostate, 
independent of the patient set-up variations. To analyze both the daily patient and prostate 
position variations, the bony anatomy template and the marker contours derived from the 
DRR, were displayed overlaying the portal image, and were manually aligned to obtain the 
best fit. The vector co-ordinates (X for left-right, Y for superior-inferior and Z for anterior-
posterior) of the measured patient (i.e. bony structures) and prostate (i.e. markers) 
displacements, as well as the in-plane rotations in the frontal and saggital plane were 
displayed on the screen and recorded.  
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 In thirteen randomly chosen patients the position of the four individual markers were 
measured and compared to the geometric center of the four markers on the DRR, to 
investigate possible marker migration within the prostate gland during treatment. For four 
patients, treated with ERB, loops of all treatment fractions were made, i.e., all the consecutive 
portal images (AP and LL) were displayed as a movie loop. 
 
Patient set-up and prostate position analysis 
 For each patient, the systematic and random gland translations were calculated for the 
three orthogonal directions separately. Also systematic and random prostate rotations were 
measured. The definitions for systematic and random errors, introduced by Bijhold et al. (21), 
were used and calculated for the “No-ERB “ and “ERB” group. The standard deviation of the 
random prostate position variations (denoted as σpr ), derived from the gold markers, is defined 
as the SD of the day-to-day variations, averaged over all patients in the group. The distribution of 
systematic prostate deviations is characterized by Σpr, defined as the standard deviation of the 
distribution of average prostate deviations per patient. The overall mean prostate deviation, Mpr , 
is the average prostate deviation in one direction over all measured fractions and all patients. The 
random, systematic and overall mean prostate position relative to the treatment isocenter 
(denoted as σpr-iso , Σpr-iso and Mpr-iso respectively) and relative to the bony structures (denoted 
as σpr-bo , Σpr-bo and Mpr-bo respectively) were measured. The analysis of the prostate motion 
relative to the bones is necessary to evaluate the possible immobilizing effect of the ERB. 
 
Off-line EPID-based correction protocol  
 For interfraction prostate position verification and correction, the so-called No Action Level 
(NAL) off-line correction protocol was used, as described by de Boer et al. (22). With this type of 
correction protocol  systematic errors can be reduced, with a minimum of extra workload and no 
extra treatment time necessary on the accelerators (20). 
 For the correction protocol, each patient was positioned and imaged during the first 
three fractions without setup correction, unless an unexpected large ( > 10 mm ) prostate 
deviation was found. Next, the systematic prostate positioning error was estimated from the 
mean error of these three fractions, and the correction was applied  from fraction 4 onwards. A 
patient set-up correction was performed by moving the couch according to the deviations found in 
the three orthogonal directions. Due to limitations in table parameters readout, corrections were 
rounded to integer millimeters. A correction of 1 mm in any one direction (1D) was considered not 
relevant, and therefore not applied. After each correction, a set of portal images was made to 
check the executed correction.  
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 From the second week on, the prostate positioning was checked weekly by digital portal 
images to deal with deviations that may arise during the course of the treatment, due to possible 
time trends (e.g. due to rectal and bladder irritation). Now, a correction was applied if the 3D 
vector length (averaged over 3 measurements) exceeded an action level of 5 mm. In this 3D 
vector, the measured 1D deviations in the three orthogonal directions are quadratically combined 
(3D  = √ ( SI2 + AP2 + LR2 )) (6).  
For the analysis, the prostate position variations (including both set-up variations and internal 
prostate motion) were calculated for each individual patient and for the whole group of patients. 
Retrospectively, it was also possible to calculate these deviations with the corrections undone, i.e. 
as if patients had been irradiated without application of the correction procedure. To evaluate the 
effect of the correction protocol, the mean 3D prostate gland deviation was calculated (one value 
for each patient) as the average of the 3D vector lengths of the deviations over all measured 
fractions with corrections and with corrections undone. 
The random and systematic variations were compared applying t-tests and F-tests, respectively. 
Analysis of variance (ANOVA) tests were applied to analyze the influence of different factors 
(presence of endorectal balloon, application of corrections). For the statistical analysis the Stata 
package was used (release 8, Stata Corporation, College Station, Texas, USA). 
 
Workload, personnel and patient experiences  
 For both patient groups an estimation of additional workload was made. Per patient the 
extra time needed (balloon handling, image acquisition and set-up correction) on the 
accelerator and time for analysis and administration was recorded. Also specific experiences 
from patients treated with an ERB, and the attending therapists were collected. 
 
RESULTS 
Gold markers: toxicity, visibility and migration 
 The implantation of the gold markers was performed by one experienced urologist 
(J.W.). Since 2001, beside this study, approximately 180 patients have undergone this 
procedure without significant problems. The procedure takes five minutes per patient. Insertion 
of gold markers in the reviewed 53 patients caused no major acute complications. Ten patients 
observed transient haematuria, five transient heamatospermia and twenty-nine patients suffered 
from slight rectal bleeding on the day of implantation. In two patients, one gold marker was not 
visible on the pelvic X-ray image and was lost by insertion of the marker in the urethra or urinary 
bladder, and excreted by urinary miction. All portal images could be registered for both bony 
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landmarks and gold markers (Fig. 2). In total 1397 treatment fractions (2794 portal images) were 
evaluated, i.e. a mean of 27 measurements per patient.  
In a randomly chosen subset of 13 patients, intraprostatic marker migration, over the 
whole treatment, was investigated. The position of each implanted marker was matched to the 
corresponding marker on the reference image for each fraction. From these data, the 
displacement of an individual marker, relative to the geometric centre of all markers, could be 
derived. The average vector length of the displacement of an individual marker was 1.0 ± 0.6 
mm. The standard deviation (SD) of a marker position, relative to the geometric centre, over all 
fractions, averaged over the 13 patients, was 0.4, 0.5, and 0.8 mm (1SD) in the LR, SI and AP 
directions, respectively. These measured displacements have to be corrected for the 
localization precision for the individual markers. The localization precision could be estimated 
from the interobserver variation for matching the marker position to the reference image. This 
variation was relatively small: 0.3 mm in the LR-direction, 0.4 mm in both the SI- and AP-
direction. With this correction by quadratic subtraction, for the localization accuracy, it can be 
stated that the migration of markers, during the observed 7 weeks of treatment, was less than 
1 mm and hence considered to be negligible.  
 
Prostate displacement relative to the pelvic bones: internal motion 
As displayed in Table 1, the internal prostate motion, measured relative to the bony 
structures, appeared to be comparable for both patient groups, irrespective of the use of an 
ERB. The systematic deviation (Σpr-bo ) ranged from 0.7 – 2.8 mm (1 SD) for the No-ERB 
group, and 1.0 – 3.0 mm (1 SD) for the ERB group.  
      
Table 1. 
 Internal gland motion: prostate displacements relative to bony structures, without balloon (No-ERB) 
and with  balloon (ERB).  
Abbreviations: Σpr-bo = systematic deviation; σpr-bo = random, day to day, deviation; Mpr-bo = overall mean deviation 
 
Σpr-bo
Systematic 
(1 SD) 
σpr-bo
Random 
(1 SD) 
Μpr-bo 
Mean 
Σpr-bo
Systematic 
(1 SD) 
σpr-bo
Random 
(1 SD) 
Μpr-bo 
Mean 
 
 
No ERB (N=30) ERB (N=22) 
x (left - right) 0.7 mm 1.3 mm - 0.6 mm 1.0 mm 
(p= 0.07) 
1.5 mm 
(p=0.19) 
- 0.5 mm 
y (sup - inf) 2.8 mm 1.9 mm 0.3 mm 3.0 mm 
(p= 0.71) 
1.8 mm 
(p= 0.41) 
0.7 mm 
z (ant - pos) 2.2 mm 2.5 mm -1.3 mm 2.5 mm 
(p=0.51) 
2.8 mm 
(p=0.39) 
- 0.7 mm 
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The random day-to-day prostate position variation (σpr-bo ) ranged from 1.3 – 2.5 mm (1 SD) 
for the No-ERB group and 1.5 – 2.8 mm (1 SD) for the ERB group. The day-to-day variation 
was largest in the anterior-posterior direction (i.e. towards the rectum): 2.5 mm and 2.8 mm for 
the No-ERB and ERB group, respectively. Application of statistical tests indicates no 
significant difference between the ERB and No-ERB groups: the p-values listed in Table 1 do 
not reach significance, neither for systematic deviations (Σpr-bo ) nor for random variations 
(σpr-bo ). 
The overall mean deviation of the prostate position relative to bone (pr-bo ) was ≤ 1 
mm, except in the AP direction for the No-ERB group (1.3 mm). In Fig. 3, all the measured 
prostate displacements in the sagittal plane (i.e. superior-inferior and anterior-posterior 
direction), with and without ERB are displayed.  
 
 Fig. 3.  
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Scatter plot of the internal prostate displacements, relative to the bony structures, in the sagittal plane, 
with ERB (left) and without ERB (right). Each point represents the displacement measured during a 
treatment fraction, after correction. The superimposed ellipse indicates the 95 % confidence region of 
the marker displacements (solid line).  
 
Also this representation of the results, as indicated by the 95 % confidence region 
calculated from the data, indicates that there is no difference in the geometrical variations 
between the No-ERB and ERB group.  
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Prostate displacement relative to the treatment isocenter 
In Table 2, the remaining prostate position variations, after correction, relative to the 
treatment isocenter are displayed.  
 
Σpr-iso
Systematic 
(1 SD) 
σpr-iso
Random 
(1 SD) 
Μpr-iso 
Mean 
Σpr-iso
Systematic 
(1 SD) 
σpr-iso
Random 
(1 SD) 
Μpr-iso 
Mean 
After Off-line 
Correction 
 
No ERB (N=30) ERB (N=22) 
x (left -right) 1.6 mm 
(p= 0.02) 
2.8 mm - 0.3 mm 1.3 mm 
(p= 0.005) 
3.1 mm 0.0 mm 
y (sup -inf) 1.3 mm 
(p< 10-4) 
2.3 mm 0.2 mm 1.8 mm 
(p= 0.003) 
2.6 mm 1.3 mm 
z (ant - pos) 1.5 mm 
(p< 10-4) 
4.3 mm -0.6 mm 1.8 mm 
(p= 0.0001) 
4.7 mm - 0.4 mm 
 Table 2.  
 Prostate displacements relative to treatment isocenter, without balloon (No-ERB) and with balloon 
(ERB), after correction (a). Retrospectively calculated systematic deviations for both groups, with 
corrections undone (b). The p-values given for the systematic displacements are the results of F-tests 
comparing the deviations with and without corrections. 
Abbreviations: Σpr-iso = systematic deviation; σpr-iso = random, day to day, deviation; Mpr-iso = overall mean deviation  
 
Here, the systematic and random prostate deviations were comparable for both patients 
groups as well. The systematic deviation (Σpr-iso ) ranged from 1.3 – 1.6 mm (1 SD) for the 
No-ERB group and 1.3 – 1.8 mm (1 SD) for the ERB group. The random day-to-day prostate 
deviation (σpr-iso) ranged from 2.3 – 4.3 mm (1 SD) for the No-ERB group and 2.6 – 4.7 (1 
SD) mm for the ERB group. In the ERB and No-ERB group, both systematic and random 
variations were largest in the anterior-posterior direction. The overall mean prostate position 
relative to the treatment isocenter (Mpr-iso ) was ≤ 1 mm, except for the superior-inferior 
direction (1.3 mm) in the ERB group. Application of an F-test to compare the systematic 
variations after corrections and with the corrections undone shows that that the effect of the 
corrections is highly significant, for both the No-ERB and ERB group and for all directions. 
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In Fig. 4, the means and the standard deviations of the prostate position relative to the 
treatment isocenter are displayed for both groups per patient.  
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Fig. 4. 
Mean prostate displacements per patient in the three axial directions, after off-line correction, without 
(No-ERB) and with endorectal balloon (ERB). The error bars represent the standard deviations (1SD), 
i.e. the random, day-to-day, interfractional prostate gland motion.  
 
 
The standard deviations represent the random variations for each patient. With or 
without balloon, there was no overall difference in the day-to-day position of the prostate 
gland. Within each group there were patients with relative large and small random deviations 
in the individual directions, ranging from ≈ 1 mm up to > 5 mm, irrespective of the presence or 
absence of the ERB. Rotations around the AP axis are practically absent. The respective 
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random and systematic rotations around the LR axis appear to be 0.4 and 0.9 degrees and 0.7 
and 1.3 degrees for the No-ERB and ERB group, respectively.  
 
Evaluation of daily portal images and movie loops 
 Evaluation of the daily portal images clearly showed presence of transient and passing 
gas in the rectum in both patient groups, resulting in deformations of the outer rectal wall 
contour. For the ERB group, it appeared that the position of the balloon varied throughout the 
treatment (i.e. depth of insertion) and gas bubbles could be observed beside the balloon, 
giving an extra extension of the rectum and displacement of the prostate. In both groups, in 10 
– 20 % of all daily treatment fractions the portal images showed passing gas and air bubbles in 
the rectum. As an example, the measured prostate deviations, relative to the bony structures, 
for one patient with ERB (Fig. 5a), and four portal images are displayed (Fig. 5b-e). Although a 
correction was performed, from fraction four on, there was still a large interfraction day-to-day 
prostate position variation throughout the next treatment fractions. In fraction number five, the 
portal images (Fig. 5b and 5d) showed evidently the presence of a gas bubble around the 
ERB. This probably caused the large deviations, mainly in the LR (5 mm) and AP (3 mm) 
directions. In fraction 9, no gas bubble, beside the ERB, was present (Fig. 5c and 5e). Here 
the deviations were relatively small (≤ 1 mm) .    
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Fig. 5.  
Measured prostate position deviations, relative to the bony structures, in the LR, SI and AP direction for 
all treatment fractions, for one patient, treated with an endorectal balloon. The measured deviations for 
these fractions are indicated (a). Portal images for fraction number 5 (b, c), fraction number 9 (b, d) are 
displayed. The endorectal balloon and surrounding air are indicated, as one contour (dashed line). 
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Fig. 6. 
Cumulative frequency distributions of mean 3D prostate displacements (vector lengths), for ERB group 
(left) and the No-ERB group (right). The solid curves represent the distribution of vector lengths after 
(offline) position correction; the dotted curves are the distributions of vector lengths without correction. 
 
 
Effect of off-line correction on prostate position 
Application of the No Action Level off-line correction protocol reduced  the systematic 
prostate deviations. The average number of corrections per patient throughout the treatment, 
according to the described off-line protocol, was nearly equal for the No-ERB and the ERB 
group; 1.6 and 1.8, respectively. Retrospectively, the systematic prostate displacements, 
relative to the isocenter were calculated for both groups, with the corrections undone (Table 
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3b). In comparison with the data from Table 3a, there is a reduction of fifty percent in the 
systematic interfraction prostate deviation due to the correction protocol, for all orthogonal 
directions and in both investigated patient groups. For example, in the anterior-posterior 
direction the resulting systematic prostate deviation is reduced for the no-ERB group from 3.9 
mm to 1.5 mm (1 SD), and for the ERB group from 4.5 mm to 1.8 mm (1 SD). In Fig. 6, the 
mean 3D displacements are displayed in a cumulative frequency distribution, for the ERB and 
No-ERB groups. The applied correction strategy had a comparable effect in both groups. The 
overall mean 3D deviation (vector length) was reduced from 6.4 mm to 2.8 mm for the ERB 
group and from 5.2 mm to 2.4 mm for the No-ERB group, respectively. After correction, the 
percentage of patients, having a mean 3D deviation ≥ 5 mm, was reduced from 68 % to 5 % 
for the ERB group, and from 67 % to 0 % for the No-ERB group. There was, as expected, no 
reduction of random deviations due to this off-line protocol. 
The effectiveness of the off-line corrections in reducing the systematic prostate position 
variations and the lack of effect of the endorectal balloon was confirmed by ANOVA tests. The 
off-line corrections in the LR and SI directions proved to be significant at p = 0.02 and p = 
0.0002, respectively. The higher p-value ( p =  0.07, not statistically significant) in the AP-
direction might be caused by the fact that the random variations (due to prostate motion) are 
highest in this direction. The presence of the balloon was not significant in the LR and AP 
directions and had a p-value of 0.027 in the SI-direction, associated with a somewhat higher 
value of pr-iso in the ERB group. 
 
Workload, personnel and patient experiences  
The application and removal of the ERB was performed by trained therapists. Every 
day a new ERB was used and lubrication facilitated a smooth rectal introduction. Overall 
patients’ acceptance of the ERB was good. Extra time was taken to explain the background of 
the ERB to the individual patient. Eighteen of the 22 ERB patients experienced more local anal 
irritation, grade 1 or higher, compared to the No-ERB group. This resolved within 3 weeks after 
treatment, in all patients. In two cases lidocaine cream was prescribed and scored as grade 2 
anal irritation. One patient, with hemorrhoids, stopped using the ERB, due to excessive anal 
irritation and hemorrhoid bleeding and was scored as grade 3 irritation. This patient was 
excluded from the analysis. For this patient, a new CT-scan, without ERB, and treatment plan 
were made and patient resumed treatment within two days. Since then, painful and bleeding 
hemorrhoids were considered to be a contra-indication for the ERB. 
On the accelerator, an extra three minutes per treatment fraction were necessary for 
the ERB procedure. For a No-ERB prostate treatment, a standard time slot of 10 min is 
booked. For the ERB prostate treatment, we now book 15 min per fraction. As described 
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earlier, the off-line portal imaging and correction protocol did not prolong our treatment time on 
the accelerator. For the correction procedure, in total about 40 min per patient is needed for 
administrative preparation, verification, and data registration (20). 
 
DISCUSSION 
In this study, the interfraction prostate gland position variations were followed on a daily 
basis by registration of fiducial gold markers, in patients treated with and without an ERB. In a 
review paper by Langen et al (1), a summary is given of known prostate motion data. The SDs 
for prostate motion, relative to the bony structures are given, but no separate data are given 
for the systematic and random organ displacements. In the present study, both random and 
systematic prostate gland displacements were calculated, because of the different impact on 
the choice of correction strategy and the impact on choice of treatment margins. Stroom et al. 
(18) and Van Herk et al. (19) proposed recipes for calculation of the CTV – PTV margins to 
account for both systematic (Σ) and random errors (σ). Their margin rules were 2Σ + 0.7σ and 
2.5Σ + 0.7σ, respectively. Thus, reduction of the systematic prostate displacement has the 
largest influence on the margin required.  
 
Fiducial gold markers 
To evaluate the daily prostate motion, fiducial gold markers were implanted in the 
prostate gland. This has been proven to be a safe and reliable method (5-10). We 
encountered no serious complications so far in over 180 patients. The insertion can be 
performed in about five minutes by an experienced urologist. One of the major concerns was if 
the markers would migrate over the course of treatment. Like other investigators, we found no 
significant marker migration (23;24). The gold markers are well visible on the portal images 
and trained therapists can execute quickly and accurately the image registration. 
 
Endorectal balloon and internal prostate motion 
Other groups have reported previously about the clinical benefits of different types of 
ERB’s, in terms of patients acceptance and reduced rectal toxicity (12-17;25). Teh et al. 
(14 ;15) investigated the combination of IMRT and an ERB. The procedure was feasible and 
produced favorable acute toxicity profiles. Data derived from McGary et al. (12) showed, in 10 
patients with a rectal balloon in situ, an internal prostate motion, measured by CT-CT image 
fusion and relative to the bony anatomy, for the superior-inferior direction with an overall mean 
of 0.43 mm and a standard deviation of 3.54 mm, representing the systematic error. Motion in 
the AP and LR direction was minimal, on the order of the measurement uncertainty (≈ 1 mm). 
No specific data were given on the distribution of the systematic and random errors for the 
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separate directions (12). Patel et al. (17) demonstrated the clinical feasibility and the rectal 
wall sparing effect of an ERB. In seven patients, the prostate motion, relative to the pelvic 
bones was measured. The mean standard deviations, representing the systematic errors, 
were 2.6 and 3.1 mm in the AP and SI directions, respectively. The LR deviation was 1 mm (1 
SD) (17). These data are comparable to our data (see Table 1). Also here, no data were 
presented on the random, day-to-day variation. D’Amico et al. (13) found a reduction of 
intrafractional prostate motion, during a measured 2-min time interval, by an ERB. The 
maximum displacement, for any direction, was reduced from 4 to 1 mm during the 2-min time 
interval, by applying an ERB. The mean displacement was reduced from 1.8 to 1.3 mm. No 
data of interfraction motion were presented (13). The group of Wachter et al. (16) in Vienna 
has a large experience in the use of an ERB for daily prostate treatment. With the use of their 
balloon, the maximum displacement larger than 5 mm, in the AP direction, was reduced from 
8/10 patients to 2/10 patients. Displacements in other directions could not be measured (16). 
 
Effect of endorectal balloon and correction protocol  
 In our study, we analyzed the effect of an ERB on the systematic and random, day-to-
day, interfraction prostate gland displacements, for all three directions in combination with an 
EPID-based correction protocol. The effect of the ERB on the position of the seminal vesicles 
could not be determined. To evaluate this, markers should be implanted into the seminal 
vesicles or repeated daily CT scans should be obtained. 
It was expected that introduction of the ERB could in addition reduce the internal 
prostate motion, mainly by reducing the random day-to-day variation. First, it was expected 
that motion could be reduced by fixation of the prostate gland between the pubic bone and the 
air-filled balloon, as seen in Fig. 1b. Secondly, the filling of the rectum by the balloon with a 
fixed amount of air, should eliminate the prostate motion due to variable rectum volume, e.g. 
by stool and or gas. However, our data show that the random day-to-day variation of the 
prostate position relative to the bony structures is not reduced with a balloon (Table 1). 
Especially for the AP direction, the random error is still relatively high, 2.8 mm (1 SD), 
compared to 1.5 mm and 1.8 mm for the LR and SI directions, respectively. For both groups, 
with or without an ERB, the overall mean internal organ motion, determined over all measured 
fractions, is low (0.5 – 1.5 mm). With balloon, for all directions, the overall mean displacement 
is less than 1 mm, comparable to the data of McGary et al. (12) and Teh et al.(15). This means 
that, although the overall prostate displacement is low, the interfraction displacements can be 
considerably high, as demonstrated in this study. 
The movie loops of all daily portal images of the investigated patients showed in 10 – 
20 % of the treatment fractions clearly the presence of gas bubbles, equally in both groups, 
(Fig. 5). So, the assumption that an ERB gives a constant rectal filling, and therefore 
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immobilizes the prostate gland, could not be confirmed in this study. The day-to-day 
interfraction prostate motion is still present, mainly in the direction towards the rectum. This is 
in agreement with observations form Husband et al. (26). In their study, the ERB used for MR 
imaging did not reduce or prevent significant rectal activity, causing prostate motion. So also 
the presence of an ERB may cause rectal wall activity and possibly pelvic muscle tension 
alterations, causing prostate motion. 
For the prostate position, relative to the treatment isocenter (Table 2), the systematic 
errors with or without balloon are reduced to less than 2 mm (1 SD), due to the NAL off-line 
correction protocol. With a minimum of extra workload and less than 2 corrections per patients, 
it was possible to reduce the systematic organ displacement by a factor two, to 1.3 – 1.6 mm 
(1 SD) (Table 2). This is in line with data from Nederveen et al (8). Because the corrections 
are applied on the fiducial markers, Σpr-iso appears to be smaller than Σpr-bo. The random, day-
to-day displacements remain relatively large; 3.1 mm, 2.6 mm and 4.7 mm (1 SD) for the LR, 
SI and AP directions, respectively. That σpr-iso comes out somewhat larger than σpro-bo can 
be understood from the fact that the former contains both the set-up variations and the 
variations due to internal prostate motion. Again, the day-to-day variation for the AP direction, 
towards the rectum, is the largest. A treatment planning study has shown that prostate motion 
in this direction can cause a significant reduction of dose to the CTV (27). Fig. 3 and 4 also 
show no marked differences between the group with and without rectal balloon. Also rotations 
did not differ in both groups. In Fig. 4, the individual mean and random displacements for all 
three directions are displayed; in both groups there are great inter-individual differences in 
organ motion. 
The investigated ERB, originally designed for MR imaging, was not developed for 
specific prostate immobilization during radiotherapy. Modification of shape (i.e. more anatomic 
conformation or greater length), amount of air inflated, or ERB in combination of medication to 
reduce bowel movements, may be opportunities to reduce the presence of gas and extra 
bowel motion to reduce the day-to-day prostate motion. This should be topic of further 
investigation.   
As shown in the present study, an off-line correction protocol is not suitable to correct 
for random (day to day) prostate displacements, observed with this ERB. On-line correction, 
with organ position verification and correction prior to the actual treatment, is apparently the 
only way to reduce these random prostate position variations. Daily prostate localization by the 
so-called BAT ultrasound system (NOMOS corporation, Sewickley, PA), is widely used for on-
line non-invasive prostate verification and correction (11). Recently, van den Heuvel et al. 
assessed the efficacy and accuracy of this system. They concluded that the ultrasound-based 
 59
 
Effect of endorectal balloon and off-line correction on daily prostate position 
adjustment showed only significant improvement in the superior-inferior direction, but not for 
the other two directions (28).  
Increasingly, implanted fiducial gold markers in combination with daily portal imaging 
are used for verification and correction strategies. On-line correction strategies, daily 
executed, have been tested in clinical practice and have shown to be effective in reducing the 
positioning variations (6). In Nijmegen we have initiated such an on-line marker-based 
correction protocol. Reliable automated marker detection systems have been developed and 
are helpful  to reduce the workload of these daily online procedures (29).  
Although the ERB appeared not to be effective in immobilizing the prostate or reducing 
position variations, it can play an important role in the further development of radiation 
treatment of prostate cancer as it may still be an effective tool in reducing rectal toxicity by 
pushing the dorsal rectal wall away from the PTV (30). These possible positive effects of the 
ERB will be a topic of future studies. 
 
CONCLUSIONS 
  This study investigated the effect of an ERB on the daily prostate motion. Implanted 
gold markers and an off-line EPID-based correction protocol were used to verify and correct 
the prostate gland position in a group of patients treated with an ERB and a group irradiated 
without an ERB. The correction protocol reduced effectively the systematic errors to less than 
2 mm (1 SD). Although the overall mean prostate position deviation was less than 1 mm, large 
random, interfraction prostate displacements, were observed, even with an ERB inserted. 
These large variations can be partly explained by the presence of gas and stool in the rectum 
besides the balloon. The largest day-to-day displacement was in the anterior-posterior 
direction, towards the rectum: up to 4.7 mm (1 SD). These random deviations in this direction 
are high in relation to the post-correction systematic prostate position deviations. 
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The use of a bladder scanner in prostate cancer irradiation 
 
ABSTRACT 
 
Purpose: To investigate the use of a bladder ultrasound scanner in achieving a better 
reproducible bladder filling during irradiation of pelvic tumors, specifically prostate cancer. 
Methods and Materials: First, the accuracy of the bladder ultrasound scanner relative to CT 
was validated in a group of 26 patients. Next, daily bladder volume variation was evaluated in 
a group of 18 patients. Another 16 patients participated in a biofeedback protocol, aiming at a 
more constant bladder volume. The last objective was to study correlations between prostate 
motion and bladder filling, by using EPID data on implanted gold markers. 
Results: A strong correlation between bladder scanner volume and CT volume (R = 0.95) was 
found. Daily bladder volume variation was very high (1 SD = 47.2%). Bladder filling and daily 
variation did not significantly differ between the control and the feedback group (47.2% and 
40.1% respectively). Furthermore no linear correlations between bladder volume variation and 
prostate motion were found.  
Conclusions: This study shows large variations in daily bladder volume. The use of a 
biofeedback protocol yields little reduction in bladder volume variation. Even so, the bladder 
scanner is an easy to use and accurate tool to register these variations.
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INTRODUCTION 
 In most pelvic cancers, better local control is achieved with a higher radiation dose (1-
3), however this is limited by the tolerance of the normal tissues (4-9). One way of achieving 
better local control, without increasing normal tissue damage, is by escalating the dose while 
conforming the dose distribution and gradient to the target volume. Dose-escalated three-
dimensional conformal radiotherapy (3D-CRT) has shown to be effective (9-11) and intensity 
modulated radiotherapy (IMRT) is very promising (12, 13) in achieving these goals.  
 Another way of limiting toxicity is by controlling the internal anatomy, e.g. irradiation 
with a full bladder. With bladder filling part of the bladder moves away from the target volume 
resulting in a smaller irradiated bladder volume. This has been shown for irradiation of bladder 
cancer and prostate cancer (14-16). Because a dose-volume relation for bladder toxicity 
exists, one can increase the prescribed dose while maintaining the same bladder toxicity 
probability (4, 5, 13, 14). Furthermore, a full bladder moves the small intestine out of the 
irradiation field (17, 18). As a result of the strong dose-volume relation for small bowel toxicity, 
this also leads to a decrease of intestinal toxicity, e.g. chronic diarrhea (4, 8). For these 
reasons, patients, who have to be irradiated for a pelvic tumor, are asked to have a full bladder 
during irradiation. However, large variations in bladder volume throughout a treatment period 
have been found (14, 15, 19-22). The observed variations cause a problem for the estimation 
of dose volume histogram based toxicity probabilities, because this assessment is only based 
on one measurement. (14, 15). Furthermore, large bladder volume variations also increase 
interfraction motion of organs like the prostate and the uterus (19-21, 23-26).  
 To date, no reports about bladder volume variation measured on a daily basis have 
been published. Nor have there been studies striving to achieve a more constant bladder 
filling, by using biofeedback. The main goal of this study was to quantitate bladder filling 
variation on a day by day basis during irradiation, using a portable ultra-sound based bladder 
volume scanner (BS). This machine was originally developed and validated for the 
measurement of bladder residue after micturition. Therefore the first objective was to validate 
the BS for larger bladder volumes. The next objective was to evaluate the usefulness of a 
biofeedback protocol, in achieving a more constant full bladder. Results of this protocol were 
compared to results from patients that were treated without biofeedback. In order to have a 
homogeneous patient population, a cohort of prostate cancer patients was chosen. The last 
goal was to evaluate the relationship between bladder filling variation and prostate 
displacement. 
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METHODS AND MATERIALS 
 
Patients 
 From April 2003 until August 2005, 60 prostate cancer (T1-3N0M0) patients were 
included in the study. From all patients informed consent was obtained. In the BS validation 
phase 26 patients were enrolled. These patients were selected if curative (primary or salvage) 
radiotherapy was planned. The remaining 34 patients (Table 1) participated in the intervention 
phase of the study. Patients were specifically selected on their ability to maintain a full bladder.  
 Control group No.(%) 
 Feedback group 
No. (%) 
Gleason grade    
 4-6 11 (61) 8 (50) 
 7 4 (22) 5 (31) 
 8-10 3 (17) 3 (19) 
cT- Stage  (TNM 6th ed.)    
 1 3 (17) 3 (19) 
 2 8 (44) 4 (25) 
 3 7 (39) 9 (56) 
PSA    
 0-10 8 (44) 7 (44) 
 10-20 8 (44) 3 (19) 
 >20 2 (11) 6 (38) 
Acute toxicity (RTOG/EORTC(28))   
GU   
 0 3 (17) 3 (19) 
 1 13 (72) 10 (62) 
 2 2 (11) 3 (19) 
GI   
 0 5 (28) 2 (13) 
 1 7 (39) 9 (56) 
 2 6 (33) 5 (31) 
Age mean (range) 70.7 (58-78) 70.0 (56-78) 
Table 1 
Patient characteristics for the control and feedback group. With respect to these characteristics, no 
significant differences between both groups were found. 
 
 
Main exclusion criteria were disorders possibly interfering with correct bladder scanning (Table 
2). Of these 34 patients, 16 were given daily feedback. The results of this group were 
compared to those of the 18 patients who did not receive feedback. Assignment to a group 
was done on a consecutive basis before the patient was asked to participate. 
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Inclusion Exclusion 
Prostate carcinoma Micturition frequency > 1/h 
Primary curative radiotherapy Nycturia >4x 
Gold marker insertion possible Urinary incontinence 
Informed consent Median laparotomy scar interfering with bladder scanning 
 Aberrant bladder form (e.g. diverticula) 
 Lymfocele interfering with bladder scanning 
 Social or psychological problems interfering with protocol compliance 
Table 2 
Inclusion and exclusion criteria. 
 
Patient preparation and treatment  
 All patients received three to six months neo-adjuvant hormonal therapy. Under trans-
rectal ultrasound guidance, four fine gold markers (1 mm diameter, 7 mm length) were 
inserted into the prostate by an urologist. After at least one week, to resolve swelling of the 
gland as a result of marker implantation, a planning CT scan (AcQsim® spiral CT; Philips 
medical systems, Bothell, WA, USA) was obtained at 3 mm slice thickness. According to 
protocol (as in many other centers in the Netherlands) patients were advised to have a 
comfortably full bladder prior to CT scanning and daily treatment. A “comfortably full” bladder 
is described by the physicians as having definite but easily tolerable micturition urge. CT 
scanning and radiation treatment were performed with patients in a supine position. For more 
details on patient positioning en treatment setup see van Lin et al. (27). A beams-eye-view 
based 3D-conformal treatment plan (orthogonal 4-field technique) was designed. Treatment 
planning was done with Pinnacle3® version 6.2b (Philips medical systems, Andover, MA, 
USA). The planning target volume consisted of the prostate only or prostate and seminal vesicles 
with a 7 mm 3D margin. Prescribed dose was 67.5 Gy to the isocentre, in 30 fractions (four times 
a week). Patients were seen weekly by the radiation oncologist, and acute urinary and rectal 
toxicity was scored using the RTOG / EORTC scale (28). 
 
 
Bladderscan measurement validity 
 For bladder volume measurements, a portable automated ultrasound based urinary 
bladder volume scanner (BS) was used (BVI 3000 BladderScan®; Diagnostic Ultrasound 
Europe B.V., IJsselstein, The Netherlands). This device is equipped with a digital display 
screen and a handheld scanning head. The scanning head is positioned at the midline above 
the pubic symphysis (Fig. 1). When activated, the 2-MHz  Fig. 1 Photograph of the bladderscan 
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.transducer rotates automatically by 15° increments and provides 12 cross-sectional areas. 
From these cross-sectional areas the bladder volume is calculated automatically. This 
machine was originally developed to measure bladder residue after micturition. Therefore, we 
first tested the accuracy of the bladder scanner in our patient population (with a larger variation 
in bladder volume). As the gold standard the bladder volume derived from the planning CT 
scan (denoted as VCT) was used. Delineation of the bladder on the CT scan was performed 
by the attending physician and checked by one observer (M.S.).  
 BS measurements were made at most ten minutes before the planning CT scan. Two 
trained technologists each performed three BS measurements. The mean of these 
measurements will be denoted as Vbl-scan. For evaluating the correlation between Vbl-scan and 
VCT, linear regression analysis was performed. Bladderscan interobserver variability (denoted 
as Δinter) was defined as the absolute value of (A-B)/C*100%. Where A and B are the mean of 
the measurements of respectively technologist A and technologist B for one patient. C is the 
mean of measurements A and B. BS intra-observer variability (denoted as σintra) was defined 
as SDmeasurements/Meanmeasurements*100% for one observer and one patient.  
 
Bladder volume measurement during treatment 
 In the intervention phase of this study, daily variation of the bladder volume during 
irradiation was investigated. Directly before the start of every treatment session, specially 
trained technologists performed three BS measurements. The mean of all measurements of a 
patient, performed during the treatment period is denoted as Vtreatm-tot. Vtreatm-rel is then defined 
as Vtreatm-tot relative to VCT. As measure of daily variation of bladder filling the SD of Vtreatm-tot 
(denoted as σbl) is used, whereas σbl-rel is defined as σbl relative to Vtreatm-tot.  
  
We also evaluated whether 
patients could accurately predict their 
bladder filling. A four point scale for 
micturition urge was used (Table 3). 
Patients were asked to score 
micturition urge at the same moment 
as bladder scanning was performed. 
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Biofeedback protocol 
 A biofeedback protocol, aimed at 
achieving a more constant bladder volume, 
was tested in a group of 16 patients. The goal 
of giving feedback was to improve the patients 
ability to distinguish between an almost 
empty.and moderately full bladder.    
Score Description 
1 “Just urinated / no urge whatsoever” 
2 “Maybe some urge” 
3 “Easily tolerable but definite urge” 
4 “Barely tolerable urge” 
Table 3 Micturition urge score 
The feedback consisted of telling the patient his daily bladder volume together with a drinking 
advice. The advice to drink more was given when the daily volume was < 80% of Vbl-scan. When 
patients had a bladder volume ranging from 80 to 120% of Vbl-scan they should drink the same 
amount the next day. When the measurement was >120% of Vbl-scan patients were advised to 
drink less. This feedback was given, every treatment day, by the technologists, directly after 
measuring the bladder volume.  
 
Prostate motion and relation to bladder filling 
 During the intervention phase the relation between changes in bladder filling and 
prostate displacement was studied. Prostate motion data were derived from our standard used 
prostate position verification and correction protocol. This gold marker and electronic portal 
imaging device (EPID) based correction protocol has been described earlier in detail (29). In 
short, this protocol uses digitally reconstructed radiographs (DRR) derived from the planning CT 
scan as reference images. EPID images made during treatment are registered to the DRR’s, 
using the intraprostatic markers as fiducials. The registration measures the deviation of the 
prostate relative to the DRR in the three orthogonal directions. For correction the so-called No 
Action Level (NAL) off-line correction protocol is applied, as described by de Boer et al (30). 
This protocol strives to minimize systematic errors, with the use of as few EPID measurements 
as possible. 
 As measure of systematic prostate deviation, we have used the mean of all EPID 
measurements (in one direction) during treatment of one patient (denoted as Mprost). Because the 
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NAL protocol minimizes the systematic prostate deviation, all calculations of Mprost were 
performed with the corrections undone. As measure of systematic change in bladder filling the 
difference between Vtreatm-tot en VCT (denoted as Δtreatm-tot) was used. Linear regression analysis 
was performed to study the relation between these values. To describe the random prostate 
motion, the SD of Mprost was used (denoted as σprost). In order to arrive at the most accurate 
estimate of random prostate deviation error, σprost was also calculated with the corrections 
undone (30, 31). For random variation in bladder filling, values of σbl were taken. To find any 
relation between σprost and σbl, linear regression analysis was performed.  
 
Workload, personnel and patient experiences  
 The time needed to train the technologists in the use of the BS was recorded. 
Furthermore an estimation of the additional workload was made. Per patient the extra time 
needed on the accelerator for bladder scanning and administration was recorded. Also specific 
experiences from patients in both groups, and the attending technologists were collected. 
 
Statistical Analysis 
 Mean volumes and SD’s were compared by applying the t-test. If F-testing showed a 
significant difference in variance or Kolmogorov-Smirnov testing showed a non-Gaussian 
distribution the Mann-Whitney U test was used. Linear regression analysis was performed to 
quantitate correlations between various variables. In the analysis of contingency tables 
Fischer’s exact test was applied. Differences were considered significant if two-tailed p-values 
were lower than 0.05. For statistical analysis SPSS® version 12 (SPSS inc., Chicago, Illinois, 
USA) was used. 
 
RESULTS 
Bladderscan measurement validity 
 Using the data of the first 26 (5 postoperative) patients BS test characteristics were 
determined. Based on a total of 156 BS measurements, values of mean Δinter and mean σintra 
were 11.3% and 6.3% respectively. Interobserver difference in delineation of the bladder on 
CT never exceeded 10 ml. Furthermore a strong correlation (R = 0,95) between VCT and Vbl-
scan was found, indicating a high accuracy of the BS (Fig. 2). 
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 Fig. 2 
Linear correlation graph showing Vbl-scan (bladder volume measured with the 
bladderscan) vs. VCT (bladder volume derived from the CT scan). 
 
 
 
Bladder volume measurement during treatment and effects of the biofeedback protocol 
  On average bladder filling during treatment (Vtreatm-tot) was better in the feedback group 
relative to the control group. Also, it approached the values measured on the planning CT 
scans more closely (Vtreatm-rel). Furthermore, daily bladder volume variations (σbl-rel) were 
somewhat smaller in the feedback group. These improvements were, however, not statistically 
significant. A summary of these measurements is shown in Table 4. Besides only about 1 in 
every 4 patients could participate in the intervention phase, because of the in- and exclusion 
criteria.  
 n Vtreatm-tot (ml) 
mean (1SD) 
VCT (ml)  
mean (1SD) 
Vtreatm-rel (%) 
mean (1SD) 
σbl-rel (%)  
mean (1SD) 
feedback group 16 313 (156) 367 (202) 94.6 (25.3) 40.1 (16.1) 
control group 18 250 (149) 348 (237) 83.2 (43.8) 47.2 (15.6) 
p-value  0.24 0.81 0.38 0.20 
 
Table 4 
Summary of bladder volume measurements during treatment. P-values are derived from t-testing of the 
differences between the control and feedback group. 
Abbreviations: Vtreatm-tot = the mean of all bladderscan measurements during treatment; VCT = the 
bladder volume derived from the CT-scan.;Vtreatm-rel = Vtreatm-tot relative to VCT.; σbl-rel = the SD 
of Vtreatm-tot relative to Vtreatm-tot. 
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 A weak but significant correlation (R = 0.31) between subjective urge score and 
bladder volume was found, although a large intra- and inter-patient variance in prediction of 
bladder volume was seen (Fig. 3). There was no indication that patients in the feedback group 
performed better in this respect (data not shown). 
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Fig. 3 Linear correlation graph showing micturition urge score versus relative bladder volume. Relative 
bladder volume was calculated by dividing the volume measured with the bladder scanner by the 
volume measured on CT (VCT). 
 
  
 A negative time trend for bladder volume during irradiation was found. This time trend 
amounts to 31% bladder volume decrease (control group) during the whole treatment period. 
The decrease of bladder volume was less pronounced in the feedback group than in the 
control group (19% vs. 31%) but not significantly different (Fig. 4). 
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Table 4 
Summary of bladder volume measurements during treatment. P-values are derived from t-testing of the 
differences between the control and feedback group. 
Abbreviations: Vtreatm-tot = the mean of all bladderscan measurements during treatment; VCT = the 
bladder volume derived from the CT-scan.;Vtreatm-rel = Vtreatm-tot relative to VCT.; σbl-rel = the SD 
of Vtreatm-tot relative to Vtreatm-tot. 
 
Prostate motion and relation to bladder filling  
 The difference (Δtreatm-tot) in bladder filling during the treatment period (Vtreatm-tot) and the 
CT scan (VCT) did not correlate with systematic prostate position deviation (Mprost). For linear 
regression graphs see Fig. 5a-c. Furthermore no linear correlation between daily variation in 
bladder volume (σbl) and random prostate motion (σprost) was found (data are not shown). The 
highest correlation coefficient (R) found in these analyses was 0.22, indicating that only 5% (R 
square) of  variance in prostate position is caused by changes in bladder filling. 
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Workload, personnel, and patient experiences 
 Bladder scanner measurements were performed by trained technologists. Learning to 
use the bladder scanner usually took about 15 minutes. On the accelerator three minutes extra 
time were needed for three BS measurements. Overall acceptance and participation of the 
patients was good. In the feedback group some patients were so enthusiastic, that they had to 
be tempered not to become obsessed with attaining the “optimal” bladder volume. Acute 
toxicity was generally mild (no grade III toxicity). There was no difference in GU nor in GI 
toxicity between both groups (Table 1). 
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Fig 5.  
Bladder filling variance versus prostate position 
deviation. 
(a) Δtreatm-tot vs. Mprost in lateral direction 
(negative value means right direction), (b) Δtreatm-
tot vs. Mprost in craniocaudal direction (negative 
value means caudal direction), (c) Δtreatm-tot vs. 
Mprost in anteroposterior direction (negative value 
means anterior direction). 
Abbreviations: Δtreatm-tot = the mean volume 
during treatment minus volume derived from CT.; 
Mprost = the mean prostate deviation during 
treatment for one patient. 
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DISCUSSION 
Bladderscan measurement validity 
 In order to establish the accuracy of the bladder scanner in the whole range of bladder 
volumes, we tested the BS in 26 patients. We found the BS measurements to be very accurate 
in assessing bladder volume, and inter- and intraobserver variability were low. Our findings 
were comparable to other studies in which mostly relative small bladder volumes were used to 
validate the bladder scanner for other purposes (32, 33).  
 
Bladder volume during treatment 
 To date, there have been no reports about bladder volume variation measured on a 
daily basis. In the current study daily bladder volume measurements were made in a cohort of 
18 prostate cancer patients. We found daily bladder volume variation to be very high (1SD = 
47.2% for the control group). Furthermore, patients had a significant decrease of bladder 
volume during the irradiation period of about 30%. Other authors investigated changes in 
bladder volume using (at most once weekly) consecutive CT scans (see Table 5).  
Although bladder filling variations found in this study were high, they are comparable to values 
found by others (14, 15, 19-22). These authors report bladder filling variations ranging from 30 
to 50%. Also a trend towards decreased bladder filling over time was noted in several of these 
studies (14, 15, 22). 
 
Biofeedback protocol 
 In this study, a protocol, meant to achieve a more constant full bladder by means of 
giving simple biofeedback, was tested. On average, bladder filling during treatment (Vtreatm-tot) 
was better in the feedback group, relative to the control group. Also, it approached the values 
measured on the planning CT scans more closely (Vtreatm-rel). Furthermore, daily bladder 
volume variations (σbl-rel) were somewhat smaller in the feedback group. These improvements 
were, however, not statistically significant. Since the data hints at just a small improvement by 
the biofeedback protocol and only 1 in every 4 patients could be included, the beneficial effect 
of the biofeedback was deemed not clinically relevant in this 
 76
The use of a bladder scanner in prostate cancer irradiation 
 
 
Author 
No. of 
patients 
No. of 
scans 
Bladder filling variation 
Bladder volume decrease 
over time 
This study 18 daily 47% (1SD) 31% 
Lebesque et al. 
(14) 
11 3 33% (1SD) 28% 
 
Roeske et al. 
(21) 
10 weekly 30% (1SD) 
50% of patients increase 
50% of patients decrease 
Melian et al. 
(20) 
8 4 
“large” 
(no specific data were 
mentioned) 
- 
Antolak et al. 
(22) 
17 4 
“large” 
(no specific data were 
mentioned) 
16% 
Zellars et al. 
(19) 
24 2 51% - 
Fiorino et al. 
(15) 
9 weekly 
ratio smallest to largest 
volume = 3.8 
47% 
Table 5 Bladder filling variation as reported in the literature. 
 
specific subset of patients (i.e. prostate cancer patients) and recruitment of patients was 
ended. The absence of a statistically significant effect of the biofeedback protocol could be 
due to the relative small number of patients.  Another cause may be the baseline micturition 
problems most prostate cancer patients have. Although only patients with no, or minor 
micturition complaints were selected in an attempt to avoid this confounder. Also acute urinary 
and rectal toxicity could impair the ability of patients to maintain a constant full bladder. 
Whether this was truly a disturbing factor is questionable, because acute toxicity was limited to 
at most grade II and did not differ significantly between groups. The lack of improvement by 
the feedback protocol might also be the result of its subjective nature. Indeed, we did find a 
significant relation between the micturition urge score and bladder filling, but this relation was 
weak. Together with the extreme variance between and within patients, such a score then 
seems quite useless. 
 Based on these findings, only asking a patient to have a full bladder during irradiation 
will not result in a constant bladder filling. More objective protocols, prescribing a certain 
amount of fluids to be drunk before irradiation, or minimum time between last micturition and 
irradiation, have reported comparable large variances in bladder volume (14, 15, 20).  
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 With the absence of effective protocols to ensure a full bladder, one can only screen 
patients for large bladder filling variations. One could make weekly or daily CT scans, but the 
use of the bladder scanner as a screening tool would be a lot easier and more cost-effective. 
This way only patients with large differences between bladder volume during treatment and 
during simulation could be identified for a repeat CT scan. From this CT scan, more accurate 
treatment plans and toxicity probabilities could be derived. Alternatively the bladder scanner 
could be used in a more directive protocol. Such a protocol would start for example by booking 
several patients together in one large time slot. The patient with the best bladder volume 
would be irradiated first. Patients with inadequate bladder filling could then drink extra fluids to 
increase their bladder volume. 
 
Prostate motion and correlation with bladder filling 
 Prostate motion as measured with our EPID protocol is in the same range as reported 
in the literature (21-24). In this study, the difference between mean treatment bladder volume 
and CT volume did not correlate significantly with mean prostate deviation. Furthermore no 
significant correlation between daily variation in bladder filling and random prostate motion 
was found. These findings seem to contradict reports of other authors, which find at least weak 
correlations between bladder filling variation and prostate position (19, 21, 23-26). One reason 
could be that, in our correlation analysis, mean values and SD’s of prostate position and 
bladder volume changes over the entire treatment were used. As the NAL protocol only yields 
limited prostate position data (i.e. not daily EPID measurements), we have chosen to use 
mean values. Compared to correlating daily bladder volume with daily prostate position 
deviation, this is quite a coarse method, and could have easily obscured the relation between 
prostate motion and changes in bladder filling. Authors using values measured on the same 
day did indeed find a weak correlation between prostate motion and changes in bladder filling 
(19, 21, 23-26). Many authors also report far stronger correlations between rectal filling 
changes and prostate motion (19, 21-26). Because rectal filling was not evaluated in this 
study, no estimation of the confounding effect of rectal filling on prostate position deviation can 
be made.  
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CONCLUSION 
This study shows bladder volume variation to be very high (1SD = 47.2%). Using the 
bladder scanner in a simple biofeedback protocol does not yield a significant decrease in 
bladder filling variation (1SD = 40.1%). This underlines the shortcomings of a protocol, in 
which patients are only asked to have a full bladder during irradiation. Even so, the bladder 
scanner is an easy to use and accurate tool to register bladder volume variations. One could 
use it as a screenings tool to identify patients with large bladder filling variations for which then 
repeat CT scans and treatment plans could be made. 
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ABSTRACT  
Purpose: To investigate the dosimetric consequences and rectal wall (Rwall) sparing effect of 
three different endorectal balloons (ERBs) for 3-dimensional conformal radiotherapy (3D-CRT) 
and intensity-modulated radiotherapy (IMRT) for prostate cancer. 
Methods and materials: In 20 patients, four planning CT-scans were made, one without ERB 
and three with ERB1, 2 or 3 inserted. Two different planning target volumes (PTV) were 
defined: prostate only (PTV-P) and prostate plus seminal vesicles (PTV-PSV). 3D-CRT and 
IMRT planning techniques were used and the prescription dose was 78 Gy. In 284 treatment 
plans, the Rwall mean dose, the Rwall NTCP, and the absolute Rwall volumes exposed to ≥50 
Gy (V50) and ≥70 Gy (V70) were calculated. For spatial dose distribution analysis, inner rectal 
wall dose maps and dose surface histograms (DSH) were generated. 
Results: Each ERB was tolerated well. In case of 3D-CRT, each ERB showed a statistically 
significant reduction all of the measured parameters. ERB2 and ERB3 performed better than 
ERB1. In IMRT, a statistically significant reduction in the Rwall dose parameters could not be 
demonstrated for any of the ERBs. For 3D-CRT and IMRT, due to the rectal dilation, ranging 
from 8 to 20 cm in circumference, the ERBs resulted in reduction of the relative inner Rwall 
surface exposed to intermediate and high-doses.  
Conclusions: In 3D-CRT, any ERB showed a significant rectal wall sparing effect. ERB2 and 
ERB3 were superior to ERB1. For both 3D-CRT and IMRT, a reduction of the relative inner 
Rwall surface exposed to intermediate and high-doses was found, which may lead to reduced 
late rectal toxicity. Development of user- and patient-friendly ERBs is warranted to increase 
their acceptability. 
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INTRODUCTION 
Dose escalation in prostate radiotherapy can improve treatment outcome, especially for 
intermediate- and high-risk patients (1). Rectal toxicity is the major limiting factor in prostate 
dose escalation and it is related to the total radiation dose prescribed and the volume of the 
rectal wall receiving a high dose (2-4). One of the challenges in radiation therapy of the 
prostate is elevating dose without increasing rectal toxicity. Nowadays, three-dimensional 
conformal radiotherapy (3D-CRT) is widely available and allows to deliver high doses to the 
prostate only (P) or to the prostate and seminal vesicles (PSV) while sparing the surrounding 
normal tissues, such as bladder and rectum, resulting in favorable toxicity profiles as 
compared to conventional radiotherapy (5). Further improvement of dose conformality can be 
achieved by intensity-modulated radiation therapy (IMRT). This technique opened the way to 
more aggressive dose escalation in prostate cancer, while maintaining the same risk of 
developing severe rectal toxicity (6). Nevertheless, implementation and actual treatment using 
IMRT, on a daily basis, is complex and therefore not yet available in every treatment center 
(7). 
It is known that the majority of cancer foci is located in the peripheral zone of the 
prostate, adjacent to the anterior rectal wall (8). Consequently, this part of the rectal wall will 
inevitably be in the high dose region. It has been demonstrated that the lateral and dorsal part 
of the rectal wall can be pushed away from the high dose region by insertion of an inflatable 
endorectal balloon (ERB). Three types of air-filled ERBs have been investigated, separately, 
for their rectal wall sparing effect in 3D-CRT and IMRT. Treatment planning studies and 
clinical studies of individual ERBs have shown that the use of an ERB can be advantageous 
(9-15).  
To date, no planning study has been performed to compare the potential rectal wall 
sparing effect for these types of ERBs in one patient group. The goal of this study was to 
investigate the dosimetric consequences and the rectal wall sparing effect of each ERB, for 
both 3D-CRT and IMRT treatment techniques using two target volumes, P and PSV, and to 
compare them to treatment plans without an ERB. 
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MATERIALS AND METHODS 
Patient selection and preparation 
Twenty patients, who were referred to our department for irradiation of localized 
prostate cancer (T1-3N0M0), were included in this study, after informed consent was given. 
Besides apparent pre-existing anal irritation and hemorrhoids, no further exclusion criteria 
were applied. Prior to CT scanning, patients used a laxative diet and a laxans (Microlax 
clysma 5 mL, Pharmacia B.V. Woerden, The Netherlands), and were intended to have a full 
bladder by drinking 500 ml of water. 
 
Endorectal balloons 
 The first ERB (ERB1) is a flexible rectal balloon tube made of soft rubber, commonly 
used in diagnostic radiology for barium enema procedures. It is a 30-cm-long two-way rectal 
tube with silkolatex coating and a silkolatex balloon (Nordmann®, Rüsch AG, Kernen, 
Germany). Deflated, the ERB has a diameter of 8 mm. The dimensions of the balloon, filled 
with 40 cc of air, are 5.0 cm in length and 4.5 cm in diameter, as described earlier by Wachter 
et al. (14, 16-18) (Fig. 1a). 
The second ERB (ERB2) was originally designed as an endorectal coil for magnetic 
resonance (MR) imaging (Medrad, Pittsburgh, PA). The latex balloon is fixed on a slightly 
flexible PVC shaft with a length of 33 cm. This ERB has a specific anatomical concave shape 
to conform to the prostate gland-rectal interface (9, 19). Deflated, the ERB has a diameter of 
10 mm. The ERB was inflated with 80 cc of air and had a length of 90 mm and a diameter of 
45 mm (Fig. 1b). This amount of air chosen was in accordance with the amount when used for 
MR imaging. ERB1 and ERB2 originate from radiological procedures and are open-air 
systems with a direct connection between the rectal lumen and the outer air. As described by 
others, in clinical practice, ERB1 en ERB2 are covered by a condom prior to daily insertion in 
order to prevent rectal content leakage during irradiation (13, 14). For hygienic reasons, we 
used no condoms but closed the open-air connection of these ERBs with clamps. 
The third ERB (ERB3) also originates from diagnostic radiology. It is a rectal balloon 
catheter consisting of a non-latex retention cuff on a rigid 15 cm shaft (EZ-EM, Westbury, NY). 
Deflated, the ERB has a diameter of 15 mm. This ERB was inflated with 100 cc of air, the 
same amount as used by the Baylor College group (11, 12, 20) and had a length of 45 mm 
and a diameter of 60 mm) (Fig. 1c). 
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(a)  (b)   (c) 
Fig 1 
The endorectal balloons: (a) ERB1, (b) ERB2 and (c) ERB3  
 
 
In all patients, the order of CT scanning was the same, according to increasing volume 
of ERBs: No-ERB, ERB1, ERB2 and ERB3 (Fig. 2). The same person (EVL) inserted all 
balloons while patients were turned on their left side. Insertion was facilitated by lubrication gel 
(K-Y gel, Johnson & Johnson, Arlington, TX). After inflation the ERB was gently pulled towards 
the anal sphincter to ensure a proper position in relation to the prostate. Within 20 minutes, 
four planning CT-scans (one without and three with ERB in situ) were obtained at 3mm slice 
thickness, resulting in 80 CT-scans (AcQsim spriral CT, Philips Medical Systems, Bothell, 
WA). Patients were positioned supine during acquisition of the CT images. 
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(a) 
 
(b) 
 
(c) 
 
(d) 
 
Fig. 2.  
Sagittal CT images of a patient with (a) No ERB, (b) ERB1, (c) ERB2 and (d) ERB 3 inserted. 
Prostate, seminal vesicles and rectal outer contours are highlighted. The planning treatment volume 
surrounds the prostate and seminal vesicles. 
 
Organ delineation and treatment planning 
 The images of all 80 CT scans were imported into the Pinnacle3 treatment planning 
system (Philips Medical Systems, Andover, MA) for 3D-CRT and IMRT treatment planning. 
The prostate gland only (P) and the prostate and seminal vesicles (PSV) were contoured in all 
CT scans and defined as clinical target volumes (CTV). In every CT-scan the outside contour 
of the ERB was delineated to determine the total volume of the ERB (amount of air plus the 
volume of the device itself).  On each slice the following surrounding normal structures were 
outlined: bladder, femoral heads, and rectal wall. The rectal wall (Rwall) representing the rectal 
wall organ volume was defined as the difference between the inner and the outer rectal wall 
contour (4, 14). Rwall was delineated from the ischial tuberosities up to the rectosigmoid 
flexure. For each patient, delineation was done over the same length to obtain the same Rwall 
volume per patient and allow intercomparison. Two independent observers performed the 
delineation of the rectal inner and outer wall contours. For 3 randomly chosen patients, the 
rectum contours for each of the 4 CT scans were delineated 5 times by each of the observers, 
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to assess the intra- and inter-observer delineation variations. These variations were expressed 
as the coefficient of variation (± 1 SD relative to the mean). 
 For every CT-scan, two planning target volumes (PTVs) were defined: a PTV for 
prostate only (PTV-P) and a PTV for prostate and seminal vesicles (PTV-PSV). To generate 
these PTVs, a 3D CTV-PTV margin of 10 mm was used for the 3D-CRT plans. For the IMRT 
plans, a CTV-PTV margin of 7 mm was used, as it was assumed that departments using IMRT 
for daily practice also use specific position verification and correction protocols, resulting in 
reduced margins (7). 
 A dose of 78 Gray (Gy) was prescribed in 39 daily fractions of 2 Gy, derived from the 
M.D. Anderson randomized trial (1). For evaluation of the rectal wall sparing effect, first, the 
normal tissue complication probability (NTCP) of the Rwall, for each individual patient over the 
different ERBs, were compared. For the NTCP calculations the Lyman-Kutcher-Burman (LKB) 
model with Emami parameters (n=0.12, m=0.15 and TD50=80 Gy) was used (21-23). 
Secondly, the mean dose of the Rwall was derived from the planning system and 
compared for all treatment plans (4, 24). From the Rwall dose volume histogram (DVH) the 
absolute Rwall volume (cc) receiving 50 Gray or more (V50) and the absolute Rwall volume 
(cc) receiving 70 Gray or more (V70) were derived (3, 25). The different diameters and lengths 
of the three ERBs resulted in different inner rectal wall surfaces. Therefore, the spatial dose 
distribution over the inner rectal wall mucosa was visualized by generating rectum dose 
surface maps (4) and dose surface histograms (DSH) (26).  
 
3D-CRT treatment planning technique 
Four coplanar beams were used, consisting of four orthogonal, equally weighted 18 MV 
photon fields (Anterior-Posterior, Posterior-Anterior, Left-Lateral and Right-Lateral). A beams-
eye-view based 3D-conformal treatment plan was designed, with individual shielding of normal 
tissue, utilizing a multileaf collimator (MLC), and a dose level of 78 Gy at the International 
Commission of Radiation units and Measurements (ICRU) reference point.  
 
IMRT treatment planning technique 
An inverse planned step-and-shoot IMRT-plan was made for every patient, consisting of 5 
coplanar, equidistant, non-opposing 10 MV photon energy beams. One beam was oriented 
posterior-anterior (PA) while the other 4 beams were equally spaced around the isocenter. The 
inverse planning system tried to meet as good as possible the objectives displayed in Table 1. 
The maximum allowable dose outside the delineated structures was 38 Gy (weight factor 1). 
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ROI Objective Dose level 
(Gy) 
Volume (%) Weight 
CTV Uniformity 78 100 10 
CTV Max Dose 82 100 8 
PTV Min Dose 74 100 10 
PTV Max Dose 78 100 8 
PTV Uniformity 78 100 1 
PTV Min DVH 74 99 10 
Rectal Wall Max Dose 75 100 50 
Rectal Wall Max DVH 60 10 20 
Rectal Wall Max DVH 50 20 10 
Rectal Wall Max DVH 40 30 10 
Bladder Max DVH 74 2 3 
Bladder Max DVH 60 15 2 
Left Femur Max Dose 50 100 1 
Right Femur Max Dose 50 100 1 
Table 1. 
IMRT treatment planning objectives and weight factors 
Abbreviations: 
ROI = region of interest, CTV = clinical target volume, PTV = planning target volume, Max Dose = 
maximum allowable dose, Min Dose = minimal allowable dose, DVH = dose volume histogram 
 
Statistical analysis 
 The Analyse-it® software (Analyse-it Software Ltd, Leeds, England) add-in for 
Microsoft Excel was used for statistical calculations. The Wilcoxon signed rank test was used 
to for paired comparison of the three measured quantities (NTCP, V70, V50) in the same 
subjects for any two different ERBs. Differences were considered significant for two-tailed p 
values less than 0.05. 
 
Patient experiences and ERB positioning 
 After each CT-scanning session, each patient was asked for his experiences regarding 
the introduction of the different balloons, i.e. the complaints during the procedure. On the CT 
scan, the position of the ERB was evaluate.  
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RESULTS 
Patient characteristics 
 The patients investigated represented a broad range of prostate and seminal vesicles 
volumes. The mean volume (± 1 SD) for the prostate was 69 cc (± 35 cc) ranging from 37 to 
187 cc. The mean volume (± 1 SD) for the seminal vesicles was 17 cc (± 5 cc) ranging from 7 
to 28 cc. 
 
Rectal wall delineation and ERB characteristics  
 Overall, the Rwall was delineated over a mean length of 11.5 cm (median 11.4 cm, 
ranging from 10.2 to 13.5 cm). The median volumes of the delineated Rwall per patient, 
compared for each of the four CT-scans, for the No-ERB, ERB1, ERB2 and ERB3, were 57.0 
cc, 58.6 cc, 48.4 cc and 55.5 cc respectively and did not significantly differ (p = 0.81). The 
Rwall delineation inter-observer co-efficient of variation was 4.4 % ± 1.6%. The Rwall 
delineation intra-observer co-efficient of variation was 4.2 % ± 1.8 %. The intra-observer 
variance was not statistically different from that found between the observers. 
 The mean total volume (± 1 SD) of the inserted ERB was 58 cc (± 7 cc) for ERB1, 108 
cc (± 6 cc) for ERB2 and 117 cc (± 11 cc) for ERB3. Insertion of the different ERBs resulted in 
an increase of the total rectal volume (Rwall outside encompasses Rwall plus rectal content). 
Without the ERB, the mean Rwall outside (± 1 SD) was 83cc (± 16 cc), 138 cc (± 18 cc) when 
ERB1 was inserted and inflated, 185 cc (± 18 cc) for ERB2 and 189 cc (± 21 cc) for ERB3. 
When evaluating the CT-scans with ERB in situ, it appeared that, despite laxation, gas and 
faecal material was present and extended the rectum, as found in our previous study (19). For 
this reason, one patient was excluded from further analysis. In this patient the Rwall outside 
volume without ERB was 138 cc. With the ERBs, the Rwall outside volume ranged from 200 to 
250 cc. For three patients, one of 4 CT scans was excluded because of large rectum 
extension due to gas and faecal material. These were the CT-scans with ERB1, No-ERB and 
ERB3, for these three patients, respectively. In total, 71 CT-scans and 284 treatment plans 
were used for the definitive analysis. 
 
Rectal wall sparing effect of the ERBs in 3D-CRT 
The 3D-CRT planning technique resulted in a good PTV coverage for all four CT-
scans; the mean dose  (± 1 SD) for the PTV-P and PTV-PSV was 76.5 Gy (± 0.6 Gy) and 77.1 
Gy (± 0.5 Gy), respectively. Examples of typical dose distributions for the 3D-CRT plans, with 
and without an ERB, are given in Fig. 3 a-b. 
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Fig. 3. 
Sagittal CT images with dose distribution, in Gy, for 3D-CRT PTV-P, for (a) No-ERB and (b) ERB2. PTV 
(prostate + 10 mm margin) and rectal outer contour are highlighted (white lines). 
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The mean Rwall dose was reduced significantly for both PTV-P and PTV-PSV by using 
any of the ERBs (Table 2).  
 
 3D-CRT IMRT 
 PTV-PSV PTV-P PTV-PSV PTV-P 
 
Mean  
Rwall 
Dose 
(Gy) 
p value 
Mean 
Rwall 
dose 
(Gy) 
p value 
Mean 
Rwall 
dose(Gy) 
p value
Mean 
Rwall 
dose(Gy)  
p value
No-ERB 60.7   48.8  40.6  35.6  
ERB 1 56.6 0.002 44.9 0.001 41.0 0.14 34.8 0.28 
ERB 2 54.4 0.003 44.2 0.002 41.5 0.67 34.4 0.49 
ERB 3 56.0 0.001 45.3 0.002 40.9 0.15 32.6 0.40 
 
Table 2. 
Mean rectal wall (Rwall) dose for the 3D-CRT and IMRT treatment techniques and for the two different 
PTVs. The p values, given for ERB1, 2 and 3, resulted from the Wilcoxon signed ranks test comparing 
the mean Rwall dose for the respective ERBs against No-ERB. 
Abbreviations: PTV-PSV = planning treatment volume for prostate and seminal vesicles; PTV-P = 
planning treatment volume for prostate only. 
 
In case of PTV-P there was no significant difference between ERB1, 2 or 3 (p values 
ranged from 0.33 to 0.89). In case of the PTV-PSV, ERB2 gave a small, but statistically 
significant reduction of mean Rwall dose compared to ERB1 (p = 0.001) and to ERB3  (p = 
0.01).  
With respect to NTCP of the Rectal Wall in PTV-PSV, any type of ERB gave a 
significant reduction compared to the treatment plan without ERB (Table 3). Both ERB2 and 3 
do also give a small, but significant NTCP reduction compared to ERB1 with p values of < 
0.0001 and 0.0027, respectively. In case of PTV-P, any of the ERBs gave a significant 
reduction of the NTCP Rwall compared to irradiation without an ERB (Table 3). ERB3, the one 
with the largest diameter, was performing statistically better than ERB1 (p = 0.03) and ERB2 
(p = 0.03), although the absolute differences in NTCP were small.  
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(a) 
 3D-CRT IMRT 
 PTV-PSV PTV-P PTV-PSV PTV-P 
 
NTCP 
(%) p value 
NTCP  
(%) p value 
NTCP  
(%) p value 
NTCP 
 (%) p value
No-ERB 24.0   13.0   6.0   4.5   
ERB 1 17.0 0.0005 9.5 < 0.0001 7.5 0.0003 5.0 0.51 
ERB 2 14.0 < 0.0001 10.0 < 0.0001 7.0 0.0001 5.0 0.33 
ERB 3 15.0 < 0.0001 9.0 < 0.0001 6.0  0.0001 4.0 1.0 
 (b) 
Table 3.  
(a) NTCP of the rectal wall, in median values, for the 3D-CRT and IMRT treatment techniques and for 
the two different PTVs. The median values are shown with the 95% confidence interval.  
(b) The p values, given for ERB1, 2 and 3, resulted from the Wilcoxon signed ranks test comparing the 
NTCP for the respective ERBs against No-ERB. 
Abbreviations: PTV-PSV = planning treatment volume for prostate and seminal vesicles; PTV-P = 
planning treatment volume for prostate; NTCP = normal tissue complication probability 
 
The amount of Rwall volume, irradiated to a dose level of 50 Gy or more, the so-called 
V50 was significantly reduced by the use of any type of ERB in case of PTV-PSV (Table 4). 
Both ERB2 and 3 gave a larger reduction of V50 in than ERB1, with p-values of 0.002 and 
0.005 respectively. There was no statistical difference between ERB2 and 3 (p = 0.63). For 
PTV-P, also all three types of ERBs gave a significant reduction in V50 compared to No-ERB. 
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ERB3 gave a significant reduction compared to ERB1 and 2, with p values of 0.0004 and 0.01, 
respectively. ERB1 and 2 did not differ (p = 0.45) significantly. 
0
10
20
30
40
50
60
3D-CRT PTV-PSV 3D-CRT PTV-P IMRT   PTV-PSV IMRT   PTV-P
V5
0 
(c
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(a) 
 3D-CRT IMRT 
 PTV-PSV PTV-P PTV-PSV PTV-P 
 
V50 (cc) p value V50 (cc) p value V50 (cc) p value V50 (cc) p value
No-ERB 42.0   27.5   21.2   18.8   
ERB 1 33.5 0.0003 22.5 < 0.0001 21.9 0.93 17.5 0.05 
ERB 2 30.0 0.0002 20.0 0.0001 21.1 0.80 16.4 0.04 
ERB 3 29.5 0.0004 19.0 < 0.0001 19.6 0.10 16.0 0.01 
(b) 
Table 4.  
(a) V50 (cc) of the rectal wall for the 3D-CRT and IMRT treatment techniques and for the two different 
PTVs. The median values are shown with the 95% confidence interval. (b) The p values, given for 
ERB1, 2 and 3, resulted from the Wilcoxon signed ranks test comparing the V50 for the respective 
ERBs against No-ERB. 
Abbreviations: PTV-PSV = planning treatment volume for prostate and seminal vesicles; PTV-P = 
planning treatment volume for prostate; V50 = rectal wall volume receiving ≥ 50 Gy in cc. 
 
The V70 was, in case of PTV-PSV, significantly reduced by using any type of ERB 
(Table 5). ERB2 en 3 gave a larger reduction than ERB1, with p-values of 0.004 and 0.003, 
respectively. There was no statistical difference between ERB2 and 3 (p = 0.60). For PTV-P, 
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all three types of ERBs gave a significant reduction of V70, compared to No-ERB. ERB3 gave 
more reduction than ERB1 and 2, with p-values of 0.0051 and 0.0319, respectively. There was 
no significant difference between ERB1 and 2 (p = 0.5416). 
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 (a) 
 3D-CRT IMRT 
 
 
PTV-PSV PTV-P PTV-PSV PTV-P 
 
V70 (cc) p value V70 (cc) p value V70 (cc) p value V70 (cc) p value 
No ERB 31.0   19.5   10.5   9.6   
ERB 1 23.5 0.0005 15.5 0.0003 12.5 < 0.0001 9.3 0.43 
ERB 2 22.0 < 0.0001 13.0 0.0008 12.9 < 0.0001 9.9 0.20 
ERB 3 21.0 0.0003 12.5 < 0.0001 10.7 0.0021 8.3 0.19 
(b) 
 
Table 5. 
(a) V70 (cc) of the rectal wall for the 3D-CRT and IMRT treatment techniques and for the two different 
PTVs. The median values are shown with the 95% confidence interval (b) The p values, given for ERB1, 
2 and 3, resulted from the Wilcoxon signed ranks test comparing the V70 for the respective ERBs 
against No-ERB. 
Abbreviations: PTV-PSV = planning treatment volume for prostate and seminal vesicles; PTV-P = 
planning treatment volume for prostate; V70 = rectal wall volume receiving ≥ 70 Gy in cc. 
 
Rectal wall sparing effect of the ERBs in IMRT 
The inverse IMRT planning technique resulted in a good PTV coverage for all four CT-
scans; the mean dose  (± 1 SD) for the PTV-P and PTV-PSV was 76.5 Gy (± 0.1 Gy) for both 
target volumes.  
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Examples of typical dose distributions for the IMRT plans, with and without ERB, are given in 
Fig. 4 a-b. 
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Fig. 4. 
Transversal CT images with dose distribution, in Gy, for IMRT PTV-PSV, for (a) No-ERB and (b) ERB3. 
PTV (prostate and seminal vesicles + 7 mm margin) and rectal outer contour are highlighted (white 
lines).  
 
The mean Rwall dose was not reduced significantly for both PTV-P and PTV-PSV by 
any of the ERBs (Table 2). A statistically significant difference in mean Rwall dose between 
the different types of ERB could not be demonstrated. 
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In case of PTV-PSV, the NTCP Rwall increased slightly, but statistically significant, by 
applying any type of ERB (Table 3). Between the different types of ERBs there was no 
significant difference (p values ranged from 0.16 to 0.46). For PTV-P, the NTCP Rwall did not 
significantly change by the use of any type of ERB. There was no statistically significant 
difference between the investigated ERBs (p values ranged from 0.33 to 0.51). 
The V50 of the Rwall (Table 4), in case of PTV-PSV, was not reduced by any type of 
ERB, compared to the V50 of the IMRT plan without ERB. When comparing the V50 between 
the three ERBs, it showed that V50 for ERB3 was slightly, but significantly lower than for ERB1 
(p = 0.005) and ERB2 (p = 0.02). There was no difference between ERB1 and 2 (p = 0.42). 
For PTV-P, ERB2 and 3 slightly, but significantly, reduced V50. The V50 in ERB3 was 
significantly lower than for ERB1 (p = 0.0003). There was no difference between ERB2 and 3 
(p = 0.21). 
The V70 of the Rwall, in case of PTV-PSV, was slightly, but significantly increased by 
any of the three ERBs, compared to the planning without ERB (Table 5). Within the group of 
ERBs there were differences: ERB1 and 3 had significantly lower V70 than ERB2, with p-
values of 0.007 and 0.0001, respectively. There was no significant difference between ERB1 
and 3 (p = 0.27). For PTV-P, no difference was found for ERB1, 2 or 3, compared to No-ERB. 
Within the group of ERBs, only for ERB3, compared to ERB2, the V70 was significantly lower 
(p = 0.04). There was no difference between ERB1 and 2 (p = 0.64) or between ERB1 and 3 
(p = 0.13). 
 
Rectal wall dose maps and dose surface histograms 
 Dose maps (displayed by virtual rectum unfolding) and dose surface histograms (DSH) 
of the inner rectal wall showed, in case of 3D-CRT, a clear sparing effect of the ERBs 
compared to the treatment plan without ERB. As an example, the inner rectal wall dose 
surface maps (Fig. 5 a-d) and DSH (Fig. 5 e) of PTV-PSV treatment plans are displayed. Note 
the differences in rectal wall dilation by the different ERBs, yielding different maximum inner 
rectal wall circumferences of 8 cm, 13 cm, 14 cm and 20 cm for No-ERB, ERB1, 2 and 3, 
respectively (Fig. 6 a-d). For the treatment plan without an ERB, over a length of 7 cm (4 – 11 
cm ab ano) the whole circumferential area of the inner rectal wall is exposed to a dose of 50 
Gy and more (Fig. 5 a). In case of ERB2, this area is limited to the ventral rectal wall (Fig. 5 c). 
The two shorter ERBs (ERB1 and 3) do not dilate the rectum on the level of the seminal 
vesicles (11 cm ab ano) and here the high dose area reached the dorsal rectal mucosa (Fig. 5 
b, d). From the DSH, it can be understood that the mucosal area exposed to doses over 40 Gy 
is reduced by the ERB (Fig. 5 e). For example, the fractional inner rectal wall area, irradiated  
> 60 Gy is reduced from 68% without ERB to 38% with ERB3 inserted. 
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  (a)      (b) 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(c)      (d) 
 
 
Fig. 5.  
Inner rectal wall dose surface maps for 3D-CRT PTV-PSV treatment plans for (a) No-ERB, (b) ERB1, 
(c) ERB2 and (d) ERB3. The dose distribution, of the inner rectal wall circumference, in Gray, is 
displayed on an unfolded rectum (i.c. the rectum is cut open at the posterior wall). On the horizontal axis 
the circumferential distance from anterior to posterior is displayed. On the vertical axis the distance from 
the most caudal delineated CT-slice is shown. 
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Fig. 5e.  
Inner Rectal Wall dose surface histogram for 3DCRT PTV-PSV treatment plans for No-ERB, ERB1, 
ERB2 and ERB3. 
 
As an example of a representative IMRT treatment plan, the inner rectal wall dose 
maps (Fig. 6 a-d) and the DSHs for IMRT PTV-P are displayed. The absolute surface area, 
irradiated to doses over 60 Gy is not evidently different between the 4 dose maps, as 
displayed in Fig 6 a-d. But due to the dilatation of the inner rectal wall, the fractional area of 
the inner rectal wall irradiated > 60 Gy is reduced from 31 % (No-ERB) to 17 – 20 % for ERB1-
3 (Fig. 6 e).  
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(c)        (d) 
Fig. 6.  
Inner rectal wall dose surface maps for IMRT PTV-P treatment plans for (a) No-ERB, (b) ERB1, (c) 
ERB2 and (d) ERB3. The dose distribution of the inner rectal wall circumference is displayed on an 
unfolded rectum (i.c. the rectum is cut open in the posterior wall). On the horizontal axis the 
circumferential distance from anterior to posterior is displayed. On the vertical axis the distance from the 
most caudal delineated CT-slice is shown. 
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Fig 6 e.  
Inner Rectal Wall dose surface histogram for IMRT PTV-P treatment plans for No-ERB, ERB1, ERB2 
and ERB3.  
 
ERB positioning and patient tolerance  
No serious events, i.e rectal bleeding or severe anal irritation, occurred during the 
introduction of the ERBs and CT scanning session. The insertion of ERB1 was very easy due 
to its flexibility and small size. After inflation, patients noticed no extra pressure on the rectal 
wall or bladder. On CT scan, the position of the ERB1 was good, except for one case, where 
the ERB pointed towards the ventral anterior wall (Fig 7 a). ERB2 was slightly flexible and had 
the longest balloon (90 mm). All patients experienced some pressure on the rectal wall and 
bladder. The positioning was good in all cases. The long shaft was very helpful for the 
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introduction and positioning of the ERB. For ERB3, the balloon with the largest diameter, the 
inflation was painful in 5 patients: they experienced a local high pressure onto the rectal wall. 
This feeling disappeared within 1 minute. Insertion and positioning was complicated, due to 
the very rigid short shaft. In one patient, the ERB pointed too far to the ventral side and 
impressed the ventral rectal wall (Fig 7 b). Although no formal scoring system was used, 
patients experienced ERB1 (the smallest) to be favorite. For the personnel, ERB2 was the 
easiest to handle and to insert also because of the closed air system. 
 (a) 
(b) 
Fig. 7.  
Example of incorrect positioning, in two different patients, of (a) ERB1 and (b)ERB3.  
Prostate and seminal vesicles are highlighted in dark grey. The outer contours of the ERB and the rectal 
outer contour are highlighted. 
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DISCUSSION 
In this prostate cancer radiotherapy treatment planning study, the dosimetric 
consequences and rectal wall sparing effect of three different ERBs were investigated for two 
different treatment techniques and two different PTVs. It appeared that, depending on the PTV 
and treatment technique (either 3D-CRT or IMRT), there were significant differences in the 
rectal wall sparing effect between the three types of ERBs, which could be correlated to the 
specific shape and size of the ERBs. 
 
3D-CRT 
 The combination of 3D-CRT and any type of investigated ERB significantly reduced the 
mean dose, NTCP, V50 and V70 for the rectal wall. In case of irradiating the prostate only (PTV-
P) it appeared that ERB3, the balloon having the largest diameter, performed the best. This 
can be explained by the greater prostate – posterior rectal wall distance. When the seminal 
vesicles are included into the PTV (PTV-PSV), ERB1 was inferior to the larger ERB2 and 3; 
ERB1 is not long and voluminous enough to separate the posterior rectal wall from the seminal 
vesicles, as clearly visible from Fig 5 b. 
 
IMRT   
Application of any ERB in combination with IMRT treatment planning did not result in a 
statistically significant reduction in NTCP or in mean dose of the rectal wall. Nevertheless, 
there were differences between the ERBs. In irradiation of the prostate only (PTV-P), the V50 
and V70 of ERB3 were lower than for ERB1 and 2, again due to its largest inner rectal wall 
circumference. In case of PTV-PSV, NTCP and V70 were slightly increased by any of the 
ERBs. Evaluation of the CT-scans showed that with ERB, the anterior rectal wall is pushed 
towards the prostatic gland and even between the seminal vesicles, resulting in a larger rectal 
wall volume being exposed to high doses, compared to the situation without ERB. This effect 
was most clear for ERB2, the longest ERB, resulting in a higher V70. 
 
So far, two groups have reported on their first clinical results of the ERB (10, 11, 14). 
The group of Wachter et al. in Vienna investigated the type of ERB referred as ERB1 in our 
study. In 10 patients four planning CT-scans were made. A four-field box technique was used. 
The PTV consisted of prostate only or prostate + seminal vesicles surrounded by a 10 mm 
margin, and a dose of 66 Gy was prescribed. In case of PTV-P, they found a significant dose 
reduction to the rectal wall, mainly at the posterior wall, as a result of the increased distance 
between prostate and posterior rectal wall. In case of PTV-PSV, this advantage was lost. At 
the level of the seminal vesicles, this small-sized ERB does not dilate the rectum, and the 
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seminal vesicles can curl around the rectum, thereby decreasing the distance between the 
PTV and posterior rectal wall (14). This is confirmed in the present study (Fig. 5b). The Baylor 
college group reported their clinical experiences in 100 patients on the combination of IMRT 
(mean dose 76 Gy) and ERB3. A favorable acute toxicity profile was found, and dose 
escalation with an ERB seemed feasible (10, 11). Patel et al. conducted a treatment planning 
study in five patients and compared 3D-CRT with IMRT, also with PTV-P and PTV-PSV (13). 
The prescription dose was 76 Gy. ERB3 was inserted and filled with only 60 cc of air, in 
contrast to 100 cc of air, as propagated by the Baylor College group and as used in our 
present investigation. A treatment plan with an inflated ERB was compared against a plan with 
a deflated ERB. They concluded that application of this ERB gave as much rectal sparing as 
highly conformal IMRT, which is comparable to our NTCP data (Table 3). IMRT plus an ERB 
produced further rectal sparing, and this type of ERB was considered to be helpful for dose 
escalation (13). In contrast to our results, they found a decrease of the V70 Rwall. This can be 
explained by the smaller amount of air present in the ERB. It should be noted that the 
comparison was made with a CT scan with a deflated ERB inserted. As stated before, the 
diameter of the deflated ERB2 is still 15 mm. The CTV-PTV margin chosen by Patel et al for 
IMRT planning was 5 mm. The deflated ERB pushes the posterior rectal wall 15 mm away 
from the prostate gland, and with the steep dose gradient of an IMRT plan, even a slight rectal 
filling (caused by this ERB shaft) might cause a rectal wall sparing effect. Also we have shown 
in our study that introduction of an ERB can cause an artificial rectal wall shift (Fig. 7).  
In clinical practice, any type of ERB is well accepted by the patients. For ERB3, 58 
percent of the patients tolerated it without problems, while the remainder experienced it to be 
uncomfortable, but tolerable. In 2/116 patients the volume of air had to be reduced from 100 to 
50 cc because of rectal discomfort (12). Also, ERB1 en ERB2 have proven to be clinically well 
tolerable. In 4/107 patients the application of ERB1 had to be stopped because of proctitis 
(14). In a group of 22 patients irradiated with ERB2, 2 patients developed transient Grade 2 
anal irritation. Painful and bleeding hemorrhoids are considered to be a contraindication for 
ERB insertion (19). In this study, the 3 ERBs were tolerated well and insertion posed no great 
problems, although in the literature it was reported that in up to one-third of the assessed 
patients the ERB positioning was suboptimal (15). Daily ERB position verification is 
mandatory. Apart from results of the dosimetric study, the patients favored ERB1. In terms of 
accurate positioning of the ERB, ERB2 was considered favorite. For hygienic reasons we 
would not use condoms for daily application, as is necessary for the present design of ERB1 
and 3. In a previous study we used a new ERB2 for every treatment fraction, and this was well 
accepted by our therapists (19).  
The ERB has often been referred to as a prostate immobilizer (9, 12-15). We have 
investigated this issue and measured the prostate motion in patients with the ERB2 daily 
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inserted and compared it to a No-ERB group. With ERB, the day-to-day interfraction prostate 
displacements remained nearly unchanged, up to 4.7 mm (1 SD) for the anterior-posterior 
direction. This was caused by the presence of gas and stool besides the ERB (19). Also in this 
study it was shown on CT-scans that any ERB, even after rigorous laxation, could not prevent 
the presence of gas and stool, causing extra filling of the rectum and so a possible shift of the 
prostatic gland. Therefore, it should be advised to use any ERB in combination with daily 
prostate position verification and correction procedures. 
In this present study, we evaluated the rectal wall sparing effect based on the dose 
distribution to the Rwall instead of the dose distribution for the entire rectum, including 
contents, as suggested by Tucker et al (4). It has become clear that, apart from the high Rwall 
doses (50 – 70 Gy) (2, 3, 25), also lower doses, up to 32 Gy may affect the risk of developing 
rectal bleeding (4, 24, 27, 28). Skwarchuk et al. (28) reported that, if the 50 % isodose curve 
(35 – 38 Gy) encompasses the outer rectal contour, the risk of rectal bleeding was increased. 
Tucker et al. (4) found that if 80 % or more of the Rwall surface was exposed to doses > 32 
Gy, the risk of late rectal bleeding was increased by 50 %. It was suggested that these low 
dose areas play an important role in the rectal mucosal regeneration of the adjacent high dose 
regions (28, 29). In other words, small areas of high-dose exposed rectal wall are believed to 
regenerate faster if surrounded by areas of low dose. Inner Rwall dose surface histograms,  
showed, also in case of IMRT, a clear reduction of relative Inner Rwall exposed to 
intermediate and high-doses by the ERBs (Fig. 5e, Fig. 6e) which may contribute to reduce 
late rectal toxicity. Further exploration and more frequent usage of Rwall DSHs can give 
insight in this matter and can help to develop better NTCP models (4, 23). From the data 
presented it can be concluded that the use of an ERB is advantageous in combination with 
prostate 4 field 3D-CRT, a treatment modality still used more frequently than IMRT techniques 
(7). The intermediate to high-dose (45 – 75 Gy) areas were significantly reduced, resulting in a 
lower NTCP of the Rwall. Although we were not able to demonstrate a clear advantage in 
terms of NTCP, mean dose, V50 and V70 reduction, the definitive role of an ERB in prostate 
IMRT has to be determined in large comparative clinical studies. The first clinical experiences 
in primary prostate cancer radiotherapy and post-prostatectomy irradiation are promising, with 
favorable acute and late rectal toxicity profiles (10, 11, 30). 
We have demonstrated that the use of a relatively large ERB (such as ERB2 and 3) in 
IMRT causes an improvement in the ratio between low and high-dose exposed surface areas, 
which may be advantageous in reducing rectal toxicity. Furthermore, the use of an air-filled 
ERB has shown to give an additional Rwall dose reduction of 15 % at the air-tissue interface 
(10). These two issues together with further improvement in IMRT treatment optimization 
(including Rwall constraints for low doses) and treatment delivery, including on-line position 
verification and correction procedures, are topics of future investigation to define the definitive 
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role of the ERB. As a result of this study, we are now in the process of developing a dedicated 
single-use ERB for daily insertion. 
 
CONCLUSION 
  This study investigated the rectal wall (Rwall) sparing effect of three clinically 
applied ERBs for 3D-CRT and IMRT prostate cancer radiotherapy treatment techniques. Two 
different treatment volumes, prostate only (PTV-P) and prostate plus seminal vesicles (PTV-
PSV), were defined. Each ERB was tolerated well, but incorrect positioning occurred in some 
cases and regular verification verification is therefore mandatory. The NTCP, mean dose, V50 
and V70 of the Rwall were calculated in 284 treatment plans. For 3D-CRT, each ERB showed a 
clear Rwall sparing effect, by reducing of all the measured parameters. The larger type ERB2 
and ERB3 performed better than the smaller sized ERB1. No statistically significant reduction 
of the parameters could be demonstrated for the combination of IMRT with any of the ERBs. 
Nevertheless, the different dilatation of the inner rectal wall, ranging from 8 to 20 cm, caused a 
shift in the ratio between high dose and low dose exposed surface areas. This might have a 
positive influence on the mucosal regeneration (28, 29), and thereby reduce the risk of rectal 
bleeding. Therefore, more clinical data and longer follow up are necessary to define the 
precise role of the ERB in combination with prostate IMRT. Development of patient- and 
therapist-friendly ERBs is warranted to increase their acceptability.  
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ABSTRACT  
Purpose: To demonstrate the theoretical feasibility of integrating two functional prostate MR 
imaging techniques (dynamic contrast-enhanced MR imaging (DCE-MRI) and 1H-MR 
spectroscopic imaging (MRSI)), into inverse treatment planning for definition and potential 
irradiation of a dominant intra-prostatic lesion (DIL) as a biological target volume for high-dose 
intra-prostatic boosting with IMRT (DIL-IMRT). 
Methods and materials: In five patients, four gold markers were implanted. An endorectal 
balloon was inserted for both CT scanning and MR imaging. A DIL volume was defined by 
DCE-MRI and MRSI using different prostate cancer specific physiologic (DCE-MRI) and 
metabolic (MRSI) parameters. The CT-MR image registration was performed automatically by 
matching 3D gold marker surface models with the iterative closest point method. DIL-IMRT 
plans, consisting of whole prostate irradiation to 70 Gy and a DIL boost to 90 Gy, and standard 
IMRT plans, where the whole prostate was irradiated to 78 Gy (IMRT-78) were generated. The 
tumor control probability (TCP) and rectal wall normal tissue complication probability (Rwall 
NTCP) were calculated and compared between the two IMRT approaches.  
Results: Combined DCE-MRI and MRSI yielded a clearly defined single DIL volume (range 
1.1 – 6.5 cc) in all patients. In this small, selected patient population no differences in TCP 
were found. A decrease in Rwall NTCP was observed in favor of the DIL-IMRT plan, as 
compared to the IMRT-78 plan. 
Conclusions: Combined DCE-MRI and MRSI functional image-guided high-dose intra-
prostatic DIL IMRT planned as a boost to 90 Gy is theoretically feasible. Preliminary results 
indicate that DIL-IMRT may improve the therapeutic ratio by decreasing the NTCP with 
unchanged TCP. A larger patient population, with more variation of the number, size and 
localization of the DIL, and a feasible mechanism for treatment implementation has to be 
studied to extend these preliminary tumor control and toxicity estimates. 
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INTRODUCTION 
The use of defining a biological target volume (BTV) and intensity-modulated 
radiotherapy (IMRT) for advanced “dose painting”, as proposed by Ling et al. (1) is gradually 
introduced into clinical practice. This has been made possible by advanced imaging 
techniques. Prostate magnetic resonance (MR) imaging techniques can be fused with 
planning computed tomography (CT)-scans and this has been shown to enable improved 
target delineation (2,3). Functional MR imaging techniques have developed over the years. 
Dynamic contrast-enhanced MR imaging (DCE-MRI) can visualize prostate cancer 
(neo)vascularity (4,5). 1H-MR spectroscopic imaging (MRSI) has been shown to provide a high 
specificity for prostate cancer (6,7). These techniques can lead to a more accurate staging and 
localization of prostate cancer (8-12) and are valid methods for early evaluation of 
radiotherapy effect (13). 
  The “classical” whole-prostate dose escalation has improved treatment outcome (14-
16). Nevertheless, intra-prostatic failures do occur and can be detected by MR imaging (17). 
Cellini et al. (18) performed an MR-based analysis of intra-prostatic failure and concluded that, 
in all their observed cases, local recurrence originates within the initial tumor volume. 
Strategies, mainly for brachytherapy and low-size (< 50 cc) prostates, have been tested to 
detect the so-called “Dominant Intra-prostatic Lesion” (DIL) by MRSI and have been given an 
extra boost dose to this DIL, to thereby increase the therapeutic ratio (19-23). To acquire high-
resolution anatomical MR data an endorectal coil is usually inserted causing deformation of 
the prostate gland. Consequently, accurate image registration with the initial planning CT scan 
(without endorectal coil) is often difficult. The CT-MR matching can be done by mutual 
information based automatic registration (24) or manually, by visual approximation (19,22). To 
overcome the difficulties in registration, we developed a gold marker based 3D CT-MR fusion 
protocol (25) where an endorectal balloon (ERB) is used during CT-scanning and treatment 
that has the same dimensions as the MR endorectal coil (26). ERBs are also used in prostate 
radiotherapy for their rectal wall sparing effect (27-29). In our daily practice, fiducial gold 
markers are used for position verification and correction procedures (30-32). These markers 
are clearly visible on both CT and T2*-weighted MR images. Reliable and accurate image 
fusion is feasible using above-mentioned conditions (25,33). 
To date, the combination of two functional MR imaging techniques (DCE-MRI and 
MRSI), gold markers and an ERB for biological image-guided external beam radiotherapy has 
not been described elsewhere. The purpose of this study was to demonstrate the feasibility of 
the fusion of these functional MR imaging techniques with CT, using gold markers as fiducials, 
and to integrate these images into inverse treatment planning to define a BTV for high-dose 
intra-prostatic DIL boosting with IMRT. The next goal was to make an estimation of the 
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potential gains, in terms of tumor control probability (TCP) and rectal toxicity, by analyzing 
normal tissue complication probability (NTCP). 
 
MATERIALS AND METHODS 
This pilot study was performed over a period of 6 months, until December 2004. 
Patients with biopsy proven prostate cancer were selected for our study. At the start of this 
study, only patients with uni-lateral prostate cancer were selected. Patient exclusion criteria 
were: previous hormonal therapy, positive lymphadenectomy, contraindications to MR imaging 
(e.g., cardiac pacemakers, intracranial clips) and contraindications to endorectal coil insertion 
(e.g., anorectal surgery, inflammatory bowel disease). Finally, five patients were enrolled in 
this study, after informed consent was given. 
In each patient, four fine gold markers (1-mm diameter, 7-mm length) were implanted 
in the prostate through trans-rectal ultrasound guidance by an experienced urologist (J.A.W.) 
(Fig. 1a). Two markers were inserted in the base, one in the apex and one in the central part 
(next to the urethra) of the prostate gland. A standard 18-gauge prostate biopsy tool was used 
(Micro-invasive topnotch, Boston Scientific, Natick, MA, US.) (Fig. 1b) and prophylactic 
antibiotics were given (ciprofloxacin 500 mg, BID, for 3 days). 
Fig.1.  (a) Fine gold fiducial prostate markers. (b) Prostate biopsy tool used for marker implantation, 
mounted on ultrasound probe. 
 
After at least 1 week, to resolve swelling of the gland after marker implantation, 
patients underwent both CT and MR imaging on the same day, within 4 hours. Patient 
positioning during both CT and MR examinations was identical to that during treatment: supine 
on a flat couch that was covered with a thin disposable paper sheet. Only a pillow and a foam 
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knee support were used for relaxed positioning of the head and legs, respectively. Prior to the 
imaging sessions, patients used a laxative diet and a laxans (Microlax clysma 5 mL, 
Pharmacia B.V. Woerden, The Netherlands), and were intended to have a full bladder by 
drinking 500 ml of water. 
 
CT and MR imaging protocol 
The planning CT scan was obtained at 3-mm slice thickness with a multi-slice CT 
scanner (150 mA, 140 kV, feed 12.5 mm, rotation 0.5s) (AcQsim spiral CT; Philips Medical 
Systems, Bothell, WA). An ERB was inserted and inflated with 80 cc of air to mimic MR 
imaging conditions and reduce prostate deformation differences. The ERB used during CT 
imaging is a modified MR endorectal balloon without the coil wiring and has the same 
dimensions and shape as the MR endorectal coil (MedRad, Indianola, PA, US) (26,29) (Fig. 
2a). 
MR imaging was performed using a 1.5T MR scanner (Magnetom Sonata, Siemens, 
Erlangen, Germany). Patients were imaged in supine position. Integrated endorectal phased-
array coils were used (Medrad, Indianola, PA, US). After digital rectal examination the 
endorectal coil was inserted and inflated with 80 cc of air. Peristalsis was suppressed by an 
intramuscular injection of 1 mg glucagon (Glucagen; Novo Nordisk A/S, Denmark) prior to the 
examination. Localizing images were acquired for anatomical orientation and to confirm coil 
positioning. The three-part scanning protocol is listed in order of acquisition in Table 1. Firstly, 
for anatomical information, T2-weighted fast spin echo (FSE) images were acquired in three 
planes (Fig. 2b). A transversal T2*-weighted gradient echo sequence (MEDIC) provided clear 
visualization of the gold markers (Fig. 2c). Secondly, MRSI was obtained using a 3D chemical 
shift imaging (3D-CSI) sequence. Thirdly, DCE-MRI was performed using one intermediate 
weighted and repeated T1-weighted imaging during 2 minutes. A dose of 0.2 mmol/kg 
gadolinium-DTPA (Magnevist, Schering, Berlin, Germany) was injected using a power injector 
(Spectris, Medrad, Indianola, PA, US) with saline flush. 
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(a)   (b) 
(c) 
 
Fig. 2. 
(a) Endoretal balloon used during CT and MR imaging.  
(b) Sagittal MR T2-weighted image (FSE) (left panel) and CT image (right panel) with endorectal balloon 
inserted. Prostate and outer rectal wall are highlighted.  
(c) Transverse MR T2*-weighted (MEDIC) image (left panel) and CT (right panel) image, gold marker is 
indicated (arrow) 
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Sequence   TR (ms)  TE (ms)  α  slice thickness  FOV       matrix in plane voxelsize 
  
      (°)  (nr of slices) (mm)  
 
FSE   4100  119 180  4.0 (15) 280  512 x 256   0.35 x 0.35  
MEDIC   700  18   30  3 (22)   285     512x448  0.56 x 0.56
  
 
3D-MRSI    640  120  PRESS   4.3 (12)  84     14 x 14   4.3 x 4.3 
(interpolated) 
 
turboFLASH (pre)  800  1.61  8 4.0 (10)  280     192 x 256   1.09 x 1.09
  
turboFLASH (post) 34  1.61  10 4.0 (10)  280     192 x 256   1.09 x 1.09
   
 
Pre = pre-contrast; post = post-contrast  
 
Table 1.  
Magnetic Resonance Imaging Protocol; Scanning Parameters 
   
 
 
Imaging registration 
CT and MR imaging sets were aligned by registering the MEDIC MR volume to the CT 
volume, using an in-house developed application as described by Huisman et al. (25). In 
summary, the markers, displayed on T2*-weighted (MEDIC) MR and CT, were semi-
automatically segmented and converted into 3D surface models (Fig. 3a, b). The 3D surface 
models from both datasets were then registered by minimizing the root-mean-square distance 
between the surfaces using the iterative closest point (ICP) method (25). The registration was 
visually verified by observing the fused CT and MEDIC MR images. The MR marker surface 
model was depicted in green while the CT marker surface model was overlaid in red with CT 
window and level set to reveal only the markers (Fig. 3c). In case the fused display 
demonstrated clearly visible mis-registrations the registration procedure was reiterated. 
 
DIL delineation 
The radiologist (J.F.), performing the DIL delineation, was unaware of the tumor 
characteristics (local staging by digital rectal examination, PSA or Gleason score) during the 
evaluation of the images. Post-processing entailed two stages. First, the acquired DCE-MRI 
and MRSI data were processed to extract functional feature images. The DCE-MRI dataset, to 
identify regions of neo-vascularity, was analyzed based on multiple physiologic parameters, 
such as the Kcp, quantifying the permeability 
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a b 
c 
Fig. 3. 
Marker registration by iterative closest point (ICP) method. Markers are semi-automatically segmented 
on (a) T2*-weighted MR image (MEDIC) and on (b) CT image. (c) MR (green) and CT (red) marker 
surface models registered by minimizing the root-mean-square distance of the separate models. 
 
 
surface area, Ktrans, defined as the volume transfer constant and ECV, for quantification of the 
extracellular volume (5,9). Then, based on these findings, the MRSI dataset was evaluated to 
make the final diagnosis of prostate cancer or normal prostate tissue, by analyzing the 
separate 1H-MR spectra of the prostate gland voxels. A choline + creatine/citrate ratio > 0.9 
was considered to be positive for prostate cancer (6,7,9,10). 
In the second post-processing stage, these DCE-MRI and MRSI feature images and 
the T2-weighted prostate images were fused; the functional images were overlaid in 
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transparent colors on T2-weighted MR images in three perpendicular planes. A 3-D editor, 
build within the registration application, was used to delineate the boundary of the DIL (Fig. 
4a). During the editing process of the DIL, the radiologist was able to switch between the DCE-
MRI and MRSI feature images and the T2-weighted MR images with the cross-section of the 
resulting tumor model visible in all planes. The definitive tumor model was then saved as a 
binary DIL volume. The registration parameters that aligned the MEDIC MR data and the CT 
data were used to align the DIL volume with the CT data. The aligned DIL volume, together 
with the MEDIC MR images and the T2-weighted MR images were then transferred and 
imported into the radiotherapy treatment planning system. An illustrated case example is 
described in the Results section. 
 
 IMRT treatment planning  
 The radiation oncologist (E.V.L.) and the radiologist (J.F.) reviewed the MEDIC MR 
images, the T2-weighted MR images and the aligned DIL volume. Together they delineated the 
prostate gland in the MEDIC and the T2-weighted MR images. The resulting contours were 
automatically transferred to the corresponding CT slices and defined as the prostate clinical 
target volume (CTV). The registered DIL volume in the image fusion window of the Pinnacle3 
treatment planning system (Philips Medical Systems, Andover, MA) was reviewed and the DIL 
CTV was defined (Fig. 4b). On each CT slice the normal surrounding structures were outlined: 
bladder, urethra, femoral heads and rectal wall. The rectal wall (Rwall) was defined as the 
difference between the inner and outer rectal wall contour (34). The Rwall was delineated from 
the ischial tuberosities up to the rectosigmoid flexure.  
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a 
b 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4  
(a) 3D editor for delineation of the DIL volume. DIL is highlighted in red  
(b) DIL volume (highlighted in red) is transferred into treatment planning system and displayed on a 
transversal MR T2-weighted image (left panel) and on a CT image (right panel). In yellow the central 
gold marker is indicated. 
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For each patient, two IMRT treatment plans were made to compare the tumor control 
probability (TCP) and predicted rectal toxicity, as estimated by the NTCP. First, the DIL-IMRT 
plan was identified, irradiating a PTV70 and a PTV90. The PTV70 was defined as the prostate 
gland  + 7 mm isotropic margin (prescription dose 70 Gy). The PTV90 consisted of the DIL + 5 
mm isotropic margin (prescription dose  
90 Gy). Next, a more standard IMRT plan (IMRT-78) was constructed, in which PTV78 
consisted of the prostate gland + 7 mm isotropic margin. For this plan the prescription dose 
was 78 Gy (14). For both plans, the dose per fraction was 2 Gy for the prostate. In the DIL-
IMRT plan, the dose per fraction for the DIL was 2.57 Gy. 
For both plans, the step-and-shoot IMRT plan consisted of seven coplanar, non-
opposing 10 MV photon energy beams. One beam was oriented posterior-anterior (PA) while 
the other six beams were configured with equidistant gantry angles. 
For both plans, equal DVH and maximum dose objectives for the normal tissues were 
defined (Table 2). In addition, the maximum allowable dose outside the delineated structures 
was set to 38 Gy (weight factor = 1). For the DIL-IMRT plan and IMRT-78 plan the following 
target volume objectives were defined. In brackets the weight factor (W) for the corresponding 
objective is noted. Objectives regarding the CTV were: minimal allowable dose of 90 % of the 
prescription dose (W=10), maximum allowable dose 110 % of the prescription dose (W=10). 
Objectives for the PTV were: minimum dose 90 % (W=2), maximum dose 110 % (W 5) and dose 
uniformity (W 1). For the PTV, also DVH objectives are defined:  > 99 % of the PTV volume 
should receive a minimal dose of 95 % of the prescription dose (W=10). For the DIL-IMRT plan, 
the maximum allowable dose within the DIL was set on 94 Gy (W=1). 
 For comparison of the IMRT-78 and the DIL-IMRT plans, the mean doses for the 
prostate and DIL were calculated. For the Rwall, the NTCP for serious (≥ grade 3 rectal 
toxicity) was computed, applying the Lyman-Kutcher-Burman model with Emami parameters 
(n=0.12, m=0.15 and TD50=80 Gy) (35-37). The resulting spatial dose distribution over the 
inner surface of the rectal wall, representing the rectal wall mucosa, was visualized by 
generating inner rectal wall dose surface maps (38). 
For TCP calculations, the Poisson-based model of Webb and Nahum was used, taking 
the interpatient variation in radiosensitivity over a representative cohort of patients into account 
(39).  The model parameters used were taken from Nahum et al. (40): a mean ± standard 
deviation radiosensitivity (αmean and σα, respectively) of 0.26 ± 0.06 Gy-1 and an α/β-ratio of 8.3 
Gy were used. Furthermore, it was assumed that the initial clonogenic cell density for the DIL 
was 107 cells/cc, and for the rest of the prostate was 105 cells/cc. Proliferation effects were 
ignored in the calculations. 
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ROI Objective Dose level 
(Gy) 
Volume (%) Weight factor 
Rectal Wall Max Dose 75 100 50 
Rectal Wall Max DVH 60 10 20 
Rectal Wall Max DVH 50 20 10 
Rectal Wall Max DVH 40 30 10 
Bladder Max DVH 70 2 3 
Bladder Max DVH 60 15 2 
Urethra Max DVH 80 50 1 
Urethra Max Dose 85 100 1 
Left Femur Max Dose 50 100 1 
Right Femur Max Dose 50 100 1 
 
Table 2. 
IMRT treatment planning objectives and planning weight factors for the normal tissues. 
Abbreviations: ROI = region of interest, Max Dose = maximum allowable dose, DVH = dose volume 
histogram  
 
RESULTS 
Imaging and post-processing 
 The marker implantation posed no problems. This procedure took five minutes per 
patient on the urology outpatient clinic. The ERB was tolerated well and no problems arose 
during the imaging procedures. The planning CT-scan took 15 minutes totally, while the MR 
imaging at the radiology department took one hour (10 minutes patient preparation and 50 
minutes imaging), which was rather strenuous for this elderly patient population. In one patient 
the MR imaging was interrupted due to lower back pain, but eventually the MR procedure 
could be finished. The post-processing was performed by an experienced radiologist in 40 
minutes; DCE-MRI evaluation 10 minutes, MRSI evaluation 20 minutes, DIL delineation five 
minutes and files preparation for transmission to the radiotherapy department five minutes. 
The next day, the radiation oncologist and the radiologist reviewed the images. The target 
volumes and normal tissues were delineated in 60 minutes. The inverse DIL-IMRT and IMRT-
78 treatment planning were performed in 1.5 – 2 hours. 
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DIL-IMRT 70-90 Gy IMRT-78 Gy 
 Mean Dose 
(Gy)   
Pat. 
No. 
PSA 
(ng/
ml) 
Gleason 
score Stage 
Prostate 
vol. (cc) 
DIL 
vol. 
(cc) 
DIL 
Loc. DIL Prostate
NTC
P 
Rwall 
(%) 
TCP 
(%) 
Mean 
Dose 
Prostate 
(Gy) 
NTCP 
Rwall 
(%) 
TCP 
(%) 
1 7.8 7 T1c 79 1.1 R-PZ 90.0 71.3 2 89 77.7 4 88 
2 8.2 6 T2a 106 1.8 L-PZ 91.2 71.6 3 85 77.8 6 85 
3  7.7 5 T2a 74 6.5 R-PZ 90.5 71.5 6 86 78.4 6 83 
4  5.8 7 T2a 41 2.2 R-PZ 90.8 71.4 5 89 78.1 6 87 
5 7.0 8 T2a 51 1.8 L-PZ 90.7 71.5 3 88 78.6 6 87 
 
Table 3 
Patient characteristics, and DIL-IMRT and IMRT-78 treatment planning results. 
 
Abbreviations: DIL Loc. = DIL localization, NTCP = normal tissue complication probability, TCP = tumor 
control probability, DIL = dominant intra-prostatic lesion, L-PZ = left peripheral zone, R-PZ = right 
peripheral zone 
 
 
Intra-prostatic IMRT boosting with DCE-MRI and MRS image guidance 
 In all 5 patients a DIL could be determined by the combined functional MR imaging 
techniques. The initial PSA level ranged from 5.8 to 8.2 ng/ml and the prostate volume ranged 
from 41 to 106 cc (Table 3). The DIL volumes ranged from 1.1 to 6.5 cc and all were localized 
in the right or left peripheral zone. 
 
An example of a comprehensive MR examination and DIL volume delineation 
procedure of a 71-year-old prostate cancer patient (Pat. no. 4 from Table 3) is shown in Fig. 5. 
The patient presented with a PSA of 5.8 ng/ml and a palpable tumor in the right prostate lobe, 
staged on digital rectal and ultrasound examination as T2. A total of eight ultrasound-guided 
biopsies were taken, four from the left and four from the right prostatic lobe. Two right 
peripheral biopsies revealed a Gleason sum seven adenocarcinoma. The T2-weighted MR 
images showed a decrease of signal intensity in the right peripheral zone, without capsular 
invasion (Fig. 5a). Evaluation of the DCE-MR imaging showed contrast kinetic parameters, 
suggesting malignancy on the right side (Fig. 5b-c). MRSI confirmed the previous findings. An 
increased choline+creatine/citrate ratio in eight voxels was found in the right peripheral zone 
(Fig. 5d-e), and a choline+creatine/citrate map was constructed to visualize the MRSI based 
tumor nodule (Fig. 4f). Based on the combined DCE-MRI and MRSI data, this prostate tumor 
was staged as T2a located in the right peripheral zone. The DIL volume was delineated within 
the 3D editor and transferred to the treatment planning system. The DIL volume was 2.2 cc 
and a 3D margin of 5 mm was drawn for PTV90. The prostate gland measured 41 cc and a 3D 
margin of 7 mm was drawn for PTV70 (Fig. 6). The DIL-IMRT planning resulted in a dose 
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distribution as displayed in Fig. 7a. For this plan a TCP of 89% was estimated and an NTCP 
Rwall of 5%. The IMRT-78 treatment plan (Fig. 7b) yielded a TCP of 87% and an NTCP Rwall 
of 6%.  
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Fig. 5 DCE-MRI and MRSI results of patient no. 4. 
(a) Axial T2-weighted MR image with decreased signal intensity in the right peripheral zone (arrows), 
without evidence of capsular invasion. DCE-MRI results are displayed in b-c.  
(b) The start-of-enhancement parameter demonstrated an earlier enhancement in part of the low-signal-
intensity lesion (arrows) compared to the left peripheral zone.  
(c) The volume transfer constant (Ktrans) was elevated in the low-signal intensity lesion (arrows) 
indicating tumor tissue. 
(d) MRSI detected elevated choline and low citrate peaks in 7 voxels. The blue box indicates the voxel, 
of which the spectrum, as displayed in Fig. 5e, originates from. 
(e) 1H-MR spectrum from a voxel in the right peripheral zone. An increased choline+creatine/citrate ratio 
indicates prostate cancer. Cho = choline, Cr = creatine and Ci = citrate. 
(f) A strongly interpolated (choline + creatine over/ citrate map was used to visualize the MRSI-based 
tumor nodule. 
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Fig 6.  
DIL-IMRT treatment volumes of patient no. 4.  
3 panel (transversal, saggital en coronal view) CT treatment planning image:  the DIL volume (red 
colorwash) and prostate (black line) were delineated with a margin of 5 and 7 mm, for PTV90 (red line) 
and PTV70 (orange line), respectively. In yellow the central gold marker is indicated. 
 
A summary of the comparison of DIL-IMRT and IMRT-78 data for the investigated 
patients is given in Table 3. Overall, in this small selected number of patients, the TCPs, 
ranging from 83% to 89% did not differ between the two IMRT plans. But in four out of five 
patients, DIL-IMRT reduced the NTCP Rwall, ranging from 1 to 3%. For every individual 
patient, the therapeutic (TCP/NTCP) ratio was increased by the DIL-IMRT plan. An example of 
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the different dose distribution pattern of the inner rectal wall surface for the two treatment 
plans is displayed in Fig. 7c-d. The combination of DIL-IMRT and a daily inserted ERB, which 
dilates the rectal wall, gives a different dose distribution over the inner rectal wall (Fig. 7c), 
compared to the IMRT-78 plan and ERB (Fig. 7d). In case of DIL-IMRT, a smaller area is 
exposed to a dose > 80 Gy, surrounded by a larger area of about 70 Gy and the dorsal rectal 
wall is exposed to doses < 40 Gy. 
 
 
 
Gy 
a
c d
b
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7.  
Transversal dose distribution: for (a) DIL-IMRT 70-90 and (b) IMRT-78 plan of patient no. 4.  
Inner rectal wall dose surface maps resulted from the (c) DIL-IMRT plan and from (d) the IMRT-78 plan. 
The dose distribution of the inner rectal wall surface is displayed by virtual rectum unfolding (i.c. the 
rectum is virtually cut open along the posterior wall). On the horizontal axis the distance from anterior 
(towards the prostate and seminal vesicles) is displayed. On the vertical axis the distance from the most 
caudal delineated CT-scan is given.  
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DISCUSSION 
In this study, we have shown the feasibility of using combined functional imaging 
techniques of the prostate gland to integrate them into inverse treatment planning and to 
define a biological target volume (BTV) (1) for high dose intra-prostatic IMRT boosting. This 
MR-based BTV was then superimposed onto a treatment planning CT with a CT-MR gold 
marker-based fusion protocol. With two different IMRT plans and commonly used TCP and 
NTCP models, preliminary data were produced to investigative the potential gains of the DIL-
IMRT concept. 
Pickett et al. (21) were the first to report on the possible advantages of incorporating 
MR imaging, both anatomical and functional, into a static field prostate IMRT plan. In their 
case report the feasibility of treating a single lobe to 90 Gy, by MRSI guidance, was 
demonstrated. Previous investigations have shown that using anatomical MR images for more 
accurate prostate delineation resulted in 30 % reduction of prostate volume and a reduction of 
the proportion of irradiated rectal wall (2,3). This is demonstrated in Fig. 6, where, as a result 
of the MR, a sharp delineation of the ventral part of the gland tissue on the CT can be made. 
Integration of anatomical prostate MR imaging with the described CT-MR marker-based fusion 
method is now implemented into our daily clinical practice.  
Due to the increasing availability and improvements in MR imaging, its role in prostate 
radiotherapy has developed rapidly over the past years. With high sensitivity and specificity, 
both DCE-MRI and MRSI can provide accurate tumor staging (4,5, 8-12). MRSI has shown to 
provide a high specificity for prostate cancer (7,41). This technique has proven to be capable 
of accurately detecting prostate cancer in the peripheral zone (9,10,12). However, the 
availability of this imaging modality is still limited. Only a few institutions have the opportunity 
and the experience to use MRSI clinically. Experience with DCE-MRI in breast and bladder 
cancer indicates that, due to neo-vascularization, malignant lesions demonstrate an earlier 
and faster enhancement compared with that of benign lesions (42,43). This technique is widely 
available and is capable of detecting regions of prostate cancer in both the peripheral and the 
central prostate gland zone (4,5,9,10). In summary, DCE-MRI can identify regions of neo-
vascularity, suggestive for prostate cancer, while MRSI can detect malignant tumor nodules on 
voxel-size with high specificity. 
 Functional prostate MRS imaging can also help to assess local tumor control in early 
stage prostate cases (13). MR-based analysis in 118 prostate cancer patients, irradiated to a 
dose of 65 – 70 Gy, revealed that all twelve observed intra-prostatic recurrences originated 
within the initial tumor (18). This supports the concept of intra-prostatic boosting, with a dose 
higher than 70 Gy, while maintaining the dose to the remainder of the prostate at an 
intermediate dose level (around 65 – 70 Gy). The concept of a BTV for prostate cancer means 
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detection and localization of dominant tumor nodules with higher tumor cell density, the so-
called DIL, in contrast to non-DIL prostate tissue where the tumor cell density is lower and 
therefore a lower irradiation dose may be sufficient. Based on that hypothesis, we tested the 
DIL-IMRT 70-90 Gy treatment planning in a small selected patient population and compared it 
with a more standard whole-prostate IMRT 78 Gy plan. Our data suggest a comparable high 
TCP, ranging from 83% to 89%, for both IMRT plans. The DIL-IMRT plan produced in 4 out of 
5 patients a lower Rwall NTCP, as compared to the IMRT-78 plan and in all patients the 
therapeutic (TCP/NTCP) ratio was increased. 
Nutting et al. (20) performed an IMRT planning study in six patients in which the DIL 
volume and localization were derived from prostatectomy specimens that were projected into 
planning CT scans. An IMRT plan (70 Gy whole prostate + 20 Gy boost on DIL) was 
compared with a whole homogeneous irradiated prostate with IMRT to 70 Gy. With the DIL 
boosting the estimated TCP increased from 64.4% to 95.6%. Instead of 70 Gy we choose for 
78 Gy, as a result of the positive MD Anderson randomized trial (14). Nutting et al. (20) 
observed a 1.8% increase of the rectal NTCP, to a mean value of 7.7% for the DIL-boost plan. 
The rectal volume was delineated as the rectal wall plus content, so a direct comparison with 
our NTCP data is difficult. With our DIL-IMRT plan the estimated Rwall NTCP decreased for 
the individual patients with 1 – 3 %, to a mean NTCP of 4 %. In our study the CTV-PTV 
margins were smaller (7 and 5 mm), while Nutting et al. (20) applied 10 mm margins, which 
also can explain the differences in NTCP. 
The TCP/NTCP ratio, as observed by Nutting et al. (20), was very dependent on the 
localization of the DIL: anteriorly in the prostate or posteriorly, close to the anterior rectal wall. 
In our pilot study, we detected the DILs in the posterior part of the peripheral zone of the 
prostate in all five patients. According to extensive pathological examinations, this is also the 
localization where the highest portion (74 %) of the cancer foci is located  (44). Nevertheless, 
we have to expand our patient population to obtain more variation of DIL localization and 
different DIL volumes to further investigate the impact on the TCP/NTCP ratio. Currently, we 
are enrolling more patients for this study. Also the effect of this novel approach on other 
surrounding radiosensitive structures, such as the neurovascular bundle, penile bulb and 
urethra has to be investigated. This will be topic of future investigations.  
In prostate brachytherapy, the MR image-guided DIL boosting concept has been tested 
for patients with a prostate gland volume < 50 cc (19,22,23). Only MRSI was used for DIL 
detection and localization. Zaider et al.(23) registered MRSI and ultrasound images for 
boosting of the intra-prostatic tumor regions. In a single patient, three different DIL volumes 
(1.36  – 3.71 cc) were defined: one from actual MRSI information and two hypothetically 
constructed. Depending on the size of the DIL, the image-guided boost yielded TCP values 
ranging from 94.3% to 96.5%, without increasing the maximum urethral dose. In comparison, 
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standard brachytherapy treatment resulted in TCP values ranging from 64.9% to 76.1%. An 
endorectal probe, filled with 100 cc of air, was used for MRSI, causing gland deformation and 
therefore difficulties arose with the registration procedure. They have developed an algorithm 
to overcome this problem and achieved absolute 3D-positional errors of 2.2 mm  1.2 (mean 
 1SD) (24). Dibiase et al.(19) and Pouliot et al.(22) encountered similar problems with 
precise MR-CT registration due to gland deformation by the endorectal coil. MRSI defined 
prostate boost volumes were manually entered into the planning system and the gland 
distortion was only addressed visually. In our study, we used an endorectal balloon (ERB) 
filled with 80 cc of air, identical to the MR endorectal coil, for CT-scanning. This resulted in 
almost equal deformation of the prostate gland in MR and CT scanning, resulting in an 
accurate DIL projection onto the CT scan. The ICP method, in which the gold marker surface 
models are automatically registered, was used (25). This yielded an MR-CT fusion precision of 
1.1 mm in a dataset of 21 patients, using five operators. 
ERBs are used in prostate radiotherapy for their rectal wall sparing effect and are well 
tolerated by most patients (27-29,38). Since two years, the ERB, as mentioned in this study, 
has been used in our department and no severe ERB-related toxicity, apart from local anal 
irritation, has been reported. The ERB is applied and removed by the therapists and per 
treatment fraction an extra three minutes is added for the whole ERB procedures (26). The 
ERB is often referred to as a prostate immobilizer, but due to presence of gas and stool 
surrounding the ERB, the day-to-day interfraction prostate displacements can be high, up to 
4.7 mm (1 SD) for the anterior-posterior direction (26). Therefore, we now use the ERB in 
combination with a gold marker based portal imaging verification and correction protocol 
(26,30-32). As reported earlier, to increase their acceptability, development of user- and 
patient-friendly ERBs is warranted (38). 
 The presented DIL-IMRT plan, in combination with a daily inserted ERB, which dilates 
the rectal wall, gives an interesting dose distribution over the inner rectal mucosa (Fig. 7c). A 
relatively small area is exposed to high doses (> 80 Gy), surrounded by a larger area of 
intermediate doses and a low dose over the dorsal rectal wall. Recent data have shown that 
this type of spatial dose distribution and also the amount of rectal wall surface irradiated to low 
doses may further reduce the Rwall NTCP (34). Therefore, in treated DIL-IMRT patients, the 
actual Rwall late toxicity may even be lower than the estimations calculated in this study, 
based on the Lyman-Kutcher-Burman model with Emami parameters (35-37). Execution of the 
DIL-IMRT concept and thorough follow-up may also provide us with additional information to 
construct more accurate Rwall NTCP models. 
Regarding the TCP calculations, it should be remarked that there is still an ongoing 
debate in the literature on the LQ parameter values especially whether the α/β ratio is low, i.e. 
in the range typical for late responding tumors (44-46). For the TCP calculations we have 
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applied parameters comparable to those applied by Nutting et al (20), i.e. an α/β value typical 
of early responding tissues (as applied by Nahum et al (40)) and further assuming a 
heterogeneous distribution of radiation sensitivities () and assuming a ratio of 100 in the 
clonogen densities between DIL  (107 cells/cm3) and the rest of the prostate (105 cells/cm3). An 
extensive comparison of different TCP models is beyond the scope of this paper. However, we 
have verified that choosing lower α/β TCP models does not alter the conclusions. If 
parameters proposed by Wang et al. (45) were used  (i.e. α/β = 3.1 Gy, α = 0.15 ± 0.04 Gy -1, 
Tpot = 42 days and number of clonogens is in the range 106-107) or those as proposed by 
Fowler et al. (46) (i.e. α/β= 1.5 Gy, α = 0.0391 ± 0.0098 Gy -1 ) the absolute TCP values 
changed, but the relative values for the DIL-IMRT and IMRT-78 plans were comparable and 
did not differ. 
The issue of multi-focality of prostate cancer is not addressed in this technical 
feasibility study. In a large pathology study, 83% of the prostatectomy specimens had more 
than one cancer focus (47). For this feasibility study we selected patients with uni-lateral 
palpable, ultrasound detected and biopsy-proven tumors. This was done to avoid possible 
extra difficulties in interpreting and executing the implementation of the described CT-MR 
fusion and DIL-IMRT planning. Pouliot et al. (22) have reported on multiple DIL volumes and it 
was possible to deliver separate boost volumes on these tumor nodules with MRS-guided 
brachytherapy, without compromising the surrounding normal tissues. In another study, a 
multiple boost implant in one patient with four tumor foci was impractical to perform (19). For 
all other patients an MRSI-guided brachytherapy boost was given successfully with toxicity 
comparable to conventional treatment. The goal of our study was to demonstrate the feasibility 
of incorporating two MR imaging techniques in a (single) external beam DIL-IMRT concept for 
a wide range of prostate gland volumes (41-106 cc). The next step will be to include more 
patients, also with more than one DIL and to investigate the possible advantages or 
disadvantages, in terms of tumor control probability and toxicity. Xia et al. (48) have already 
demonstrated the feasibility of planning two DILs up to 90 Gy with IMRT on a selected patient 
case, but their DIL volumes were derived from MRSI only and, due to ERB induced gland 
deformation in the MRS study, the MR-CT image fusion was a visual approximate process. 
The DIL-IMRT concept may not be applicable in the case of more than two or three DILs 
localized near the rectal wall or urethra, due to unacceptably high estimated toxicity scores. 
Currently, we are also enrolling bi-lateral prostate tumors with multiple DILs and we are further 
evaluating the presented intra-prostatic IMRT boosting under DCE-MRI and MRSI guidance. 
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CONCLUSION 
 In this study, the feasibility was demonstrated to integrate two functional prostate MR 
imaging techniques into inverse treatment planning, for the definition of a dominant intra-
prostatic lesion (DIL) for high-dose intra-prostatic boosting with IMRT (DIL-IMRT). In all 
patients the combination of DCE-MRI, identifying regions of neo-vascularity, suggestive for 
prostate cancer, and MRSI, detecting tumor nodules with high specificity, yielded a clearly 
defined single DIL volume. This DIL volume could be accurately transferred to the 
radiotherapy treatment planning system, by CT-MR image registration based on matching 3D 
gold marker surface models and usage of the same type of ERB for CT and MR imaging. 
Compared to the IMRT-78 plan, the DIL-IMRT plan estimated a similar TCP, but a decreased 
Rwall NTCP. This resulted in an increase of the therapeutic (TCP/NTCP) ratio, in favor of the 
DIL-IMRT plan. Also the typical Rwall spatial dose distribution, as a result of the DIL boosting, 
may indicate a further reduced actual rectal toxicity. 
Before bringing DIL-IMRT into clinical practice, a larger patient population, with more variation 
in the number and localization of the DIL, has to be studied, additionally including the 
preliminary tumor control probabilities and toxicity estimates. 
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ABSTRACT  
Purpose: To investigate prospectively the rectal wall (Rwall) spatial dose distribution, toxicity 
and mucosal changes after prostate cancer radiotherapy with or without an endorectal balloon 
(ERB). 
Methods and materials: 24 patients with ERB and 24 without ERB (No-ERB) were treated 
with three-dimensional conformal radiotherapy (3D-CRT) to a dose of 67.5 Gy. The Rwall was 
divided into 16 mucosal areas and Rwall dose surface maps were constructed. After three 
months, six months, one year and two years a rectosigmoidoscopy was performed and each 
mucosal area was scored on telangiectasia, congestion, ulceration, stricture and necrosis. Late 
rectal toxicity was correlated to the endoscopic findings. 
Results: The ERB significantly reduced the Rwall volume exposed to doses > 40 Gy. Late 
rectal toxicity (grade ≥ 1) was reduced significantly in the ERB group. 146 scopies and 2336 
mucosal areas were analyzed. Telangiectases were most frequently seen and appeared after 
six months. At one and two years, significantly less high-grade telangiectasia (T 2-3) was 
observed in the ERB group at the lateral and posterior part of the Rwall. In mucosal areas 
exposed to doses > 40 Gy, less high-grade telangiectases (T 2-3) were seen in the ERB group 
compared to the No-ERB group. 
Conclusions: An ERB reduced the Rwall volume exposed to doses > 40 Gy, resulting in 
reduction of late rectal mucosal changes and reduced late rectal toxicity. Although further 
analysis is needed, these data suggest an ERB-induced increased tolerance for late Rwall 
damage. 
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INTRODUCTION  
Numerous studies have investigated the relationship between the delivered dose 
distribution to the rectum and the risk of late rectal toxicity in prostate cancer radiotherapy. 
Exposure to high dose (> 60 Gy) (1-4) as well as intermediate doses (32 – 50 Gy) is 
associated with higher risk of late rectal bleeding (5-8). Perhaps more important is the pattern 
of the spatial dose distribution over the inner rectal wall (Rwall), as seen on Rwall dose maps. 
Cluster model analysis indicated that the size of Rwall mucosa, exposed to doses between 27 
and 43 Gy, was significantly associated with late rectal toxicity (5). Therefore, to prevent 
increasing late toxicity rates in dose escalation, one should not only focus on the high doses 
but also on the intermediate Rwall doses and on the spatial dose distribution. Endorectal 
balloons (ERB) have been tested to reduce toxicity by decreasing the Rwall volume being 
irradiated (9-17). This Rwall sparing effect has been evaluated for three different ERBs by 
construction of inner Rwall dose maps that revealed an advantageous spatial dose distribution 
(14). The ERB reduced the Rwall surface exposed to intermediate and high doses, by pushing 
the lateral and posterior Rwall away from the high-dose region. An air-filled ERB may cause 
an additional dose reduction to the superficial anterior rectal mucosa due to the dose build-up 
effect, without underdosing the prostate gland (12). Clinical studies in patients irradiated with 
an ERB have shown a favorable low late rectal toxicity rate (9, 12).  
Late rectal, radiation induced, mucosal changes (i.e. telangiectasia, mucosal 
congestion and ulceration), as being the pathologic cause of late rectal bleeding (18) have 
been evaluated by endoscopy (19, 20). The incidence and evolution of these mucosal 
radiation effects were studied in both symptomatic (“bleeders”) and a-symptomatic (“non-
bleeders”) patients. First, a strong correlation was observed between the presence and 
severity of telangiectases and the radiation dose administered to the Rwall mucosa (19, 20). 
Secondly, patients with more severe high-grade telangiectasia had a higher probability (66 – 
80 %) of developing late rectal bleeding. Therefore, high-grade mucosal changes were 
assumed to be predictive for late rectal bleeding, many years after completion of the treatment 
(18). 
In patients irradiated with or without an ERB no comparative study has yet been 
conducted to prospectively investigate late rectal mucosal changes and to correlate these 
findings to a detailed Rwall dose distribution. The first goal of this study was to display and 
analyze the differences in geographical dose distributions over the inner Rwall mucosa. The 
second goal was to compare the rectal mucosal changes, as observed by periodical 
standardized endoscopy, and to correlate these to the Rwall dose distributions and to the 
commonly used late toxicity grading scales. 
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MATERIALS AND METHODS 
Patient preparation and treatment 
Forty-eight patients were irradiated for localized prostate cancer (T1-3N0M0) and, after 
informed consent was given, included in this study. Apparent pre-existing anal irritation, an 
active inflammatory bowel disease or hemorrhoids, were exclusion criteria. Patients were 
randomly assigned to receive a treatment with (“ERB group”, n = 24) or without ERB (“No-ERB 
group”, n = 24) over a period of twelve months, i.e. the year 2002. Details on preparation and 
treatment have been described earlier (21). In brief, four fine gold markers were inserted under 
ultrasound guidance for prostate position verification and correction (Hospimed International 
B.V., Dalfsen, The Netherlands). A planning CT-scan was obtained at 3mm slice thickness 
(AcQsim spiral CT; Philips Medical Systems, Bothell, WA). The planning target volume (PTV) 
was defined as the prostate plus seminal vesicles, both expanded with a 9 mm 3D margin. The 
rectum was delineated from the ischial tuberosities up to the rectosigmoid flexure; both the 
inner and outer Rwall contours were outlined (6, 16). A beams-eye-view based 3D-conformal 
treatment plan was designed, with individual shielding of normal tissues (Pinnacle3 treatment 
planning system; Philips Medical Systems, Andover, MA). With an orthogonal, equally 
weighted, 18 MV photons four-field isocentric technique, a dose of 67.5 Gy was delivered in 7.5 
weeks (four fractions per week), applying 2.25 Gy daily fractions (Fig. 1).  
The ERB was inflated with 80 cc of air and had a length of 90 mm and a diameter of 45 mm 
(22) (Medrad, Indianola, PA). Before every treatment fraction, a new ERB was inserted by the 
attending radiation therapist. Patients were positioned supine, on a flat couch and a foam knee 
support. A correction protocol (21) was applied during treatment, to reduce systematic 
positioning errors using a camera-based electronic portal imaging device (Theraview NT, 
Cablon Medical B.V., Leusden, The Netherlands). 
All patients were seen weekly during the treatment period and every three months 
afterwards. Acute and late urinary and rectal toxicity items were scored during each visit, 
according to the Radiation Therapy Oncology Group and the Fox Chase Modified Late Effects 
Normal Tissue Task force radiation morbidity scales (4). Late toxicity was evaluated over the 
period of the first 30 months after completion of the radiotherapy.  
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(a) 
(b) 
 
 
Fig. 1. 
Transversal CT images with dose distribution, in Gy, for (a) No-ERB and (b) ERB patient. 
Prostate and seminal vesicles (yellow lines), Planning target volume: prostate and seminal vesicles + 9 
mm margin (thin white lines) and rectal outer contour (thick white lines) are highlighted.  
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Endoscopy and mucosal scoring system 
 All patients underwent a standardized rectosigmoidoscopy by a trained and experienced 
endoscopist, three months, six months, one year and two years after completion of the radiation 
treatment. A sodium-phosphate enema 133 ml (Tramedico B.V., Weesp, The Netherlands) was 
given 20 minutes before the examination. A mucosal mapping and scoring system, as described 
by Wachter et al., was used (20). The inner Rwall mucosa was divided into four distance levels in 
caudo-cranial direction, as measured from the anus; 0 - 4 cm, 4 – 8 cm, 8 – 12 cm and 12 – 16 
cm. At each level, four mucosal areas (anterior, left-lateral, right-lateral and posterior) were 
defined, resulting in 16 mucosal areas to be evaluated per patient. Each mucosal area was 
scored on five distinct endoscopic items; the presence and grading of telangiectasia (grade 0 – 
4), mucosal congestion (grade 0 – 3), ulceration (grade 0 - 4), stricture (grade 0 – 4) and necrosis 
(grade 0 –1), according to an internationally accepted scoring system for radiation induced 
proctitis (20). 
The different grades of telangiectasia are abbreviated as “T 0” up to “T 3” (Table 1). Low-grade 
telangiectasia was defined as the presence of T 1. High-grade telangiectasia, predictive for 
late rectal bleeding (19, 20), was defined as the presence of T 2 or T 3, and is abbreviated in 
the text as T 2-3. 
 
Grading Telangiectasia Abbreviation 
0 none T 0 
1 a single telangiectasis T 1 
2 multiple non-confluent telangiectases T 2 
3 multiple confluent telangiectas T 3 
 
Table 1. Grading system used for telangiectasia per mucosal area 
  
 140
 
Reduced late rectal mucosal changes with endorectal balloon 
The endoscopist was unaware if the patient was irradiated with or without an ERB and how long 
ago the treatment was completed. The grading scores were noted on a scoring list and 
transferred to the radiotherapy department for further evaluation. Thus the endoscopist was also 
not informed about the scoring data of previous investigations. 
  
 In both groups, patients who experienced any form of late ( > 3 months after end of 
treatment) rectal bleeding, ranging from slight rectal blood loss to bleeding needing medical 
intervention, were identified as “bleeders”. The highest observed telangiectasia scores (max 
mucosal Rwall T score), as observed over the course of all endoscopies were correlated to 
late rectal bleeding and compared with the “non-bleeders”.  
  
Rectal wall dose surface maps and EUD 
After the definitive treatment plan was made, the spatial dose distribution over the inner 
Rwall mucosa was visualized by generating Rwall dose surface maps (5, 14). The dose 
distribution on the inner Rwall surface was displayed by means of virtual rectum “unfolding”. 
Corresponding with the division of the inner Rwall into mucosal areas for the endoscopic 
evaluation, the Rwall dose surface map was divided into16 areas. To correlate the endoscopic 
findings to the radiation dose of that area, the generalized equivalent uniform dose (EUD) for 
every separate mucosal area was computed. The generalized EUD represents the uniform 
dose, which leads to the same probability of injury as the corresponding inhomogeneous dose 
distribution of each mucosal area. For calculation of the Rwall EUD, the value α = 6 was 
chosen for the normal tissue-specific parameter that describes the dose-volume effect, 
according to Wu et al. (23). Illustrated case examples are described in the Results section. 
Each mucosal area was assigned to a EUD bin (0 - 20, 20 – 40, 40 – 60 and > 60 Gy) and the 
incidences of the separate dose bins were computed for both the No-ERB and ERB group. To 
demonstrate the overall differences in spatial dose distribution over the inner Rwall mucosal 
areas for each treatment group, two patient group mean EUD mucosal area maps were 
constructed. Finally, for each separate mucosal area, assigned to a EUD dose bin, the 
presence of high-grade telangiectasia (T 2–3) was counted and compared between the No-
ERB and ERB patients. 
 
Statistical analysis 
 Differences in the observed toxicity scores were analyzed by chi-square tests or Fisher 
exact tests. The association between EUD and toxicity was analyzed by means of contingency 
tables for the mucosal areas in specific EUD bins (0 - 20, 20 – 40, 40 – 60 and > 60 Gy). 
Differences were considered significant for two-tailed p-values less than 0.05. For the statistical 
analysis the Stata package was used (Stata Corporation, College Station, Texas, USA).
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RESULTS 
Patient tolerance and toxicity 
 As described earlier, the transrectal implantation of the gold markers was a safe and 
simple procedure and the ERB was tolerated well by the patients (21). 
The acute urinary and rectal toxicity scores were similar for the No-ERB (n=24) and 
ERB group (n=24). Grade 1 urinary toxicity was scored in 19 cases and grade 2 in 4 cases in 
the No-ERB group and in 13 and 7 patients in the ERB group, respectively. No grade 3 acute 
urinary toxicity was observed in both groups. The main complaints were increased urinary 
frequency, and in two patients of each group a temporary catheterization was necessary. In 
the No-ERB group, acute grade 1 rectal toxicity was scored in 12 cases and grade 2 in 7 
cases and in the ERB group in 11 and 7 patients, respectively. The main complaints were 
increased defecation frequency, and slight mucous discharge. In the ERB group, in two out of 
the seven patients with grade 2 toxicity, mild rectal bleeding occurred, which resolved within 
two weeks after radiotherapy. No grade 3 acute gastro-intestinal toxicity was observed in both 
groups. 
 
After 30 months of follow-up, the late urinary toxicity in both groups was mild (no grade 
3 or 4) and comparable for both groups; grade 1 and 2 was scored for the No-ERB group in 8 
and 3 cases, respectively and for the ERB group in 3 and 3 cases, respectively. Main 
complaints were increased frequency and nocturia more than twice baseline. One ERB patient 
experienced minor hematuria after two years, which resolved spontaneously after two months 
(no confirmative cystoscopy was performed). 
The observed late rectal toxicity (grade 1 or higher) was significantly lower for the ERB 
group (p = 0.003). Grade 1 was experienced in 14 patients in the No-ERB group and in 5 
patients in the ERB-group. Grade 2 rectal bleeding occurred in one patient in the No-ERB 
group. In one patient from the No-ERB group a grade 3 rectal bleeding, resulted in two 
blood transfusions and five laser coagulations. In the ERB group no grade 2 or 3 rectal toxicity 
occurred. 
 
“Bleeders” and “non-bleeders” 
In the No-ERB group, 8 patients (33 %) experienced some form of late rectal bleeding 
(“bleeders”) (Table 2).  
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No-ERB ERB
Max. T score Non-bleeders Bleeders Total Non-bleeders Bleeders Total
T 0 1 0 1 0 0 0
T 1 2 0 2 2 0 2
T 2 9 4 13 14 2 16
T 3 4 4 8 5 1 6
Total 16 8 21 3
 
 
Table 2.  
 Number of non-bleeders and bleeders per treatment group, stratified by maximum telangiectasia score 
(Max. T score) of the mucosal Rwall on endoscopy. 
 
The onset was between 9 and 24 months (median 18) after radiotherapy. The patient 
with grade 2 bleeding needed two laser coagulations after which the bleeding resolved 
completely. The patient with grade 3 rectal toxicity needed five coagulations and two 
transfusions, but after 30 months of follow-up, this patient still experienced intermittent (once 
per month) minor rectal bleeding. Five patients experienced occasional (once per few days to 
once a week) blood; this all resolved spontaneously after 5 to 20 months. One patient has had 
every two or three days blood spots on his stool, since 13 months post-irradiation. 
In the ERB group, 3 patients (13 %) were identified as bleeders (Table 2), starting 10, 
23 and 29 months after radiotherapy; in two patients, bloody discharge appeared once a week, 
which resolved completely. In one patient only once a month some blood spots appeared on 
the stool.  
Due to the limited size of the two groups, the difference in late rectal bleeding was not 
statistically significant (p = 0.17) 
 
Endoscopic findings 
 A total of 146 rectosigmoidoscopies were performed. The average duration of each 
procedure was 10 minutes and no complications occurred. The distribution of the number of 
endoscopies was as follows: after three months: 18 and 13, after six months: 11 and 18, after 
one year: 21 and 23 and after two years: 22 and 20, for the ERB and No-ERB group, 
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respectively. A total of 2336 mucosal areas was inspected and graded for the five endoscopic 
scoring items. 
In none of the patients mucosal stricture or necrosis was observed. In nine mucosal 
areas of five patients (three ERB and two No-ERB), grade 1 superficial micro-ulcerations (< 1 
cm2 ) were detected. All but one resolved spontaneously. Mucosal congestion of the analyzed 
mucosal areas was equally often observed in the ERB (9 %) and No-ERB (10 %) group. In 
four patients (two ERB and two No-ERB), grade 3 congestion (diffuse confluent reddening and 
edematous mucosa) was scored. In three patients this congestion was resolved at the next 
endoscopy. Overall, no differences were observed between the two groups in the presence of 
mucosal congestion (data not shown). 
  
Telangiectasia (grade 1 – 3) was seen in 29 % (No-ERB) and 20 % (ERB) of the 
mucosal areas. The evolution over time is displayed separately for low-grade T 1 (Fig. 2a) and 
high-grade T 2-3 (Fig. 2b). In both patient groups the low- and high-grade telangiectasia 
became apparent after 6 months and reached a peak at one year. For T 1 the incidences in 
both groups decreased after one year. For the high grade T 2-3 the peak incidence was also 
reached after one year, but after two years no evident decrease could be observed in both 
groups. At 6 months a higher incidence in T 1  (p = 0.09) was seen in the ERB group. One 
year after radiotherapy, significantly less T 1 (p = 0.045) and T 2-3 scores (p = 0.0003) were 
apparent in the ERB group. At two years, the incidence of T 2-3 was still lower in the ERB-
group (p = 0.0003), but for T 1 the difference was no longer statistically significant (p = 0.15). 
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Fig. 2. 
Percentage of mucosal areas scored with (a) low-grade (T 1 score) or (b) high-grade (T 2-3 score) 
telangiectasia at endoscopy after radiotherapy. 
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The two years scores, after full expression of the telangiectases, were used to analyze the 
spatial distribution of T 1 (Fig. 3a) and T 2-3 (Fig. 3b) over the anterior, lateral and posterior 
Rwall. T 1 telangiectasis was not only seen at the anterior or lateral Rwall, but also at the 
posterior wall in both groups. The differences between the No-ERB and ERB group were not 
statistically significant. For T 2-3, a significant reduction was seen at the lateral Rwall (p = 
0.007) and posterior Rwall (p = 0.05), in favor of the ERB group (Fig. 3b). For the anterior wall, 
there was also a difference, but did not reach statistical significance (p = 0.07).  
 
Correlation endoscopic findings and late rectal bleeding 
In the No-ERB and ERB group, all patients that experienced rectal bleeding, had one or 
more mucosal areas with high-grade T2-3 telangiectasia (Table 2). In the two patients who 
needed laser coagulations extensive confluent T 3 telangiectases in multiple areas were 
observed.   
Overall, there was no statistically significant difference in the occurrence of the maximum 
mucosal Rwall score of T 2-3 between the two groups (21 vs. 22, p = 1.00). T 0-1 scores never 
led to late rectal bleeding, T 2-3 scores did in 38 % of the No-ERB patients and in 14 % of the 
ERB patients. So, although there was no difference in T 2-3 scores between the two groups, a 
trend was noticeable (not yet statistically significant p = 0.088) of less late rectal bleeding for 
patients with T 2-3 in the ERB group. 
 The presence of mucosal congestion or superficial micro-ulcerations could not be related 
to late rectal bleeding (data not shown).  
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Fig. 3.  
Percentage of anterior, lateral and posterior mucosal areas scored with (a) low-grade (T 1 score) or (b) 
high-grade (T 2-3 score) telangiectasia at two years after radiotherapy. 
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Rectal wall dose surface maps and EUD 
Examples of the projected dose distribution on the Rwall in beams eye view and dose 
surface maps, for a No-ERB and an ERB patient, are displayed in Fig. 4a and Fig. 5a, 
respectively. Next, the dose grid, displayed over the unfolded inner Rwall, is presented (Fig. 
4b and Fig. 5b). This individual dose grid was used to compute the EUD in each of the 16 
mucosal areas, resulting in a Rwall EUD map for each patient (Fig. 4c and Fig. 5c). In Fig. 4d 
and 5d, the endoscopy telangiectasia scores, at one and two years, are displayed. For good 
comparison with the dose maps, the EUD and T score of the posterior mucosal areas are 
presented in duplicate. The No-ERB patient (Fig. 4) had a EUD of the anterior and lateral 
Rwall mucosal areas (0 – 8 cm) of 59 – 67 Gy and the posterior Rwall (0 – 8 cm) was exposed 
to 47 – 49 Gy. At one year, T 1 and T 2 telangiectases were seen on the anterior and lateral 
Rwall (0 – 8 cm). After two years, circumferential high-grade T 2 was scored. Clinically, this 
patient experienced grade 2 rectal bleeding. In the ERB patient example (Fig. 5), the Rwall 
EUD map revealed a high dose irradiation to the anterior Rwall (59 – 67 Gy), an intermediate 
dose to the lateral Rwall (44 – 56 Gy) and a low dose (30 - 35 Gy) for the posterior Rwall 
mucosal areas. At the one-year mucosal assessment, the anterior Rwall areas were scored as 
T 1 and T 2 (Fig. 5 d, upper panel). Up to 8 cm, the lateral and posterior areas were scored as 
T1. At two years, the telangiectases at the lateral and posterior Rwall areas were resolved. On 
the anterior side, one mucosal area was scored as T 2 and two areas as T 1. In 30 months of 
follow-up, this patient developed no rectal bleeding. 
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Patient without ERB
EUD
R-P R-L A L-L L-P
12-16 cm 2 2 2 2 2
8-12 cm 32 42 54 46 32
4-8 cm 49 61 67 64 49
0-4 cm 47 59 64 61 47
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R-P R-L A L-L L-P
12-16 cm 0 0 0 0 0
8-12 cm 0 0 0 0 0
4-8 cm 0 1 1 1 0
0-4 cm 0 1 2 1 0
T score 2 years
R-P R-L A L-L L-P
12-16 cm 0 0 0 0 0
8-12 cm 0 0 0 0 0
4-8 cm 2 2 2 2 2
0-4 cm 2 2 2 2 2
Patient without ERB Inner Rectal Wall Localization
R-POST R-LAT ANT L-LAT L-POST
15 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
14 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
13 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
12 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
11 3 3 3 3 3 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 3 3 3 3
10 13 13 13 13 14 15 16 18 19 20 21 22 22 22 21 20 19 18 16 14 14 13 13 13
9 34 34 34 35 38 42 48 54 59 61 62 63 63 63 61 60 56 48 42 37 36 35 34 34
8 37 36 37 37 38 40 42 45 50 53 57 60 63 63 62 61 58 53 48 43 40 38 37 37
7 38 39 39 40 42 47 55 62 65 67 67 67 67 67 67 67 67 66 64 58 50 44 40 39
6 43 44 45 47 51 58 62 65 66 67 67 68 68 67 67 67 67 67 66 64 60 54 47 44
5 39 40 42 46 52 58 64 66 67 68 68 68 68 68 67 67 66 65 61 53 45 41 39 39
4 52 54 56 60 63 65 66 67 67 68 68 68 68 68 68 67 67 67 66 65 62 60 60 60
3 44 46 50 54 59 64 66 67 67 67 67 67 67 67 67 67 67 67 66 64 59 53 49 46
2 41 42 43 46 51 57 61 64 66 67 67 67 67 67 67 67 66 64 62 57 51 48 45 42
1 49 50 53 55 57 61 63 64 65 65 66 66 66 66 65 65 65 64 63 60 58 57 54 52
0 31 31 31 31 31 32 32 33 34 36 37 37 36 36 36 36 34 32 31 31 31 31 31 31
c
a
d
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Fig. 4.  
Patient treated without endorectal balloon (No-ERB).  
(a) Rectal wall (Rwall) left-lateral beams eye view dose projection (left panel) and unfolded inner Rwall 
dose surface map (right panel).  
(b) Inner Rwall calculated dose grid. 
(c) Rwall equivalent uniform dose (EUD) mucosal dose map.  
(d) Telangiectasia score (T score) per mucosal area at one year (upper panel) and at two years (lower 
panel). 
Abbreviations: R-POST = right posterior Rwall; L-POST = left posterior Rwall; R-LAT = right lateral 
Rwall; L-LAT = left lateral Rwall;  ANT =  anterior Rwall.  
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9 33 33 33 33 33 33 39 53 62 64 64 65 64 64 64 63 59 47 36 33 33 33 33 33
8 35 35 34 34 34 35 39 50 62 66 66 67 67 67 66 66 64 52 40 35 34 34 34 35
7 35 35 35 35 35 35 39 48 61 66 67 67 67 67 67 66 64 56 43 37 35 35 35 35
6 35 35 35 35 35 36 43 59 65 67 67 67 67 67 67 66 62 46 37 35 35 35 35 35
5 35 35 35 35 35 35 37 45 60 66 67 67 67 67 67 67 66 59 42 36 35 35 35 35
4 35 35 35 35 35 38 47 56 63 66 67 67 67 67 67 66 60 47 41 36 35 35 35 35
3 35 35 35 35 35 36 40 54 64 66 66 67 67 66 67 66 66 59 44 37 36 35 35 35
2 35 35 35 35 35 36 39 44 54 61 65 66 66 66 66 66 65 62 56 50 41 37 36 35
1 34 34 34 34 35 35 35 36 38 42 48 53 57 56 55 52 46 42 37 36 35 35 34 34
0 32 32 32 32 33 33 33 34 34 34 34 34 34 33 33 33 32 32 32 32 32 32 32 32
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Fig. 5.  
Patient treated with endorectal balloon (ERB) 
(a) Rectal wall (Rwall) left-lateral beams eye view dose projection (left panel) and unfolded inner Rwall 
dose surface map (right panel).  
(b) Inner Rwall calculated dose grid. 
(c) Rwall equivalent uniform dose (EUD) mucosal dose map.  
(d) Telangiectasia score (T score) per mucosal area at one year (upper panel) and at two years (lower 
panel).  
Abbreviations: R-POST = right posterior Rwall; L-POST = left posterior Rwall; R-LAT = right lateral 
Rwall; L-LAT = left lateral Rwall;  ANT =  anterior Rwall.  
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In the ERB group, a significantly higher proportion of the Rwall mucosal areas were exposed 
to lower doses in comparison to the No-ERB group (Fig. 6); for 0 - 20 Gy (p = 0.03) and for the 
20 – 40 Gy (p = 0.014). The percentages of mucosal areas exposed to higher doses were 
significantly lower, in favor of the ERB group: 40 – 60 Gy (p = 0.048), 60 - 68 Gy (p = 0.043). 
The maximum observed EUD did not exceed 68 Gy. 
 
0%
10%
20%
30%
40%
50%
0-20 Gy 20-40 Gy 40-60 Gy 60-68 Gy
Equivalent uniform dose
M
uc
os
al
 a
re
as No ERB
ERB
Fig. 6.  
Percentage of rectal wall mucosal areas exposed to 
irradiation dose, for patients treated without endorectal 
balloon (No-ERB) and with endorectal balloon (ERB). 
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The patient group mean EUD mucosal area maps are displayed in Fig. 7. For the ERB-
group, the rectal distension by the ERB resulted in mean lower doses, less than 40 Gy, over 
all the posterior mucosal areas. For the anterior mucosal areas, the mean EUDs, at the level 
of the prostate (0 – 8 cm ab anum) were not different between the ERB and No-ERB group. At 
the level of the seminal vesicles (8-12 cm, anterior and lat) the mean doses are higher for the 
ERB group. At that level, the anterior Rwall is being pushed towards the seminal vesicles 
explaining the higher Rwall dose there. 
 
T 2-3 score 
1 year 
EUD (Gy) No-ERB ERB p -value
0 - 20 4% 0% 0.12
20 - 40 6% 5% 0.69
40 - 60 23% 11% 0.017
60 - 68 48% 33% 0.13
2 years
EUD (Gy) No-ERB ERB p -value
0 - 20 0% 0%
20 - 40 11% 5% 0.41
40 - 60 30% 14% 0.02
60 - 68 52% 28% 0.03
 
 
Table 3. Mucosal areas exposed to different dose levels,with high-grade 
telangiectasis score (T 2-3)at one and two year’s endoscopy assessment. 
Abbreviations: EUD = equivalent uniform dose. 
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Correlation endoscopic findings and dose per mucosal area 
As displayed in Table 3, after one and two years the intermediate dose (40 – 60 Gy) 
exposed mucosal areas for the ERB group showed significantly less high-grade telangiectasia. 
The incidence of T 2–3 was reduced to approximately half, compared to the No-ERB group. 
For the high-dose (60 – 68 Gy) exposed areas, the percentage of areas showing T 2-3 at two 
years was also significantly reduced in favor of the ERB group. After one year this difference 
did not reach statistical significance. For the lower dose exposed mucosal areas (0 - 20 Gy 
and 20 – 40 Gy), the incidence of T 2–3 was low (< 10 %) and not statistically different 
between the two patient groups. 
     
No ERB group
Mean EUD
R-P R-L A L-L L-P
12-16 cm 2 2 2 2 2
8-12 cm 29 36 43 37 29
4-8 cm 49 60 67 61 49
0-4 cm 46 54 60 56 46
ERB group
Mean EUD
R-P R-L A L-L L-P
12-16 cm 2 2 2 2 2
8-12 cm 30 46 55 49 30
4-8 cm 37 57 67 60 37
0-4 cm 35 46 58 50 35
 
 
Fig. 7.  
Patient group mean EUD mucosal area maps for (a) the No-ERB group and (b) ERB 
group  
Abbreviations: EUD = equivalent uniform dose; ERB = endorectal balloon; A = 
anterior Rwall; L-L =  left lateral Rwall; R-L =  right lateral Rwall; L-P = left posterior 
Rwall; R-P = right posterior Rwall. 
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DISCUSSION 
 In this study, the late rectal mucosal changes, induced by 3D conformal radiotherapy 
(3D-CRT) for prostate cancer, have been prospectively followed by regular endoscopies in 
patients irradiated with and without an ERB. As expected, telangiectasia was seen most 
frequently after two years. The development and severity of telangiectasia in the irradiated 
rectal mucosa is considered to be the major pathologic change resulting in late rectal bleeding 
causing, among other anorectal symptoms, a severe reduction of quality of life (18, 24). The 
relation between the high dose delivered to the Rwall and the observed late rectal toxicity is 
well known (1-4). Also, it has been suggested that intermediate doses (6-8), especially the 
spatial dose distribution of dose areas below 45 Gy, to the Rwall play an important role in this 
phenomena (5). Earlier, we have demonstrated the Rwall sparing effect of different ERBs by 
reduction of the Rwall volumes exposed to high and intermediate doses, for both 3D-CRT and 
intensity-modulated radiotherapy (IMRT) (14). One of these ERBs we have been using 
clinically for the present study. After being instructed by the physician, the attending therapists 
were capable to apply the single-use ERB and, with some experience, this procedure adds 
two minutes to the daily treatment time. This ERB could not reduce the day-to-day interfraction 
prostate displacements (21) and now we use the prostate ERB in combination with a daily on-
line gold-marker based portal imaging protocol. The ERB was also shown to be of value for 
CT-MR image fusion in image-guided radiotherapy (25). 
 
Previously, others have reported that the ERB is well tolerated, and the related acute 
toxicity resolved quickly with standard interventions (10-13, 16, 17, 21). This is in line with the 
present observations, where no grade 3 acute toxicity was observed.  
Late toxicity data for radiotherapy with the use of an ERB are now coming available. 
The Baylor College group irradiated 116 men with IMRT (mean dose 76 Gy) and a daily-
applied 100 cc ERB (12). After a median follow-up of 31 months, they reported a grade 2 and 
3 late rectal toxicity rate of 6.9% and 1.7%, respectively. D’Amico et al. reported a 10% 
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estimate of grade 3 rectal bleeding, after two years, in 57 men treated with four-field 3D-CRT 
(dose 75.6 Gy) and a 60 cc ERB, applied in 15 of the 40 radiation treatments (9). Both authors 
reported a reduction of the volume of the rectum receiving 70 Gy or more, due to the ERB (9, 
12). No statements were made about reduction of Rwall dose exposure in lower dose regions 
and no endoscopic assessment has been reported yet. Although it is recognized that the 
patient population in the present study is smaller and the prescribed dose is lower than the 
afore-mentioned two studies, the late rectal toxicity rate (Grade 1 or higher) after 30 months 
was significantly lower for the ERB group. In the ERB-group no rectal bleeding requiring 
medical interventions occurred. Longer follow-up is necessary before definitive conclusions 
can be drawn, because the onset of late anorectal symptoms can extend beyond two or three 
years after completion of radiotherapy (1, 5, 18, 24, 26-29). 
 
To our knowledge, this is the first comparative prospective analysis of late rectal 
mucosal changes in two patients groups, No-ERB and ERB, by periodical standardized 
rectosigmoidoscopy, independent of the existence of radiation related symptoms. Zelefsky et 
al. (27) reported endoscopic findings in 57 patients presenting with late rectal bleeding after 
high-dose 3D-CRT, up to 81 Gy. Exact numbers were not provided, but most patients had 
telangiectases of the anterior wall and only patients reporting severe grade 3 rectal toxicity had 
rectal ulceration. At our endoscopic assessments, performed up to two years and with a 
maximum Rwall dose of 68 Gy, no rectal ulcerations have been observed yet. Wachter et al. 
(20) performed a single sigmoidoscopy in 44 patients irradiated with a dose of 66 Gy, four-field 
3D-CRT, and a 40 cc air-filled ERB at a median of 29 months after treatment. In contrast to 
our study, no individual Rwall dose surface maps were used for dose-response analysis. 
Further, the Rwall dose exposure per mucosal area was not a calculation from the treatment 
planning system, but an estimation derived from the lateral beam’s-eye view. Corresponding to 
our data, a good correlation was observed between the endoscopic findings and the estimated 
Rwall dose; the occurrence of grade 3 telangiectasia was strictly limited to high-dose (> 60 Gy) 
regions at the anterior wall, while grade 1 and 2 telangiectasia were observed at the whole 
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circumference, corresponding to the medium (30 – 60 Gy) and low-dose (< 30 Gy) regions. 
Also a good correlation between clinically apparent symptoms and the endoscopy scores was 
found. Nine patients (20%) experienced late rectal bleeding. In 66% of these patients grade 2-
3 telangiectasia were observed compared to 15% in the non-bleeders. On the other hand, in 
five patients without rectal bleeding, grade 2-3 telangiectasia were seen. These findings 
correspond to those of the present study. It was postulated that, not only the high dose regions 
at the anterior rectal wall but also the dose distribution of the whole circumference is relevant 
in the development of late rectal bleeding (20).  
The importance of reducing high dose exposure to the posterior Rwall has been 
recognized previously (30) and interventions such as lateral rectal shielding have reduced late 
rectal morbidity (31). The present study has shown that the ERB reduced the dose to the 
posterior and lateral Rwall mucosa, while maintaining a high dose to the anterior mucosa (Fig. 
1b, 5, 7). This resulted in a significant reduction of T 2-3 after one and two years (Fig. 2b) and 
attributed to a reduced late rectal toxicity in the ERB group. This reduction of severe late rectal 
changes was mainly seen, as expected, in the lateral and posterior Rwall mucosal areas (Fig. 
3b). 
 
The observed onset of bleeding symptoms correlated well with larger studies, where 
rectal bleeding appeared most often between 12 and 30 months of follow-up (1, 3, 27-29). This 
is in line with the presented endoscopic findings, where T 2-3 developed in the first year after 
treatment and reached a peak at the one-year assessment (Fig. 2b). In another prospective 
analysis, in 20 prostate cancer patients (65 Gy, four-field box technique, without ERB), every 6 
months up to 3 years after treatment, rectosigmoidoscopies were planned (19). A statistically 
significant correlation was found between multiple telangiectases, rectal bleeding and mucosal 
discharge. In line with our observations, the development of telangiectasis evolved at a rate 
parallel to the development of rectal bleeding. Eighty percent of the patients, who developed T 
2-3, experienced late rectal bleeding. In five patients with telangiectasia spontaneous mucosal 
improvement was seen. Detailed data on localization, spatial dose distribution and the 
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estimated dose on these mucosal areas were not provided. As concluded by the authors, this 
improvement may be an explanation for the observation that rectal bleeding resolves in 
patients with mild symptoms after radiotherapy. We also saw improvement of mucosal 
changes during follow-up (Fig. 5e) and relief of late rectal bleeding. One can hypothesize that 
the probability of regeneration of rectal mucosa, and thus amelioration of rectal bleeding after 
time, may depend first, on the size and the severity of Rwall damage and secondly, on the 
dose distribution in surrounding areas. We will, therefore, continue to perform endoscopies to 
gain more insight in the development and evolution of mucosal changes in relation to rectal 
bleeding and other anorectal symptoms, such as fecal frequency and incontinence. 
This mucosal recovery phenomena can then be studied more in detail, e.g. by means 
of cluster model analysis, as proposed by Tucker et al. (5). In their case-control study, a two-
dimensional cluster model of late rectal toxicity was tested. In this model, the probability of 
rectal complications does not only depend on the dose-wall histogram, but also on the spatial 
distribution of radiation damage. It was concluded that a dose range of 27 to 43 Gy (median 32 
Gy) might be associated most significantly to grade ≥2 rectal toxicity. We have shown that the 
ERB, in combination with the applied 67.5 Gy four-field 3D-CRT, yielded a dose reduction of the 
posterior Rwall (0-8 cm) from 48 Gy (No-ERB) to 36 Gy (ERB) (Fig. 7). With reduction of 
treatment margins or improvement of dose delivery (e.g. IMRT) the dose delivered to the 
posterior and lateral Rwall may even further be reduced, well below the recommended 32 Gy (5).  
 
Finally, surprising differences were observed in Rwall dose-effect relationships 
between the two groups. In both groups, all bleeders had mucosal areas with T 2-3 scores. 
But in the ERB group, only 14% of the patients with T 2 or T 3 scores developed late rectal 
bleeding, while in the No-ERB group this was 38% (Table 2). This difference could not be fully 
explained by the difference in spatial dose distribution or volumetric Rwall reduction of the 
ERB. In the ERB group, in Rwall mucosal areas exposed to intermediate (40 – 60 Gy) to high 
doses (60 – 68 Gy), a significant reduction of severe telangiectases was observed after two 
years, compared to the No-ERB group (Table 3). This might be caused by an increased 
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tolerance of the Rwall mucosa for development of severe late changes in patients treated with 
an ERB. This increased tolerance might either have a physical origin: dose build-up in the 
superficial Rwall due to the presence of an air cavity (12), or a radiobiological origin: stretching 
of the Rwall leading to hypoxia. 
Before definitive conclusions can be drawn on the possible beneficial effects of an ERB 
in prostate cancer 3D-CRT and IMRT, longer follow-up and thorough assessment of late 
symptoms and effects is necessary. As we have shown, the ERB can still be further improved 
(14). Also this study has shown that an ERB can be advantageous in prostate cancer 
radiotherapy. Therefore, and to further increase its acceptability, we are currently in the 
process of developing a more patient- and therapist-friendly ERB for daily usage. 
 
CONCLUSION 
  This study prospectively investigated the differences in late rectal wall (Rwall) mucosal 
changes in prostate three-dimensional conformal radiotherapy (3D-CRT) with or without an 
endorectal balloon (ERB), by periodical endoscopic assessment. The ERB reduced 
significantly the Rwall volume exposed to intermediate and high doses and significantly less 
severe late mucosal changes were seen at one and two years. Acute toxicity was mild in both 
groups. Although longer follow-up is warranted, at 30 months late rectal toxicity was reduced 
in the ERB group. In intermediate and high-dose exposed Rwall mucosal areas less high-
grade telangiectases (T 2-3) were seen after two years in the ERB group compared to the No-
ERB group. These observations suggest an ERB-induced increased tolerance for late Rwall 
damage. 
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SUMMARY 
For localized prostate cancer (Pca) evidence is growing for improved tumour control 
(PSA-relapse free survival) with higher radiotherapy doses (1-3). But if this improved 
biochemical control can be translated into survival gain, remains to be answered (4,5). This 
needs to be clarified in randomized trials with long follow-up, such as the ongoing RTOG 
0126 trial comparing two dose levels; 70.2 Gy and 79.2 Gy. This study is designed to test for 
an overall survival end point and will need an accrual of 1520 patients. But, as recently 
shown in a large Scandinavian randomized trial, local treatment can positively influence 
survival (6). Overall survival after prostatectomy was superior over watchful waiting, in men < 
75 years and localized favourable Pca. The cost of dose escalation is an increase of late 
toxicity (2,3,7). This is recently summarized in a comprehensive review on outcome and 
toxicity in Pca 3D-CRT (5). Before offering Pca patients a higher dose, the physician has to 
be aware of the potential risks and has to inform the individual patient. One of the challenges 
of the future Pca radiation treatment is to fully explore the technical possibilities and tools for 
reducing toxicity in this growing patient population with, in general, a long life expectancy. 
 
The aim of this thesis was to describe the steps we took in Nijmegen to improve the 
radiation treatment for localized Pca. We focused on narrowing the size of the radiation 
fields, by margin reduction, or avoidance of irradiating the surrounding normal tissues (e.g. 
rectum and bladder). The ultimate goal will be targeted deliverance of a high tumor dose, 
with a minimum of expected damage leading to considerable impairment of quality of life (8).  
 
 In chapter 2, an improvement of patient positioning (set-up) was achieved with the 
implementation of the couch height set-up method and a technologist-driven off-line 
correction protocol. The patient position was assessed on bony landmarks with a camera-
based portal imaging system. The couch height set-up resulted in reduction of the systematic 
position deviations in the ventro-dorsal direction and reduced the number of corrections 
within the correction protocol. On average, 10 position measurements were performed and 
0.6 corrections per patient were needed. The systematic positioning errors were reduced to 
1.3-1.6 mm (1 SD), while the daily random errors were 1.7-2.2 mm (1SD). As a result of this 
study, we reduced our treatment margins around the prostate and seminal vesicles to 8 mm 
and 9 mm, respectively.  
Since 2002, the bony landmarks are not used as surrogate for prostate position 
anymore, because the prostate moves independently from the bony structures (9). Now, in 
all patients the urologist implants transrectally, under ultrasound guidance, gold markers into 
the prostate. As described in chapter 3, the implantation is a simple and safe procedure. In 
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209 men, a 6.2% moderate complication rate, defined as pain requiring analgesics, fever, 
nausea/vomiting or an allergic reaction on the antibiotics, was observed. Hematuria, lasting 
longer than 3 days, hematospermia and rectal bleeding (average duration 2.5 days) occurred 
in 3.8%, 18.5% and 9.1% of the patients, respectively. It was concluded that marker 
implantation did not differ from diagnostic prostate biopsies in terms of experienced 
complaints and complications. 
In 2002, the endorectal balloon (ERB) was used only in a few centers worldwide for 
Pca radiotherapy. Early reports suggested improved prostate immobilization resulting in 
reduced daily position variation. In chapter 4, we have shown that the prostate position 
variations, measured on implanted gold markers, were comparable in patients irradiated with 
ERB or without ERB. Especially, the daily prostate motion in the anterior-posterior direction 
remained relatively high; 4.7 mm (1 SD). Stool and gas besides the ERB could be an 
explanation for this. Also, the motion of the prostate relative to the bones was not reduced by 
the ERB. With regard to the implanted markers, our data confirmed that migration of the 
markers within the prostate is negligible. This study also showed the effectiveness of the 
applied marker-based correction protocol in reducing the systematic prostate position 
variations.  
In chapter 5, the issue of the generally recommended full bladder Pca irradiation was 
addressed. A full bladder is advantageous in terms of reduced bladder toxicity and could 
effect, comparable to the variable filling of the rectum, the prostate position variation during 
daily treatment. The daily bladder filling was measured with a bladder ultrasound scanner. 
Although patients were instructed to have a full bladder, a very high daily bladder volume 
variation (47 % (1 SD)) was found. Applying a scanner-based biofeedback protocol did not 
change the average bladder filling or reduce the daily filling variation. In this study, no 
significant correlation between bladder filling and daily prostate motion could be observed.  
 
After our first positive ERB experiences, in terms of patients’ tolerance and staff 
acceptance, it was decided to test and compare the so-far known different types. The three 
investigated ERBs were quite different in shape, volume and manual handling. In chapter 6, 
we have shown the different resulting spatial dose distributions over the inner rectal wall 
(Rwall mucosa) for high-dose (78 Gy) three-dimensional conformal radiotherapy (3D-CRT) 
and intensity-modulated radiotherapy (IMRT). Based on calculations of the expected late 
rectal toxicity and radiation exposed volumes of Rwall, it was concluded that, for both 3D-
CRT and IMRT, a reduction of the relative inner Rwall surface exposed to intermediate and 
high-doses was found, which may lead to reduced late rectal toxicity. The two ERBs with 
larger volumes were superior over the smaller one. We concluded that none of the three 
 163
Summary, conclusions, future perspectives 
ERBs had the ideal design, and therefore the development of a more user- and patient-
friendly ERB is warranted. 
Advanced magnetic resonance (MR) imaging techniques were introduced into our Pca 
treatment preparation and planning. An in-house developed CT-MR image fusion tool, based 
on gold markers and an ERB, resulted in a highly accurate matching of these images (10). 
Simultaneously, IMRT treatment planning became available in our department. In Chapter 7, 
a concept of a biological target volume in Pca RT was tested. It was shown that it was 
technically feasible to integrate two functional prostate MR imaging techniques (dynamic 
contrast-enhanced MR imaging (DCE-MRI) and 1H-MR spectroscopic imaging (MRSI), into 
IMRT treatment planning. The DCE-MRI and MRSI were able to define the dominant tumor 
bearing regions within the prostate (the so-called intra-prostatic lesion (DIL)). Next, this DIL 
was used for high-dose intra-prostatic boosting with IMRT (DIL-IMRT). DIL-IMRT (90 Gy on 
the DIL and 70 Gy on the other part of the prostate) resulted in reduced expected late rectal 
toxicity, compared to homogeneous (78 Gy) prostate irradiation. It was hypothesized that the 
typical Rwall spatial dose distribution, as a result of the DIL boosting, may indicate a further 
reduced actual rectal toxicity. 
 
In chapter 8 acute and late toxicity rates for patients treated with an ERB are 
compared to patients irradiated without an ERB. This was not a randomized study, but these 
data suggested a reduced late rectal toxicity in the ERB-group after a moderate dose of 67,5 
Gy. It was possible for each patient, to calculate and display the dose over the inner rectal 
wall (Rwall) as Rwall surface dose maps. This spatial dose distribution was compared to the 
radiation-induced mucosal changes, as observed in repeated rectosigmoidoscopy. After a 
follow-up of 30 months, 146 scopies were performed in 48 patients. The ERB clearly reduced 
the Rwall volume exposed to high doses, resulting in decrease of late rectal mucosal 
changes. Interestingly, in Rwall areas exposed to doses > 40 Gy, less severe Rwall damage 
was seen in the ERB group, compared to the No-ERB patients. This observation may 
suggest an ERB-induced increased tolerance for late Rwall damage. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
For the future the following issues are of major importance: 
  
1. PROSTATE POSITION VERIFICATION AND CORRECTION STRATEGIES  
   
Control of prostate position is essential in high-dose Pca radiotherapy, because large 
systematic shifts of the prostate relative to the irradiation field can cause considerable 
underdosage and loss of local tumour control (11). Position verification based on implanted 
gold markers is superior to the usage of bony landmarks, because the prostate moves 
independently form the pelvic bones (12). We have shown that the gold markers are safe 
and a simple tool for portal imaging based correction procedures. In our setting, one 
dedicated urologist is responsible for the implantation and it takes about 10 minutes per 
patient in an outpatient setting.  
 
During the radiotherapy treatment the prostate position is checked and corrected by 
trained technologists, under supervision of the physician. As described, the off-line correction 
protocol reduces the position variation, enabling to use smaller treatment margins (13). 
Recently, we have started an on-line correction protocol for the anterior-posterior direction 
(towards the rectum) and re-position the patient, if necessary, before the daily treatment has 
been given. As a result, we have reduced the treatment margin towards the rectum to 5 mm. 
We continue to improve our portal imaging based correction procedures in close 
collaboration with our technologists, who are responsible for executing these protocols. 
Another method of prostate position verification is the so-called kilovoltage Cone-beam CT. 
This imaging system is integrated into the lineair accelerator and is able to construct 
volumetric CT images of the area to be irradiated after a single gantry rotation. Preliminary 
results look promising, but the usage for prostate position verification is hampered due to 
image distortion when bowel gas is present (14). With a cheaper portal imaging system and 
gold markers, image quality is constantly good and either off-line or on-line correction 
protocols can be executed fast and in a reliable way. 
As the bladder concerns, despite a laborious bladder scanner based biofeedback 
protocol, we did not observe a reduction of bladder filling variation. In our study, the amount 
of bladder filling did not influence the prostate position. As a consequence, we continue to 
instruct patients to be treated with a comfortable full bladder but no extra checks on bladder 
filling are being performed. 
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2. ENDORECTAL BALLOON  
 
As demonstrated, the endorectal balloon is expected to be advantageous in reducing 
late rectal toxicity in high-dose radiotherapy. So far, we have treated 50 patients with an ERB 
at a moderate dose level (67.5 Gy) with 3D-CRT. Based on our clinical experience and 
planning studies, we are now developing a dedicated single-use Pca ERB for daily treatment 
use. Patients treated with this ERB will be followed closely, and the acute and late toxicity 
profile will be monitored. More late Rwall damage data, derived from repeated 
rectosigmoidoscopies, will be collected to confirm if the ERB is associated with an increased 
tolerance of the Rwall for late rectal damage. Work in progress is to study the role of the ERB 
in reducing the incidence of fecal incontinence, as preliminary planning study data have 
suggested a reduction of the dose onto the anal wall. Peeters et al. (7) have indicated a clear 
dose volume effect for the anal wall and the presence of fecal incontinence. 
 
3. HIGH DOSE RADIOTHERAPY  
 
As proven in a large Dutch randomized trial, a higher radiotherapy dose yields a 
better tumour control in a subset of patients with localized Pca (1). This higher dose also 
resulted in higher late rectal toxicity. This can raise an interesting question if patients really 
prefer a better tumour control at the cost of increased toxicity. This issue was recently 
investigated at our department and it was concluded that the majority of the Pca patients is 
reluctant to accept these higher toxicities (15). 
These results emphasize the importance of a well-informed patient and the necessity 
to be careful to elevate the treatment dose without taking measures to prevent increased late 
toxicity (4). Besides the gold markers and the endorectal balloon, we have integrated 
anatomical MR imaging for better definition of the prostatic gland and the normal surrounding 
tissues, which lead to smaller irradiated volumes, as studied by the group of the Netherlands 
Cancer Institute (16). Advanced DCE-MRI and MRSI techniques will be used for further 
exploration of the DIL-IMRT concept, as a measure of decreasing the Rwall volume to be 
irradiated. It is certain, that the role of MR imaging will be expanding in the near future. Pre-
treatment staging will be more accurate, resulting in tailor-made treatment decisions (17, 18) 
and perhaps CT-based planning will be replaced by MR-based planning systems (19).  This 
staging is particularly important to discriminate between localized or locally advanced 
disease and decide whether radiotherapy should be combined with hormonal therapy. 
Although beyond the scope of this thesis, the role of hormonal therapy in combination with 
high-dose Pca radiotherapy has not been established yet (20, 21). The adverse effects of 
this systemic treatment are well known and long term androgen deprivation increased late 
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rectal toxicity in Pca radiotherapy (22). In the literature it has been suggested that, for certain 
subsets of Pca patients, high dose radiotherapy (> 74 Gy) would result in comparable tumour 
control as the combination of hormonal treatment and conventional doses (≤ 70 Gy) (23, 24).  
A relatively novel approach in high-dose Pca radiotherapy is hypofractionation. There 
is evidence from clinical studies that the a/b ratio for Pca may be low, which would 
correspond to an increased fractionation sensitivity, i.e. a biological equivalence in outcome 
can be achieved by giving a higher radiation dose per fraction at a lower total dose. For 
example, 76 Gy in 2 Gy daily fractions may be equivalent to 70.2 Gy in 2.7 Gy daily fractions 
(26). Kupelian et al. (23) conducted a hypofractionation study, prescribing 70 Gy in 28 daily 
fractions of 2.5 Gy. They presented an excellent 5-years PSA-relapse free survival of 85% in 
this group with localized Pca. Persistent late rectal and urinary toxicity rates at 5 years were 
low, 5% and 8% respectively. In this study, no impact of hormonal therapy on biochemical 
relaps free survival was noted. In Nijmegen we have adopted this scheme for the 
intermediate and high-risk Pca patients, in combination with gold marker based correction 
and daily ERB. 
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Meerdere studies hebben laten zien dat bestraling met hogere dosis voor niet 
gemetastaseerd prostaatkanker betere resultaten geeft. Hiermee blijft de prostaatkanker 
merkstof in het bloed, het zogenaamde prostate specific antigen (PSA) langere tijd laag. 
Of deze langere periode van laag PSA zich vertaalt in een langere 
prostaatkankeroverleving moet nog blijken omdat deze patiënten nog niet zo lang onder 
controle zijn en we moeten wachten op de resultaten 10-15 jaar na deze behandeling. 
 
Een hogere dosis op de prostaat geeft ook een hogere dosis op de omgevende 
organen zoals de blaas, de darm en de anus. Het is gebleken dat de patiënten die met 
een hogere dosis bestraald zijn ook een grotere kans op complicaties hebben zoals 
bloedverlies uit de endeldarm en toename van incontinentie voor ontlasting, vaak pas 
onstaan jaren na de radiotherapie. Onderzoek door de groep van Dr. Van Tol-Geerdink, 
van onze afdeling, liet zien dat patiënten bevreesd zijn voor deze verhoogde kans op late 
bijwerkingen. In deze studie hadden ze de keuze voor een lagere of iets hogere 
bestralingsdosis. De meerderheid koos voor de lagere bestralingsdosis uit vanwege de 
toename van verwachte late bijwerkingen. 
 
Eén van de uitdagingen voor de toekomst voor bestraling van prostaatkanker om 
een behandeling te geven met de minste kans op bijwerkingen, maar waarbij wel een 
goede kans op genezing kan bestaan. Doel van dit proefschrift was om de diverse 
technische hulpmiddelen te testen, die ervoor zouden zorgen dat de bijwerkingen kunnen 
worden verminderd. 
 
In hoofdstuk 2 wordt een nieuwe methode van patiënt positionering op de 
bestralingstafel beschreven. Een patiënt wordt 25-35 keer bestraald en de bedoeling is 
dat hij elke dag op dezelfde wijze wordt gepositioneerd aan de hand van de inktlijnen die 
op zijn huid zijn getekend tijdens de CT scan, als voorbereiding op de behandeling. 
Tijdens de bestraling kunnen foto's worden gemaakt (de zgn. portal images) waarop de 
botstructuren van het bekken te zien zijn. Aan de hand van deze botstructuren kan 
gecontroleerd worden of de patiënt goed gepositioneerd is. Met een zogenaamd off-line 
portal imaging correctieprotocol kan zo nodig een verschuiving van de bestralingstafel 
worden uitgevoerd zodat de bestraling nog preciezer kan worden uitgevoerd. Met de 
zogenaamde digitale tafelhoogte in combinatie met een off-line correctieprotocol was het 
mogelijk om de patiënten nog nauwkeuriger te positioneren en bleek het aantal 
correcties per patiënt te worden gereduceerd. Dit resulteerde in een verkleining van de 
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veiligheidsmarge om de prostaat tot 8 mm in plaats van 1 cm zodat minder darm en 
blaas bestraald hoefden te worden. 
 
Sinds 2002 worden bij alle patiënten goudmarkers in de prostaat ingebracht. 
Deze goudstaafjes van 1 bij 7 mm worden door de uroloog via de darm in de prostaat 
ingebracht. Het voordeel van de goudmarkers is dat ze goed zichtbaar zijn op de portal 
images. Het blijkt namelijk dat het corrigeren op de bekken-botstructuren geen 
betrouwbare methode is, omdat de prostaat onder invloed van met name de darmvulling 
en ademhaling kan verschuiven onafhankelijk van de botstructuren.  
In hoofdstuk 3 wordt de procedure van het inbrengen van de goudmarkers beschreven 
in 209 patiënten. In slechts 6 % van de gevallen traden geringe bijwerkingen (m.n. pijn 
en koorts) op als gevolg van de goudmarkerimplantatie. Het inbrengen duurt slechts 10 
minuten en patiënten ervaren gemiddeld minder pijn van het inbrengen dan bij het 
nemen van prostaatbiopten t.b.v. de diagnose prostaatkanker. 
 
In hetzelfde jaar 2002 is begonnen met het testen van de zogenaamde 
endorectale ballon bij prostaatkankerbestraling. De endorectale ballon bestaat uit een 
flexibel staafje met aan het uiteinde een ballon dat in de endeldarm ter hoogte van de 
prostaat wordt opgeblazen tot een volume van 80 of 100 cc. Het voordeel van deze 
ballon is dat de achterwand van de darm wordt weggeduwd van de prostaat en daarmee 
kan een deel van het slijmvlies van de endeldarm buiten het bestralingsgebied gehouden 
worden. Eerdere onderzoeken uit de USA en Oostenrijk hebben laten zien dat het 
gebruik van een dergelijke ballon leidt tot minder bijwerkingen, met name minder rectaal 
bloedverlies. Een ander voordeel van deze ballon zou zijn het fixeren van de prostaat 
tussen de darm en het schaambeen. In hoofdstuk 4 is getest of de endorectale ballon 
de prostaat inderdaad kan immobiliseren. Bij twee  patiëntengroepen (bestraald met of 
zonder ballon) is de dagelijkse positievariatie van de prostaat vergeleken aan de hand 
van de goudmarkers en portal images. Er was geen verschil tussen de beide groepen. 
Met name de positievariatie richting de endeldarm bleef onveranderd hoog. Ondanks de 
endorectale ballon bleek er toch lucht en darminhoud naast de ballon te zitten die de 
verandering van prostaatpositie kon verklaren. 
 
In hoofdstuk 5 is het nut van een volle blaas tijdens prostaatbestraling 
onderzocht. Een volle blaas is een voordeel omdat daarmee het grootste deel van de 
blaaswand buiten het bestralingsgebied ligt en daardoor minder blaasirritatie op kan 
treden. Over het algemeen worden patiënten geadviseerd om tijdens de dagelijkse 
bestraling een goed gevulde blaas te hebben door vlak vóór de bestraling nog extra te 
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drinken. Uit ons onderzoek bleek dat, ondanks deze strikte voorschriften, de variatie in 
blaasvulling over de bestralingsdagen zeer groot was. Ook het dagelijks meten van de 
blaasvulling mbv een blaas-echo bleek geen verbetering of vermindering van de 
blaasvullingsvariatie op te leveren. Verder werd er geen relatie gevonden tussen de mate 
van blaasvulling en de positie van de prostaat. Sindsdien gebruiken wij de blaas-echo 
niet meer voor het controleren van de blaasvulling. 
 
Na onze eerste klinische ervaringen met de endorectale ballon, is er een planningsstudie 
(hoofdstuk 6) uitgevoerd waarbij drie verschillende typen endorectale ballonnen werden 
getest en vergeleken op de mate van rectumwandsparing tijdens hoge doses 
radiotherapie. Voor zowel de meer conventionele 3-D conformatieradiotherapie als voor 
de meer geavanceerde intensiteits-gemoduleerde radiotherapie (IMRT) bleek dat de 
endorectale ballon een duidelijke bescherming zien van het darmwand. De ballonnen 
met het grootste volume gaven een groter rectumwandsparing. Verder kwam naar voren 
dat eigenlijk geen van de drie geteste ballonnen patiëntvriendelijk was en is besloten om 
een eigen endorectale ballon te ontwerpen. 
 
In samenwerking met de afdeling Radiologie van het UMC St Radboud is de rol 
van de magnetische resonantie afbeelding (MRI) van de prostaat onderzocht. Uit eerder 
onderzoek bleek dat de MRI een scherpere afbeelding van de prostaat geeft in 
vergelijking met de CT-scan zoals die wordt gebruikt voor bestralingplanning. Het 
vaststellen van het bestralingsvolume met behulp van een MRI leidt tot een kleiner 
bestraald volume omdat de CT het prostaatvolume tot wel 30% kan overschatten. Met 
behulp van de goudmarkers bleek het mogelijk te zijn om met hoge precisie de MR- en 
CT-beelden samen te voegen (fuseren) in het radiotherapie planningssysteem.  
 
In hoofdstuk 7 is een relatief nieuw concept getest voor prostaatkanker 
bestraling. Met geavanceerde MRI-technieken is het mogelijk om binnenin de prostaat de 
eigenlijke prostaattumor goed te lokaliseren. Voor een aantal patiënten is een IMRT-
bestralingsplan gemaakt waarbij het kankerdeel van de prostaat bestraald wordt tot een 
extra hoge dosis en de rest van de gezonde prostaat tot een gemiddelde dosis. Uit deze 
theoretische planningsstudie kwam naar voren dat met deze bestralingstechniek 
eenzelfde tumorcontrole kon worden bereikt, met een lagere verwachte 
darmbeschadiging in vergelijking met de standaard bestraling waarbij de hele prostaat 
een gelijke bestralingsdosis krijgt. 
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In hoofdstuk 8 wordt aangetoond dat na 30 maanden bestraling met de 
endorectale ballon minder darmbijwerkingen geeft. Twee patiënten groepen (met en 
zonder ballon bestraald) werden vergeleken. Bij al deze patiënten zijn over een periode 
van twee jaar regelmatig darmonderzoeken (sigmoïdoscopieën) verricht. De patiënten, 
bestraald met ballon, hadden duidelijk minder darmschade. Uit dit onderzoek komen 
aanwijzingen dat de endorectale ballon wellicht een extra beschermende werking zou 
hebben op de darmwand tegen hoge doses bestraling. Oorzaken hiervoor zijn nog niet 
bekend. 
 
De komende jaren zal ons onderzoek van de prostaatbestraling zich richten op een 
drietal onderwerpen. 
 
1. Nog verdere verbetering van de procedures om de positie van de prostaat tijdens de 
bestraling te kunnen controleren en corrigeren. Inmiddels zijn we al gestart met een 
correctieprotocol waarbij de bestralingslaboranten voorafgaande (zgn on-line) aan de 
bestraling controleren wat de positie van de prostaat is en waarbij, voordat de echte 
bestraling gegeven wordt, een correctie van het bestralingsveld kan worden uitgevoerd. 
De uitkomsten hiervan zijn veelbelovend en inmiddels hebben is de veiligheidsmarge 
rondom de prostaat richting de darm nog verder  verkleind naar 5 mm. 
 
2. De endorectale ballon zal in een grotere groep patiënten worden toegepast. Deze 
mannen zullen nauwkeurig gevolgd, tot jaren na de bestralingsbehandeling. Ook zullen 
regelmatig darmonderzoeken worden uitgevoerd om te kijken wat de eventuele schade 
aan de darmwand zal zijn.  We hebben een eigen “Nijmeegse ballon” ontworpen in 
samenwerking met Hospimed International B.V. te Dalfsen, die nu door ons dagelijks 
wordt gebruikt. .Inmiddels is ook een onderzoek gestart om te zien of de endorectale 
  
RectalPro©, www.hospimed.nl 
ballon ook een mogelijke beschermende werking zou kunnen hebben op het anale 
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kanaal. Er zijn aanwijzingen dat met de endorectale ballon een lagere bestralingsdosis 
op de anus en de omringende spieren komt. Hierdoor zou de kans op incontinentie voor 
ontlasting kunnen afnemen. Dat is dan van voordeel, met name wanneer er in de 
toekomst met een hogere bestralingsdosis bestraald zal gaan worden. 
 
3. Onlangs heeft een Nederlandse studie laten zien dat een hogere bestralingsdosis een 
Een verdere nieuwe ontwikkeling binnen de prostaatbestraling is de zogenaamde 
betere kans op tumorcontrole geeft. Inmiddels wordt ook in Nijmegen deze hoge 
bestralingsdosis gegeven. Tot nu toe wordt de gehele prostaat een hogere 
bestralingsdosis bestraald. De verwachting is dat we in de nabije toekomst, op basis van 
de MRI-beelden, het concept van een deelbestraling van de prostaat, met extra hoge 
dosis, klinisch  kunnen gaan testen. Verder zijn er aanwijzingen in de literatuur dat het 
geven van een extra hoge dosis op de prostaat zou kunnen volstaan en dat hiermee de 
hormonale behandeling (in combinatie met bestraling) zou kunnen vervallen, voor 
bepaalde groepen patiënten. 
 
 
hypofractionering. Bij prostaatkanker is het mogelijk is om een goede tumorcontrole te 
krijgen als de bestralingsdosis per dag wordt opgehoogd en waarbij dan in minder 
behandelingsdagen eenzelfde biologische tumordosis kan worden gegeven. Dit heeft 
grote voordelen voor de patiënt, die hoeft dan minder bestralingsbehandelingen te 
ondergaan, en voor de bestralingsafdeling in verband met de bezetting van de 
bestralingstoestellen en de eventuele wachttijden. De eerste onderzoeken vanuit andere 
instituten hebben laten zien dat deze aanpak ook goede resultaten geeft met zeer 
acceptabele bijwerkingen op langere termijn. Inmiddels is in Nijmegen gestart met een 
dergelijk hypofractioneringsschema in combinatie met de geïmplanteerde goudmarkers 
en de endorectale ballonnen. 
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Ik ben trots en blij met dit resultaat.  
 
Dit had ik niet durven dromen toen ik 12 jaar geleden in Nijmegen aan de opleiding tot 
radiotherapeut begon maar het is zover, het “boekje” is geschreven en ligt voor u. 
Dit proefschrift is tot stand gekomen door samenwerking met meerdere afdelingen en 
vele enthousiaste en gedreven collega’s en ik wil iedereen bedanken die heeft 
bijgedragen aan de totstandkoming ervan. Enkelen wil ik in het bijzonder noemen 
 
Zonder de medewerking van mijn patiënten die ik nog regelmatig zie op de polikliniek 
Radiotherapie, was dit proefschrift er niet geweest. Mijn oprechte dank voor jullie 
vertrouwen en durf. 
Professor dr. J.W.H. Leer, mijn promotor. Beste Jan Willem, jij hebt me aangenomen als 
staflid in 1998. Ik wil je bedanken voor je vertrouwen en de kans die je me hebt gegeven 
om de bestraling van prostaatkanker in Nijmegen om te vormen naar zijn huidige vorm, 
met alle “toeters en ballonnen”. 
Ook mijn co-promotor dr. A.G. Visser verdient alle lof. Beste Andries, jouw deur stond 
altijd open en ik kon uitgebreid al mijn plannen met je delen. Je hebt me bijgestuurd waar 
nodig en zonder jouw inbreng was dit niet mogelijk geweest. 
Professor dr. J.A. Witjes, beste Fred. Ik voel me vereerd om samen met jou onze 
plannen voor de toekomst uit te werken. Al jaren sta je op maandagochtend klaar om de 
goudmarkers bij onze patiënten in te brengen; dat was de basis van dit proefschrift. Ook 
de andere leden van de afdeling Urologie wil ik danken voor hun enthousiaste 
medewerking. 
Lisette van der Vight, “onze” research laborante. Jij vormt de rode draad door het hele 
proefschrift en je bent nauw betrokken geweest bij de totstandkoming en verwezenlijking 
van alle gepubliceerde onderzoeken. Dank voor je tomeloze inzet en accuratesse. We 
zullen je missen. 
Dr. J.J. Fütterer, beste Jurgen. Vooral door jouw enthousiasme is het gelukt om een 
solide brug te slaan tussen de afdelingen Radiologie en Radiotherapie. Ook onze 
samenwerking is nog lang niet voorbij. Onder de bezielende leiding van professor dr. 
Jelle Barentsz en professor dr. Arend Heerschap is de rol van de MR prostaat imaging 
voor de prostaatbestraling vastgelegd in mooie publicaties. Mijn dank gaat ook uit naar 
dr. ir. Henkjan Huisman en drs. Stijn Heijmink. 
Dr. D.J. de Jong, beste Dirk. Ook jij bent onbevangen en met groot enthousiasme de 
samenwerking met onze afdeling aangegaan. De gegevens die we aan het verzamelen 
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zijn, zijn van grote waarde en een eerste publicatie is een feit. Ik dank ook drs. Mariëlle 
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De overige stafleden van de Radiotherapie, dank dat jullie mij de tijd en ruimte hebben 
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Jeroen Jansen en Mark Glaap, mijn fietsvrienden. Tijdens onze tochten op de 
mountainbike zijn de mooiste ideeën voor het onderzoek ontstaan. 
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